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General introduction and outline of the thesis
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IntroduCtIon
Invasive aspergillosis (IA) is a severe opportunistic infection that is mainly caused by 
Aspergillus fumigatus [1,2]. It is the most common invasive fungal disease (IFD) in im-
munocompromised patients with an underlying hematological disease, including those 
with acute myeloid leukemia (AML) receiving remission induction or consolidation 
chemotherapy, and recipients of allogeneic hematopoietic stem cell transplantation 
(alloHSCT) [1,2]. Not only does it lead to an increase in morbidity and mortality among 
these patients [3,4], but also to an increase in medical costs [5]. Given these facts, it is 
essential to optimize management of IA (including early diagnosis, adequate antifungal 
therapy and prevention) in high-risk patients with an underlying hematological disease. 
Currently, the first line therapy is voriconazole, an antifungal agent from the class 
azoles [6]. Before the introduction of mold-active azoles in the 1990s, mortality rates as 
high as 90% have been reported in patients with an underlying hematological disease 
[3,4]. When the recommended therapy with voriconazole is initiated promptly, a rela-
tively low mortality between 26% to 39% at 12 weeks after diagnosis is observed [5,7,8]. 
Early diagnosis is therefore highly important to treat IA without any delay. 
Another strategy in the management of IA is prevention through antifungal prophy-
laxis. Antifungal prophylaxis with azoles, echinocandins and polyenes have shown to be 
effective in preventing IA in high-risk patients with an underlying hematological disease 
[9-12]. At present, mold-active azoles posaconazole and voriconazole are recommended 
in patients with prolonged neutropenia or in allogeneic alloHSCT recipients with active 
graft-versus-host disease (GVHD) [6]. Besides reducing the incidence and IA-related 
mortality, antifungal prophylaxis may also be cost-effective. This thesis focuses on IA 
in high-risk patients with an underlying hematological disease and in particular on its 
epidemiology, prevention and diagnostics.
InvAsIve AsPergIllosIs: InCIdenCe, mortAlIty, rIsk fACtors And 
PreventIon
In the management of IA, it is important to monitor the local incidence and mortal-
ity in high-risk patients as these are subjected to continuous changes, such as altera-
tions in antifungal prophylaxis and the emergence of azole-resistant A. fumigatus and 
intrinsically azole-resistant sibling species. Moreover, risk factors should be identified 
to recognize the subset of patients who are at highest risk and will benefit most from 
antifungal prophylaxis. Chapter 2 describes the incidence, mortality and risk factors 
of IA in alloHSCT recipients who were transplanted in the Erasmus University Medical 
Center over the past decade.
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As mentioned earlier, IA is not only associated with an increased morbidity and mor-
tality, but also with a substantially increase of medical costs in patients with an underly-
ing hematological disease [3-5,7,8]. Given these observations and the fact that hospital 
resources are not infinite, preventing IA is an attractive strategy to reduce IA-related 
mortality and costs. Although posaconazole and voriconazole are recommended as an-
tifungal prophylaxis [6], other antifungals from other classes can be used as prophylaxis 
as well [10,12]. Inhalation of aerosolized liposomal amphotericin-B (L-AmB) has been 
shown to be effective and safe in preventing IA [10,13]. It has the advantages of (i) no 
systemic side effects in compare to intravenous L-AmB and other antifungal prophylaxis, 
and (ii) retaining azoles in case of therapy. In 2008, it was implemented as standard of 
care for patients with AML receiving intensive chemotherapy in the Erasmus University 
Medical Center. Chapter 3 describes the efficacy and cost-effectiveness of L-AmB inhala-
tions on the incidence and mortality of IA in high-risk patients with AML.
dIAgnosIs of CerebrAl AsPergIllosIs
The diagnosis of IA is made according to the revised definitions of the European Or-
ganization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) 
[14]. In the revised definitions, one of the microbiological criteria is the detection of 
galactomannan (GM), a cell-wall component of Aspergillus that is released during cell 
growth [15]. Although the detection of GM antigen has been well validated in serum 
and bronchoalveolar lavage (BAL) fluid of immunocompromised patients [16,17], less 
is known about its diagnostic performance in cerebrospinal fluid (CSF) to diagnose 
cerebral aspergillosis (CA). Based on three small studies, GM antigen testing in CSF 
seems to be promising, even though no formal cut-off was established [18-20]. Chapter 
4 describes the results of a study that investigated the diagnostic performance of GM 
antigen in CSF of patients with suspected CA.
deteCtIon of Azole-resIstAnt Aspergillus fumigAtus In InvAsIve 
AsPergIllosIs
Over the past decade, azole resistance in A. fumigatus has emerged worldwide [21,22]. 
This is worrisome as IA with an azole-resistant A. fumigatus is associated with very high 
mortality rates of almost 90% [23,24]. Azole resistance is often caused by mutations in 
the Cyp51A gene that encodes for the lanosterol 14α-demethylase, the target enzyme 
for azoles. Two mutation combinations in this Cyp51A gene, e.g. TR34/L98H and TR46/
T289A/Y121F, account for a large part of azole-resistant mechanisms [23,25,26] and are 
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believed to have developed in the environment due to azole exposure in agriculture 
[27,28]. 
Detection of azole resistance in IA is challenging for two reasons. First, a positive cul-
ture is required for conventional detection of resistance. However, cultures are positive 
in at most one-quarter of the cases and therefore diagnosis is often made indirectly by 
detection of galactomannan (GM) antigen [8,29]. Second, conventional microbiological 
tools for azole susceptibility testing are not widely available and time consuming. The 
lack of a fast and readily available azole susceptibility testing compromises the initiation 
of adequate therapy in case of azole resistance. Hence, there is a need for development 
of newer diagnostic techniques to intercept this problem.
Among the novel diagnostics are Aspergillus polymerase chain reaction (PCR) assays 
that detect and identify Aspergillus to the species level in different specimens [30-32]. 
The AsperGenius® multiplex real-time PCR is a commercially available Aspergillus assay. 
In addition to detecting Aspergillus, it detects the aforementioned two most common 
mutation combinations of A. fumigatus that are associated with azole resistance. Chap-
ter 5.1 describes the results of the single-center study that investigated the diagnostic 
performance of this assay on BAL fluid samples of patients from the hematology depart-
ment and intensive care unit. To confirm the results of the single-center study, subse-
quently a multicenter study was performed in a larger BAL sample set from patients 
with an underlying hematological disease. Moreover, we evaluated in this second study 
if PCR detection of the aforementioned mutation combinations correlated with azole 
treatment failure and mortality. The results of this multicenter study are described in 
Chapter 5.2. 
deteCtIon of Azole-resIstAnt sIblIng sPeCIes In InvAsIve 
AsPergIllosIs
IA is mainly caused by Aspergillus fumigatus, an Aspergillus species from the section 
Fumigati [1,2]. Occasionally, IA is caused by Aspergillus species that are morphologically 
similar to A. fumigatus [33,34]. These so called ‘sibling species’ or ‘cryptic species’ also 
belong to the Aspergillus section Fumigati and are often intrinsically resistant to azoles. 
As voriconazole is the recommended first line therapy [6], fast identification and suscep-
tibility testing of these sibling species is important to select the appropriate antifungal 
therapy. However, this is problematic as cultures are not available in the majority of the 
patients with IA [8,29]. Moreover, if a culture is available, identification and susceptibility 
testing is difficult as these sibling species often have poor sporulation and can only be 
distinguished by additional testing. Chapter 6 describes two patients with proven IA 
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caused by azole-resistant sibling species and the contribution of the aforementioned 
AsperGenius® assay in their identification.
summAry
Several studies were performed to investigate the incidence, mortality, risk factors and 
diagnostics of IA. Chapter 2 focusses on the incidence, mortality and risk factors of IA 
in alloHSCT recipients. Chapter 3 describes the efficacy and cost-effectiveness of L-AmB 
inhalations on the incidence and mortality of IA in patients with AML receiving intensive 
chemotherapy. The subsequent chapters focus on the diagnostics in IA. In chapter 4, 
the diagnostic performance of GM in CSF is described. Chapter 5.1 and 5.1 present the 
results of two studies that evaluated the diagnostic performance of a novel PCR-assay 
that can not only detect Aspergillus, but also the two most common Cyp51A mutations in 
A. fumigatus that confer to azole resistance. Chapter 6 describes the contribution of this 
novel PCR-assay in identifying sibling species and is followed by a general discussion in 
chapter 7.
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AbstrACt 
Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients are at risk for 
invasive aspergillosis (IA). We conducted a retrospective study to determine incidence, 
outcome and risk factors for IA in alloHSCT recipients.
methods
Patients who underwent their first alloHSCT between 2004 and 2014, were included. 
IA was classified according to the proven or probable EORTC/MSG criteria. In addition, 
patients with a positive microbiological criterium but with non-specific radiological 
findings, were defined as having non-classifiable IA. The 12-month IA incidence and 
mortality were determined. Within the total cohort, a nested case-control study was 
performed to determine risk factors for IA.
results
Of 663 alloHSCT recipients, 86 developed IA within the 12 months post-transplantation 
(1.8% proven, 7.4% probable and 3.8% non-classifiable IA). Twelve-month all-cause mor-
tality was 45.6% in patients with IA and 26.2% in those without IA (p-value<0.01). For the 
nested case-control study, 99 patients with proven/probable/non-classifiable IA were 
compared to 198 patients without IA. Backward logistic regression showed the following 
independent risk factors: neutropenia (OR 16.22; p-value<0.01), lymphocytopenia (OR 
5.70; p-value<0.01), reactivation of cytomegalovirus (OR 5.27; p-value=0.02), creatinine 
>135 µmol/l (OR 2.48; p-value=0.03), pulmonary comorbidity (OR 2.67; p-value=0.01); 
and use of prednisolone 1-1500 milligram (OR 4.06; p-value<0.01) and >1500 milligram 
(OR 45.05; p<0.01) in the 4 weeks preceding the IA. Pre-transplant IA was not identified 
as an independent risk factor for post-transplant IA. 
Conclusion
At twelve months post-transplantation, 13.0% of the patients had developed IA and 
had a decreased survival compared to patients without IA.. Several independent risk 
factors were found, but surprisingly pre-transplant IA was not among them. A higher 
dose of prednisolone was associated with a higher risk for IA, suggesting a dose-effect 
relationship. 
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IntroduCtIon
Invasive aspergillosis (IA) is a common invasive fungal disease (IFD) in recipients of 
allogeneic hematopoietic stem cell transplantation (alloHSCT) [1-12]. The reported 
incidences vary between 2.3% and 15.0%, and mortality is substantial in this particular 
patient group [1-4,6-8,10]. Primary prophylaxis with voriconazole or posaconazole can 
reduce the incidence of IA in alloHSCT recipients and is recommended in those with 
graft-versus-host disease (GVHD) who are in need of systemic corticosteroid or other 
anti-GVHD therapies [13-15]. However, apart from GVHD, many other risk factors for 
post-transplant IA have been described, such as older age, neutropenia, non-related 
donor, reactivation of cytomegalovirus (CMV) and a history of pre-transplant IFD [1-
4,6,9,10,12,16,17]. Also, a genetic predisposition has been identified [18]. IA is most 
frequently observed in the first year post-transplantation, but a substantial part of the 
recipients develops IA later [1,6,7]. Therefore, the best timing and duration of primary 
prophylaxis should be individualized. Recognizing risk factors may help in selecting 
those patients that are at highest risk and benefit most of primary prophylaxis. We 
conducted a retrospective single-center study to study the incidence, mortality and risk 
factors for post-transplant IA in alloHSCT recipients.
metHods
study design
The study was performed at Erasmus University Medical Center (Rotterdam, the Neth-
erlands), a tertiary referral hospital with three hematology departments at two sites. 
We reviewed medical files of all patients who underwent their first alloHSCT between 
January 2004 and December 2014. Data were obtained till the end of the study (1st of 
April, 2015). The following information was retrieved from medical files: age, sex, under-
lying hematological disease, date and donor type of alloHSCT, conditioning regimen 
pre-transplantation, relapse of hematological disease post-alloHSCT, documentation of 
IFD before and after alloHSCT, acute and chronic GVHD, renal and hepatic impairment, 
pulmonary comorbidity, reactivation of CMV, neutropenia, lymphocytopenia, number 
of CD3+ T cells, use of systemic corticosteroids, European Group for Blood and Marrow 
Transplantation (EBMT) risk score and mortality.
The study consisted of two parts. First, in the total cohort we assessed (i) the inci-
dence of IA at 12 months post-transplantation and overall, and (ii) the incidence of IA 
per calendar year of transplantation and per donor type. Also, we determined (i) the 
all-cause mortality at 12 months post-transplantation and overall, (ii) the IA-related 
mortality, defined as mortality within 6 weeks of proven, probable or non-classifiable 
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IA diagnosis, and (iii) the non-relapse mortality (NRM). Furthermore, the incidence and 
timing of IFD other than IA were evaluated. 
Second, a nested case-control study was performed within the total cohort to iden-
tify risk factors for developing post-transplant IA. Cases were defined as patients with 
proven, probable or non-classifiable IA after alloHSCT. Controls were patients without 
IA. The following patients were excluded: (i) patients with possible IA, (ii) patients with 
IFD other than IA, (iii) patients having an episode of IA before alloHSCT who continued 
to receive on antifungal therapy for this episode after alloHSCT. These exclusion criteria 
were used to ascertain as much as possible that the cases had and the controls had not 
developed an IA after alloHSCT. Every case was matched randomly to 2 controls using 
age at transplant (±5 years), year of transplant (±1 year) and follow-up time as match-
ing variables. Matching was performed using IBM® SPSS, version 21 (plug-in “Fuzzy”). 
To ensure that risk factors could also be studied in controls, the follow-up time of the 
two matched controls was at least as long as the case. Except for lymphocytopenia and 
CD3+ T cell, variables that varied over time (i.e. acute or chronic GVHD, renal or hepatic 
impairment, reactivation of CMV, neutropenia, use of prednisolone) were assessed dur-
ing the time frame of 1 month preceding the diagnosis of IA in the cases. In the rare 
event that renal and hepatic function had not been tested in the indicated time period, 
the last observation was carried forward with a maximum of 6 months. For controls, the 
same variables were obtained at the number of days after alloHSCT that corresponded 
to this time-frame in the corresponding matched case. Lymphocytopenia and CD3+ T 
cells were assessed 3 months or as the first encountered number preceding IA diagnosis, 
respectively, since these 2 variables were not determined in time frame of 1 month in 
the majority of the patients. 
Antifungal prophylaxis with fluconazole 400 milligrams daily was given during the 
post-transplantation conditioning-induced neutropenia. Primary prophylaxis for IA 
consisted of voriconazole 200 milligrams twice daily and was prescribed to patients 
with GVHD who were treated with second line anti-GVHD treatment. First line treatment 
consisted of voriconazole in case patients were not treated with primary prophylaxis 
beforehand.
definition of Ifd 
IFD was categorized as proven, probable or possible according to the revised European 
Organization for Research and Treatment of Cancer/Invasive Infectious Diseases Study 
Mycoses Group (EORTC/MSG) consensus criteria [19]. In addition, patients with appro-
priate host criteria and positive microbiological findings but with non-specific radiologi-
cal features were classified as non-classifiable disease. Although this category is not yet 
included in the EORTC/MSG definitions, these patients are treated similarly to those with 
probable IA given their similar outcome [20]. The same diagnostic protocol, which has 
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been described elsewhere [21], was used in the entire time period. If multiple periods of 
IA were suspected for a given patient, the period with the highest IA classification was 
selected.
definitions of potential risk factors
To assess renal and hepatic impairment as risk factors for IA, the highest levels of 
creatinine, bilirubin and alanine aminotransferase (ALAT) in the 1-month observation 
period were used. To grade hepatic impairment, we used and modified the Common 
Terminology Criteria for Adverse Events (version 4) of the National Cancer Institute 
[22]. Hepatic impairment was graded after the highest grade for total bilirubin or ALAT 
level. Pulmonary comorbidity was based on the pulmonary function testing that was 
performed as a standard procedure prior to alloHSCT and categorized according to 
the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) [23]. Neutropenia 
was defined as a neutrophil count of <0.5x109/l for 10 consecutive days or more and 
lymphocytopenia as a lymphocyte count of <1.0x109/l. Acute and chronic GVHD were 
defined according to the updated Glucksberg classification and National Institutes of 
Health Consensus, respectively [24,25]. All patients were categorized according to the 
EBMT risk score [26]. For the use of corticosteroids, the cumulative dose in milligrams of 
prednisolone was calculated in the indicated time frame. 
statistical analysis
Statistical analysis was performed using IBM® SPSS (version 21) and Stata (version 13). 
Clinical characteristics were analyzed using Chi-square test or Mann-Whitney U test as 
appropriate. We used a backward likelihood logistic regression to determine potential 
risk factors for IA. A p-value of <0.05 was considered statistically significant. 
results 
In total, 663 patients received their first alloHSCT between January 2004 and December 
2014. The median age at alloHSCT was 52.8 years (range 16.7 to 71.1). The most frequent 
underlying hematological disease was acute leukemia (53.5%), followed by lymphoma 
(11.9%), myelodysplastic syndrome (9.2%), myeloproliferative neoplasms (8.6%), plasma 
cell neoplasm (6.9%), chronic lymphocytic leukemia (4.7%) and other hematological 
disorders (5.1%). The mean follow-up was 39.8 months (range 0 to 134.5). 
Proven, probable, possible or non-classifiable IA was found in 109 (16.4%) recipients 
after 12 months post-alloHSCT and overall in 137 (20.7%)(table 1). Over a period of 10 
years, the 12-month incidences of IA ranged from 6.4% to 33.3% per alloHSCT year 
(p<0.01)(table 2). An increase in the incidence was observed in 2012 and 2013 (figure 
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1). The 12-month incidences in matched related, matched unrelated and cord blood 
alloHSCT were 11.8%, 17.4% and 27.3% (p<0.01), respectively. The mean time from al-
loHSCT to development of IA was 266 days with a range of 9 to 2093 days (figure 2). In the 
total cohort, the all-cause mortality 12 months after alloHSCT was 29.1% and the overall 
all-cause mortality was 45.2%. Patients with proven, probable and non-classifiable IA 
had a higher mortality in compared to patients without IA at 12 months (45.6% versus 
26.2%; p-value<0.001) as well as in overall (63.1% versus 41.1%; p-value<0.001). The IA-
related mortality was 26.3% (36/137). Figure 3 shows the cumulative incidence of NRM 
with relapse as competing risk of patients with IA versus those without IA (NRM at 5 
years 49±5% versus 16±2%, respectively, p<0.001).
table 1. Invasive aspergillosis (IA) after allogeneic hematopoietic stem cell transplantation (alloHSCT) per 
donor type.
Classification 
of IA
number of patients (%) at 12 months
number of patients (%) in entire follow-up 
time or end of the study
total
n = 663
matched 
related
n = 270
matched 
unrelated
n = 305
Cord 
blood
n = 88
total
n = 663
matched 
related
n = 270
matched 
unrelated
n = 305
Cord 
blood
n = 88
IA (all) 109 (16.4) 32 (11.9) 53 (17.4) 24 (27.3) 137 (20.7) 43 (15.9) 68 (22.3) 26 (29.5)
Proven 12 (1.8) 2 (0.7) 5 (1.6) 5 (5.7) 13 (2.0) 2 (0.7) 6 (2.0) 5 (5.7)
Probable 49 (7.4) 12 (4.4) 29 (9.5) 8 (9.1) 58 (8.7) 15 (5.6) 34 (11.1) 9 (10.2)
Possible 23 (3.5) 11 (4.1) 6 (2.0) 6 (6.8) 34 (5.1) 15 (5.6) 12 (3.9) 7 (8.0)
non-classifiable 25 (3.8) 7 (2.6) 13 (4.3) 5 (5.7) 32 (4.8) 11 (4.1) 16 (5.2) 5 (5.7)
no IA 554 (83.6) 238 (88.1) 252 (82.6) 64 (72.7) 526 (79.3) 227 (84.1) 237 (77.7) 62 (70.5)
table 2. Invasive aspergillosis (IA) after allogeneic hematopoietic stem cell transplantation (alloHSCT) per 
transplantation year.
Classification 
of IA
number of patients (%) per year of alloHsCt
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
IA 
Possible 0 0 3
(5.1)
1
(1.8)
1
(1.9)
0 2
(4.2)
3
(4.2)
3
(4.9)
8
(10.7)
Probable 6
(9.8)
1
(2.1)
1
(1.7)
3
(5.4)
1
(1.9)
2
(2.9)
4
(8.3)
5
(7.0)
6
(9.8)
13
(17.3)
Proven 2
(3.3)
0 1
(1.7)
0 1
(1.9)
3
(4.4)
0 2
(2.8)
2
(3.3)
0
non-classifiable 1
(1.6)
2
(4.3)
1
(1.7)
4
(7.1)
1
(1.9)
2
(2.9)
1
(2.1)
2
(2.8)
3
(4.9)
4
(5.3)
no 52 
(85.2)
44
(93.6)
53
(89.8)
48
(85.7)
50
(92.6)
61
(89.7)
41
(85.4)
59
(83.1)
47
(77.0)
50
(66.7)
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figure 1. Incidence in percentage of invasive aspergillosis at 12 months per year of allogeneic hematopoi-
etic stem cell transplantation. Arrow: In mid-2011, a long-lasting demolition and construction of a neigh-
boring hospital building started at the site where patients underwent their allogeneic hematopoietic stem 
cell transplantation.
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figure 2. Time distribution from allogeneic hematopoietic stem cell transplantation to diagnosis of inva-
sive aspergillosis (IA), invasive mucormycosis (IM) and invasive candidiasis (IC).
Aspergillus cultures were positive in 59 of the 103 patients with proven, probable or 
non-classifiable IA. Three cultures were isolated from lung biopsies, 1 from sinus biopsy, 
1 from cerebral abscess and the remaining from respiratory specimens (sputum and/or 
bronchoalveolar lavage). A. fumigatus was found most commonly (n=53), followed by 
A. terreus (n=4), A. flavus (n=2) and A. niger (n=1). Two patients had a co-infection with 
an A. fumigatus and A terreus. Cultures with azole-resistant A. fumigatus were detected 
in 6 patients with proven (n=1), probable (n=3) and non-classifiable IA (n=2), and were 
isolated in the period of 2011 to 2014. Two of the 6 (33%) patients infected with an 
azole-resistant A. fumigatus died within 6 weeks after diagnosis.
IFD other than IA was found in 13 patients, of whom 11 within 12-months post-trans-
plantation. Eight patients developed invasive candidiasis (IC) due to C. albicans (n=4), 
C. glabrata (n=2), C. tropicalis (n=1) and C. species (n=2). One patient had a co-infection 
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with C. albicans and C. glabrata. Invasive mucormycosis was observed in 3 patients (all 3 
rhizomucor species). Two patients were diagnosed with proven IFD based on a positive 
biopsy, but no species was determined. Nine of these 13 patients were also diagnosed 
with IA, of whom 5 concurrently with the other IFD.
Within the total cohort, a nested case-control study was performed to determine the 
risk factors for IA. Figure 4 shows the inclusion for the nested case-control study. Thirty-
nine patients were excluded: 34 patients with possible IA, 4 with IFD other than IA, 1 who 
was already diagnosed with an IA before alloHSCT. Three more patients were excluded 
because of an uncertain diagnosis of IA as they recovered without antifungal treatment. 
Therefore, 103 potential cases and 518 potential controls were available. Matching 
yielded no controls for 4 cases. Consequently, 99 patients with IA (13 proven, 55 prob-
able and 31 non-classifi able) were matched to 198 controls according to age, year of 
alloHSCT and follow-up duration. The clinical characteristics of the nested case-control 
study are shown in table 3. Cases suff ered more often from renal and liver impairment, 
reactivation of CMV and neutropenia during the month preceding IA. Furthermore, 
acute or chronic GVHD and the use of systemic corticosteroids was signifi cantly higher 
in the group with IA. After performing a backward logistic regression, the following risk 
figure 3. Non-relapse mortality in patients with proven, probable and non-classifi able invasive aspergil-
losis (IA) versus patients without IA.
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factors were found: neutropenia, lymphocytopenia, pulmonary comorbidity, reactiva-
tion of CMV, creatinine >135 µmol/l and use of corticosteroids (table 4). A higher cumu-
lative dose of corticosteroids in the month preceding IA was associated with a higher 
risk for IA. Pre-transplant IA, acute and chronic GVHD were eliminated among others in 
the analysis. Patients receiving corticosteroid therapy and those with acute or chronic 
GVHD are a large overlapping population. Therefore, an extra analysis was performed to 
investigate the role of GVHD when acute and chronic GVHD were taken in one variable. 
Univariate analysis showed that the presence of any GVHD (acute GVHD grade II-IV or 
chronic moderate/severe GVHD) was associated with an odds ratio of 4.03 (95% CI 2.38 – 
6.81; p<0.001). However, when any GVHD was added to the existing model, it was again 
eliminated (OR 0.83, 95% CI 0.33 – 2.11; p=0.70), and the same risk factors as described 
above remained significant.
526 no IA137 IA 
518 potential
controls
103 cases
198 matched 
controls99 cases
34 excluded
possible IA
4 excluded
no control
8 excluded
- 4 no IA, other IFD
- 1 IA  before alloHSCT, continued after alloHSCT
- 3 recovered from suspected IA without antifungals
663 alloHSCT patients
1:2 SPSS Matching
Age (+/- 5 years)
alloHSCT year (+/- 1 year)
Follow-up time control ≥ case
figure 4. Inclusion for azole therapy failure and 6-week mortality analysis.
AlloHSCT, allogeneic hematopoietic stem cell transplantation. IA, invasive aspergillosis. IFD, invasive fungal 
disease.
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table 3. Clinical characteristics of 297 allogeneic hematopoietic stem cell transplantation (alloHSCT) recipi-
ents included in the nested case-control study.
Patients without 
IAa
n = 198
Patients with proven, 
probable or non-
classifiable IAb
n = 99
p-value
Age at alloHsCt in years, median (range) 54.9 (20 – 70) 54.0 (21 – 71) 0.889
male sex, n (%) 110 (55.6) 59 (59.6) 0.507
underlying disease, n (%) 0.315
Acute leukemia 102 (51.5) 42 (42.4)
Lymphoma 26 (13.1) 14 (14.1)
Other 70 (35.4) 43 (43.4)
donor type, n (%) 0.071
Matched related donor 76 (38.4) 26 (26.3)
Matched unrelated donor 99 (50.0) 55 (55.6)
Cord blood 23 (11.6) 18 (18.2)
myeloablative conditioning, n (%) 33 (16.7) 17 (17.2) 0.883
use of anti-thymocyte globulin during 
conditioning, n (%)
45 (22.7) 22 (22.2) 0.922
Proven, probable, non-classifiable or possible IA 
before alloHsCt, n (%)
28 (14.1) 14 (14.1) 1.000
serum creatinine >135 umol/l, n (%) 38 (19.2) 37 (37.4) 0.001
Hepatic impairment, n (%) <0.001
ALAT and bilirubine < upper normal limit 66 (33.3) 8 (8.1)
ALAT and/or bilirubine grade I 73 (36.9) 30 (30.3) 0.262
ALAT and/or bilirubine grade II 33 (16.7) 23 (23.2) 0.173
ALAT and/or bilirubine grade III - IV 26 (13.1) 38 (38.4) <0.001
moderate or severe pulmonary comorbidity, n 
(%)
69 (34.8) 49 (49.5) 0.015
Cmv reactivation, n (%) 5 (2.5) 21 (21.2) <0.001
neutropenia of ≥10 days, n (%) 11 (5.6) 25 (25.3) <0.001
lymphocytopenia, n (%) 118 (60.2) 90 (91.8) <0.001
Cd3+ t cells, median (range) 0.442 (0.005 - 5.319) 0.337 (0.000 - 2.218) 0.006
Acute gvHd, n (%) <0.001
No acute GVHD or acute GVHD grade I 181 (91.4) 72 (72.7)
Grade II - IV 17 (8.6) 27 (27.3)
Chronic gvHd, n (%) 0.009
No chronic GVHD or limited chronic GVHD 175 (88.4) 76 (76.8)
Moderate or extensive 23 (11.6) 23 (23.2)
use of corticosteroids (prednisolone equivalent 
dose in milligrams), n (%)
<0.001
0 127 (64.1) 21 (21.2)
1 to 1500 59 (29.8) 34 (34.3) 0.393
>1500 12 (6.1) 43 (43.4) <0.001
Insufficient data 0 1 (1.0) -
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table 4. Risk factors for developing invasive aspergillosis after allogeneic hematopoietic stem cell trans-
plantation according to backward likelihood logistic regression analysis.
variable odds ratio (95% CI) p-value
Neutropenia 16.26 (5.64 - 46.71) 0.000
Lymphocytopenia 5.70 (1.88 - 17.31) 0.002
Reactivation of cytomegalovirus 5.27 (1.36 - 20.36) 0.016
Creatinine >135 µmol/l 2.48 (1.10 - 5.57) 0.028
Moderate / severe pulmonary comorbiditiy 2.67 (1.22 - 5.85) 0.014
Use of prednisolone 
1 to 1500 milligrams 4.06 (1.62 - 10.16) 0.003
>1500 milligrams 45.05 (14.35 - 141.42) 0.000
dIsCussIon
In this retrospective study of 663 alloHSCT recipients, we found an incidence of proven, 
probable, non-classifiable IA of 13.0% within the 12-months after transplantation and 
15.5% in the entire follow-up time available. As expected, all-cause mortality was signifi-
cantly higher in patients with than without IA. Moreover, the independent risk factors 
for IA we observed were neutropenia, lymphocytopenia, pulmonary comorbidity, CMV 
reactivation, renal impairment and the use of systemic corticosteroids. A higher cortico-
steroid use was associated with a higher risk of IA. 
The incidence, mortality and risk factors of IA were investigated in recipients who 
received their alloHSCT in our hospital over a decade. Only the period with the highest 
IA classification per patient was registered. Therefore, the true incidence of IA may be 
underestimated as some patients were treated with antifungal therapy more than once. 
Previous studies reported mostly on the incidences of proven and probable IA. In the 
table 3. Clinical characteristics of 297 allogeneic hematopoietic stem cell transplantation (alloHSCT) recipi-
ents included in the nested case-control study. (continued)
Patients without 
IAa
n = 198
Patients with proven, 
probable or non-
classifiable IAb
n = 99
p-value
ebmt risk score, n (%) 0.122
0 to 2 52 (26.3) 18 (18.2)
3 to 7 146 (73.7) 81 (81.8)
a No IA was defined as no proven IA, no probable IA, no non-classifiable IA or no possible invasive fungal 
disease.
b IA, invasive aspergillosis. Proven and probable IA was defined according to the revised European Orga-
nization for Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/
MSG) criteria. Non-classifiable is defined as a patient with EORTC/MSG host and microbiological criteria 
fulfilled and a pulmonary infiltrate without a halo or air-crescent or well-defined nodule. 
30 Chapter 2
current study, we found a 12-month and overall incidence of proven and probable IA 
of 9.2% and 10.7% respectively. These observed incidences fall within the previously re-
ported incidences of 12-month (2.3% to 7.4%) and overall (2.5% to 15%) risk respectively 
[1-4,6-8,10]. A significant increased incidence was found among recipients of alternative 
donor transplants. This observation was also seen in other studies [3,5,8]. However, we 
did not find donor type to be an independent risk factor for developing IA in the nested 
case-control study. This may have to do with the smaller sample size of the nested case-
control group. Another interesting finding was that 20.4% of all the infections occurred 
after the first year of transplantation, indicating a continued risk in certain alloHSCT 
recipients, which has been previously described as well [1,6,11]. 
In 2012 and 2013, there was a significant increase in the incidence of IA. There may 
be different reasons for this observation. First, a long-lasting demolition and renovation 
of a neighboring hospital building was initiated from 2011 onwards at one of the two 
sites where all alloHSCT patients were transplanted and followed after alloHSCT. Hos-
pital constructions or demolitions have been associated with increased IA in patients 
with underlying hematological disease [27,28]. Second, azole resistance has emerged 
over the past decade [29]. A recent study found 16.2% resistance against voriconazole 
in cultures of A. fumigatus that were isolated between 2011 to 2013 from high-risk 
patients of a Dutch tertiary referral hospital [30]. In our total cohort, 6 recipients had 
probable or non-classifiable IA due to azole-resistant A. fumigatus. As fungal cultures 
often remain negative and because antifungal susceptibility testing was not a standard 
procedure in the first half of the observation period, the actual number of patients 
infected with azole-resistant A. fumigatus may have been higher. As primary prophylaxis 
with triazoles will not prevent azole-resistant IA, the emergence of azole resistance may 
have contributed to the increased incidence in IA as well. Formerly, primary prophylaxis 
was prescribed in our center to alloHSCT recipients with GVHD who were treated with 
second line anti-GVHD treatment. More recently, it was extended to patients who are 
treated with high-dose systemic corticosteroid therapy.
Patients with proven, probable or non-classifiable IA had a significantly higher 
mortality compared to patients without IA in the total cohort. In the total cohort, we 
found an IA-related mortality (=6-week mortality after diagnosis of IA) of 26.3%. Two 
other studies have described the mortality 6 weeks after diagnosis of IA: Neofytos et al. 
found a comparable 6-week mortality of 21.5%, but the 6-week mortality observed by 
Nucci et al. was substantially higher (63%) [8,11]. However, the population studied by 
these authors has been a more heterogeneous group of patients, including recipients of 
autologous hematopoietic stem cell transplantation. 
To investigate potential risk factors for IA, we performed a nested case-control study 
within the total patient cohort. Except for lymphocytopenia and CD3+ T cells, all variables 
that changed over time were assessed in the month before diagnosis of IA in cases and 
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in the same time-frame post-alloHSCT in the controls. This design was chosen to ensure 
that the identified time-varying risk factors really contributed to IA. It is similar to the 
study design of Corzo-León et al. [1], except that our cases also consisted of recipients 
with non-classifiable IA in addition to those with proven and probable IA. We think it is 
correct to include non-classifiable IA cases as well because they have the same outcome 
and are treated in the same way as patients with probable or proven IA [20]. Neutrope-
nia, lymphocytopenia, pulmonary comorbidity, reactivation of CMV, renal impairment 
and use of prednisolone were found to be independent risk factors. Moreover, the use 
of a higher dose of prednisolone was associated with a higher risk for developing IA, 
suggesting that the effect of prednisolone on IA is dose dependent. Neutropenia, CMV 
reactivation and corticosteroid use have been previously described as important risk 
factors for IFD [2,6,12,16,17]. However, this study is the first to identify renal impairment 
as an independent risk factor for IA [1,11,16]. Remarkably, and in contrast to some of the 
other studies, the diagnoses of pre-transplantation IA or acute/chronic GVHD were not 
found to be independent risk factors [1-3,6,9,10,12,16]. Perhaps pre-transplant IA was 
not found to be risk factor, because patients with pre-transplant IA are often treated 
with secondary prophylaxis during alloHSCT. Also, selection bias may partially explain 
this finding because a subset of patients in need for an alloHSCT with uncontrolled IA 
may no longer be eligible for the transplantation. GVHD was analyzed as acute and 
chronic GVHD and in an additional analysis as one single variable, but was not found to 
be a risk factor. As patients with acute or chronic GVHD are almost always treated with 
corticosteroids, these variables are strongly associated. GVHD did not remain significant 
in the final model presumably because of the stronger effects of corticosteroids. The risk 
further increased when the cumulative dose of corticosteroids increased. 
The major limitation of this study was its single-center and retrospective design. 
Therefore, the analysis of potential risk factors was limited to the available variables 
and population size. Ideally, a multi-center prospective study should be performed to 
determine the incidence, mortality, risk factors and the impact of primary prophylaxis. 
Especially the efficacy of primary prophylaxis should be evaluated in due time in the 
light of increasing azole resistance. However, this would have its own challenges as the 
policies of primary prophylaxis after alloHSCT differ among the Dutch transplantation 
hospitals and may change if the incidence of azole resistance continues to increase over 
the coming years. 
In conclusion, an incidence of proven, probable and non-classifiable IA was found 
of 13.0% at 12-months post-transplantation and 15.5% in overall. Mortality was signifi-
cantly higher in patients with IA than those without. Different independent risk factors 
were found: neutropenia, lymphocytopenia, pulmonary comorbidity, reactivation of 
CMV, renal impairment and use of prednisolone. The results are important as it may help 
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clinicians in starting or adjusting antifungal prophylaxis in the appropriate patient at 
the correct time.
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AbstrACt
background
Chemotherapy-induced neutropenia can be complicated by invasive pulmonary 
aspergillosis (IPA). In 2008, liposomal amphotericin-B (L-AmB) inhalation was shown to 
prevent IPA in a placebo-controlled trial. Patients with acute myeloid leukemia (AML) 
are the subset of hematology patients at high risk for IPA. In 2008, L-AmB inhalation 
prophylaxis became standard of care for all AML patients in Erasmus University Medical 
Center. In this study, the efficacy and cost-effectiveness of L-AmB inhalation were evalu-
ated in a prospective cohort of AML patients. 
methods
In total, 127 consecutive AML patients received chemotherapy and prophylactically 
inhaled L-AmB during their 1st and 2nd chemotherapy cycles; 108 patients treated for 
AML at the same sites from 2005 to 2008 served as controls. A standardized diagnostic 
protocol was used and probable/proven IPA served as the primary endpoint. Diagnostic 
and therapeutic costs were also comprehensively analyzed and compared. 
results
A significant decrease in probable/proven IPA in the L-AmB inhalation group was ob-
served (L-AmB 9.5%, control 23.4%, p=0.0064). Systemic antifungal therapy given at 
any time during the entire AML therapy decreased from 52.8% to 29.9%. Per patient 
equipment and drug costs for the L-AmB inhalation (1292 euro/patient) were more than 
compensated by a decrease in costs for diagnostics and therapeutic voriconazole use 
(minus 1816 euro/patient). No L-AmB inhalation related serious adverse events were 
observed. 
Conclusion
In an unselected AML patient group, L-AmB inhalation resulted in a significant and 
substantial decrease in IPA and was cost saving. Now that azole resistant becomes more 
frequent, non-azole based prophylaxis may become an attractive strategy. 
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IntroduCtIon
Patients with acute myeloid leukemia (AML) treated with high-dose chemotherapy are at 
high risk for invasive pulmonary aspergillosis (IPA), which is associated with an increased 
morbidity and mortality [1,2]. Moreover, IPA increases the medical cost substantially: the 
mean additional per-patients costs are 8360 euros for possible IPA and 15280 euros for 
probable/proven IPA [3]. Given these observations and the fact that hospital resources 
are finite, preventing IPA is an attractive strategy to reduce mortality and IPA-related 
costs.
Administration of aerosolized liposomal amphotericin-B (L-AmB) is a promising 
candidate in preventing IPA. Aspergillus fumigatus conidia are inhaled and germinate in 
the lungs; therefore delivering aerosolized L-AmB directly to this site of infection may 
prevent IPA. A significant decrease in IPA was shown when inhaling L-AmB compared to 
placebo in a randomized controlled trial (RCT) [4]. No impaired lung function measure-
ments or systemic side effects due to L-AmB inhalations were observed [5]. 
In 2008, prophylactic L-AmB inhalation was implemented as standard of care for AML 
patients of the Erasmus University Medical Center (Rotterdam, the Netherlands). In this 
prospective cohort study, the efficacy and cost-effectiveness of L-AmB inhalations on 
the incidence of IPA were evaluated in an unselected real-life AML population. 
metHods
Patient population 
This study was performed at the Erasmus University Medical Center, a university referral 
hospital in Rotterdam, the Netherlands. We studied hospitalized patients with newly 
diagnosed or relapsed AML, myelodysplastic syndrome (MDS) with excess of blasts 
or chronic myeloid leukemia (CML) in blast crisis, who were aged ≥18 years and were 
treated during the period of September 2008 through August 2012. Patients were 
included after providing written informed consent. All patients were treated with remis-
sion induction and consolidation chemotherapy according to the Hemato-Oncology 
voor Volwassenen Nederland (HOVON) guidelines [6,7]. The following information was 
obtained: age, sex, number of chemotherapy cycles, type of hematopoietic stem cell 
transplantation (HSCT), duration of neutropenia, mortality and invasive fungal disease 
(IFD). Patients were excluded if they had proven, probable or possible IPA before start 
of the prophylactic inhalation therapy. The control group consisted of 108 historical pa-
tients with AML, MDS or CML treated with high-dose chemotherapy during the period of 
April 2005 through April 2008. Control patients did not receive prophylactic inhalation 
therapy and were not included in the L-AmB inhalation group if hematologic disease 
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relapsed on a later point in time. Both groups received prophylaxis with oral fluconazole 
400 milligrams daily (or intravenous when oral intake was impossible). The institutional 
review board approved the study. According to the diagnostic protocol for evaluation of 
neutropenic fever, patients underwent high-resolution computed tomography (HRCT) 
at day 5 of unexplained fever despite treatment with antibiotics. HRCT was repeated 5-7 
days later if fever persisted. Patients with intrapulmonary lesions underwent broncho-
scopically-guided bronchoalveolar lavage (BAL) of the most representative lung lesion. 
BAL fluid was cultured for bacteria, mycobacteria and fungi, as well as measurement of 
galactomannan antigen levels. A galactomannan level of ≥0.5 in BAL fluid was consid-
ered positive. If bronchoscopy was impossible to perform because of the location or 
small size of the lung lesion and serum galactomannan was negative (<0.5), a biopsy of 
the lung lesions was performed if feasible. Voriconazole was the first-line therapy for IPA. 
l-Amb inhalation
Prophylactic inhalation of 12.5 milligrams L-AmB (AmBisome; Gilead Sciences Europe 
Ltd., Uxbridge, UK) was used twice a week and was initiated at the start of the 1st remission 
induction chemotherapy cycle. Nebulization of L-AmB was performed with an adaptive 
aerosol delivery (AAD) system (Prodose® AAD nebuliser from 2008 to 2011, Akita® AAD 
nebuliser from 2011; Romedic, Meerssen, the Netherlands). Both are advanced nebulizer 
systems that adapt to individual breathing patterns, nebulizing only during inspiration 
and therefore the intrapulmonary delivery of the prescribed dose was guaranteed. They 
generate particles with a mean diameter of 1.9 µm; optimal deposition in the peripheral 
lung regions is therefore ensured. Inhalation was continued until neutrophil recovery, 
which was defined as two consecutive neutrophil counts ≥0.2 x109/l or one ≥0.5 x109/l, 
after which patients were discharged from the hospital. It was re-initiated during the 
next chemotherapy cycle until neutrophil recovery. Inhalation therapy was not contin-
ued during autologous or allogeneic HSCT following chemotherapy.  
IPA classification
IPA was categorized according to the updated criteria of the European Organization for 
Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) [8]. Neutropenic 
patients are considered to have possible IPA if a new and otherwise unexplained well-
defined intrapulmonary nodule (with or without halo sign), an air-crescent sign, or a 
cavity within an area of consolidations is radiologically documented. Probable IPA is 
diagnosed when on top of these radiological findings microbiological proof of Aspergil-
lus fumigatus infection is documented by galactomannan antigen detection or cultures 
of Aspergillus fumigatus. Proven IPA is defined as histopathologic evidence of invasive 
mold infection and microbiological proof of Aspergillus fumigatus infection. Patients 
with more than 1 episode of IPA during hematological treatment were classified accord-
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ing to the highest diagnostic IPA category (e.g., a patient with possible IPA during the 
1st cycle of chemotherapy but probable IPA at a later point in time was categorized as 
having probable IPA). In addition, patients who could not be categorized into possible, 
probable or proven IPA but were treated with antifungal therapy were subdivided into 
the following categories: patients with nonspecific intrapulmonary abnormalities with 
positive galactomannan antigen detection, patients with nonspecific intrapulmonary 
abnormalities with negative galactomannan antigen detection, and patients with nor-
mal CT and negative galactomannan antigen detection. IFD was defined as a culture or 
biopsy proven infection with a yeast or non-Aspergillus mold.
Primary endpoint
The primary endpoint was the incidence of proven or probable IPA during 1st and 2nd 
cycles of chemotherapy until 28 days after neutrophil recovery. 
secondary endpoints
Secondary endpoints were (1) the incidence of proven or probable IPA 12 weeks after 
the end of all hematological treatment (including HSCT) (2) the incidence of proven, 
probable or possible IPA 12 weeks after at the end of all hematological treatment (in-
cluding HSCT) (3) the incidence of proven, probable or possible IPA during the 1st and 
2nd cycles of chemotherapy (4) overall and IPA-related (=attributable) mortality 12 weeks 
after recovery from neutropenia from the last chemotherapy cycle.
Cost calculations
All costs were studied from a hospital perspective. Costs taken into account were the 
total hospital-based costs per patient. We distinguished diagnostic costs, costs for medi-
cal treatment, costs for hospital stay, and costs for the transfusion of blood products. 
Diagnostic costs taken into account were radiological imaging, microbiological investi-
gations (blood cultures, staining and cultures of BAL fluid specimens, and galactoman-
nan antigen measurement in serum or BAL fluid specimen) and other diagnostics, e.g. 
bronchoscopy, pathology, colonoscopy, gastroscopy, echocardiogram. Costs of the 
medical treatment included costs for antifungal and antibiotic treatment, and costs for 
L-AmB inhalations. Costs of transfusions included costs for erythrocytes, thrombocytes, 
and/or fresh frozen plasma. Included extramural costs were all costs mentioned above 
when they occurred between the 1st and 2nd cycle of chemotherapy. The extramural costs 
after the 2nd chemotherapy cycle were limited to antifungal costs only and no longer 
than 4 weeks after discharge of the 2nd chemotherapy cycle. This was done so to avoid 
bias as patients that subsequently undergo a 3rd chemotherapy cycle will get this 3rd 
cycle (and its accompanying diagnostics and transfusion costs) within 1 or 2 weeks after 
the 2nd chemotherapy cycle, while an allogeneic transplantation will generally take place 
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later in time. The evaluation was patient based and started from day 1 of hospitalization 
of the 1st cycle of high dose chemotherapy for newly diagnosed or relapsed AML, MDS 
with excess of blasts or CML in blast crisis, which means that for each patient the costs of 
the 2 consecutive treatment episodes were totaled. 
In the Netherlands, a detailed fee-for-service system is used for the remuneration of 
the medical interventions and diagnostic procedures, enabling the calculation of the 
costs. Therefore, medical costs were calculated by multiplying the volumes of health 
care use per patient with the corresponding official Euro unit prices for each diagnostic 
or therapeutic procedure. For drugs, the actual number of milligram administered was 
multiplied by the costs per milligram, as charged by the hospital pharmacy. The costs 
for inpatient days were calculated by multiplying the number of days with the unit price 
as charged for a nursing ward or intensive care unit (ICU), counting the hotel costs only. 
To be able to compare the costs between groups in an unbiased way, the cost cal-
culations for the primary analysis were limited to the first two chemotherapy cycles. 
The reasons that we could not include the AML therapy that followed (e.g. 3rd chemo-
therapy cycle, HSCT) are threefold. Firstly, over the 7 years of the study period the risk 
classification of AML changed substantially which resulted in a shift of patients from the 
intermediate to the high risk AML category. The consequence is that more patients in 
the L-AmB group underwent an allogeneic HSCT (36% versus 26%). Secondly, if L-AmB 
inhalation is indeed effective and therefore reduces the incidences of IPA, it will also 
have an impact on the AML therapy given after the 1st and/or 2nd chemotherapy cycle 
because patients that have an IPA during the 1st or 2nd chemotherapy cycle will be less 
likely to undergo an allogeneic HSCT. Thirdly, prophylaxis with L-AmB inhalations was 
only given to patients admitted to the hospital during AML therapy. During the 1st and 
2nd chemotherapy cycles all patients stayed in the hospital until neutrophil recovery. In 
contrast, only part of the patients stayed in the hospital for the 3rd chemotherapy cycle. 
statistical analysis 
Baseline characteristics and incidence of IPA and IFD were tested with the independent 
sample t-test or Fisher’s exact test as appropriate. Cost difference between the control 
group and L-AmB group were analysed using the Mann-Whitney U test. Since cost data 
per patient (but not per day care) are typically highly skewed, we used nonparametric 
bootstrap techniques to derive a 95% confidence interval for the differences in distribu-
tions of the direct medical costs. For the analysis of IPA incidence during all AML therapy 
(including 3rd chemotherapy cycle or HSCT), patients were censored 3 months after 
hospital discharge from the last AML treatment episode. For the primary endpoint a 
2-sided P value <0.05 was considered to be statistically significant. Analyses were done 
with SPSS version 20. GMC, SP and BJAR analyzed the data. 
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results
From September 2008 through August 2012, 127 patients in the L-AmB group received 
high dose chemotherapy or a HSCT during 310 treatment episodes. 226 of these were 
for the 1st or 2nd cycle of chemotherapy. The control group consisted of 108 historical 
patients who were treated during the period of April 2005 through April 2008 and had in 
total 262 treatment episodes. 200 of these were for the 1st or 2nd cycle of chemotherapy. 
Two patients, 1 of the control group and 1 of the L-AmB group, could not be included 
in the cost-calculation population as they had an unusual combination of AML therapy 
during 1 hospital admission (1 patient had the 1st, 3rd chemotherapy cycle and HSCT in 
1 treatment episode, and 1 patient had the 1st chemotherapy cycle and HSCT in 1 treat-
ment episode). From 3 patients only the 1st chemotherapy cycle could be included in the 
cost-calculation population as they had their 2nd chemotherapy cycle combined with 
an allogeneic HSCT in the same hospital admission (1 L-AmB and 2 controls). Baseline 
characteristics of the study groups are summarized in table 1. 
table 1. Characteristics of the cohort of 233 patients with acute myeloid leukaemia-myelodysplastic syn-
drome treated with high dose chemotherapy.
 Characteristics Control group
n = 108
l-Amb 
inhalation group
n = 127
p-value
Age, mean years (range) 52.1 (20.2 - 76.9) 55.7 (20.4 - 79.7) 0.051
Male gender, n (%) 61 (57.0%) 67 (53.2%) 0.5983
Diagnosis, n (%) >0.1
  Acute myeloid leukaemia 90 (83.3%) 113 (89.0%)
  Myelodysplastic syndrome with excess of blasts 18 (16.7%) 12 (9.5%)
  Chronic myeloid leukaemia in blast crisis 0 2 (1.6%)
Mean duration neutropenia per chemotherapy treatmenta, n (%) 0.1
  <10 days 0 1 (0.8%)
  ≥10 – 20 days 14 (13.2%) 17 (13.6%)
  ≥20 days 92 (86.8%) 107 (85.6%)
a Neutrophil count <0.5 x109/l or leucocyte count <1.0 x109/l. 
The incidence of IPA during the 1st and 2nd cycles of chemotherapy is given in table 2. 
Twenty-five patients (23.4%) in the control group developed probable or proven IPA versus 
12 patients (9.5%) in the L-AmB group, a significant decrease in probable or proven IPA 
(p=0.0064). In a separate analysis, the incidence of probable or proven IPA according to 
treatment episode was analysed for the entire cohort of 235 patients and included all IPA 
cases diagnosed until 3 months after all therapy had been completed, including HSCT if ap-
plicable (table 3). During the 1st chemotherapy cycle, 16 of 108 patients in the control group 
developed probable or proven IPA versus 10 of 127 patients in the L-AmB group (p=0.1). In 
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total, 92 patients in the control group received the 2nd chemotherapy cycle and 99 patients 
in the L-AmB group. During the 2nd chemotherapy cycle, control patients developed IPA 
significantly more often than L-AmB patients (p=0.0246). The difference in IPA numbers 
in table 2 versus table 3 is explained by the fact that 6 patients with IPA were excluded 
from table 2 (2 patients with unusual combination of chemotherapy in 1 hospital stay as 
mentioned above, 1 patient receiving the 2nd chemotherapy cycle combined with HSCT in 
1 hospital stay, and 3 patients who developed IPA during or shortly after their HSCT). 
table 2. Incidence of IPA and IFI during 1st and 2nd cycles of chemotherapy according to control versus L-
AmB inhalation group.
 Category Control group
n = 107
l-Amb 
inhalation group
n = 126
p-value
Count % Count %
IPA
  Probable or proven IPA 25 23.4% 12 9.5% 0.0064
  No IPA and no antifungal therapy 54 50.5% 92 73.0% 0.0004
  Possible/probable/proven  34 31.8% 18 14.3% 0.0014
    Possible IPA (specific abnormalities on CT but culture plus 
antigen negative)
9 8.4% 6 4.8%
  Treatment for nonspecific abnormalities on CT, culture or 
antigen positive
0 3 2.4%
  Treatment for nonspecific abnormalities on CT, culture or 
antigen negative
10 9.3% 10 7.9%
  Empirical therapy (CT normal, antigen negative) 9 8.4% 3 2.4%
IFD
  No IFD 101 94.4% 120 95.2% 1.0000
  Candida spp. 2 1.9% 3 2.4%
  Mucor spp. 2 1.9% 3 2.4%
  Other IFDa 2 1.9% 0
NOTE. IPA, invasive pulmonary aspergillosis. IFD, invasive fungal disease, excluding Aspergillus spp. CT, com-
puted tomography. 
a Other IFD, including Cladosporium-speciës, undefined fungal species.
table 3. Incidence of proven/probable invasive pulmonary aspergillosis (IPA) according to treatment.
 treatment Control group
n = 108
l-Amb inhalation group
n = 127
p-value
Overall 28/108 15/127 0.0066
1st chemotherapya 16/108 10/127 0.0994
2nd chemotherapya 11/92 3/99 0.0246
3rd chemotherapy 0/34 0/38 NA
Allogeneic HSCT 1/28 2/46 1.0000
NOTE. HSCT, hematopoietic stem cell transplantation. All 235 patients were used for this analysis, included 
patients who underwent HSCT. 
a Patients who had their 1st or 2nd chemotherapy cycle combined with another chemotherapy cycle or HSCT 
and developed proven/probable IPA are counted in the initial chemotherapy group.
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No difference in the incidence of IFD other than Aspergillus species was seen (table 
2). During the 1st and 2nd chemotherapy cycle, systemic antifungal therapy decreased 
from 49.5% to 27.0% (table 2). Systemic antifungal therapy given at any time during the 
entire AML therapy decreased from 52.8% to 29.9%. We did not observe any major safety 
issues and no treatment-related serious adverse events were seen. The incidence of ICU 
admission during the 1st or 2nd chemotherapy cycle was comparable in both groups 
(20 in controls, 23 in L-AmB). None of the ICU admissions in the L-AmB group could be 
related to L-AmB inhalation.
A detailed overview of all medical costs is given in table 4. The control group had 
higher costs related to diagnostics (1101 euro/patient, p<0.0001) and related to voricon-
azole therapy (715 euro/patient, p=0.0031) in comparison to the L-AmB group. There-
fore, the costs per patient for nebulization equipment and L-AmB drug acquisition (1292 
table 4. Mean medical costs (Є) per hospital admission and per patient, control versus L-AmB inhalation 
group.
Cost category Hospital admission for chemotherapy cycle p-values
Control group l-Amb inhalation group
1
n = 94
2
n = 77
1+2d
n=13
Total mean 
cost
n=107
1
n = 111
2
n = 83
1+2d
n=15
Total mean 
cost
n = 126
Total 
mean 
costs
Diagnostics
  Total 1625 1561 3789 3011 1237 963 1557 1910 0.0000
  Radiologic 622 539 1467 1113 502 345 588 739 0.0000
  Microbiologic 826 861 1801 1564 580 543 817 966 0.0000
  Othera 177 161 521 334 155 76 152 205 0.0082
Medication
  Total 2629 4251 7558 6287 4371 6107 4267 7530 0.4325
  Voriconazoleb 1144 1429 4492 2579 815 1469 1497 1864 0.0031
  L-AmB inhalation NA NA NA NA 1292 NA 1292 1292 NA
  Other antifungalsc 951 2370 1874 2769 1709 2955 647 3529 0.5524
  Antibiotics 533 453 1192 939 555 389 830 844 0.1553
Hospital stay 26231 28995 45146 49395 26698 26227 41994 45795 0.1046
Transfusions 7276 7071 15873 13409 7716 6383 11645 12388 0.1113
Total costs 37761 41878 72366 72102 40022 38388 59463 67624 0.2806
NOTE. NA, not applicable. Because costs are typically highly skewed, p-values were derived from 1000 non-
parametric bootstrap samples drawn with replacement.
a Other diagnostic costs (e.g., include bronchoscopy, pathology, colonoscopy, gastroscopy and echocar-
diogram).
b Voriconazole first 8 days intravenous, followed by oral voriconazole if oral intake was possible at that time.
c Increased other antifungal costs in L-AmB group were caused by intravenous L-AmB use in 6 patients 
(median 38 days).
d Group of patients who had their 1st and 2nd chemotherapy cycle in one hospital admission. 
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euro/patient) were more than compensated by the significant decrease in per patient 
costs of diagnostics and voriconazole therapy. The overall treatment costs per patient 
were 4478 euro/patient less in the L-AmB group. This was not significantly different from 
the control group because extreme outliers mainly drove this difference.
IPA-related death, defined as death within 6 weeks after IPA diagnosis was seen in 2 
patients (1.9%) in the control group versus 3 (2.4%) in the L-AmB group. During the 1st or 
2nd chemotherapy cycle, 14/107 patients (13.1%) died in the control group versus 15/126 
(11.9%) in the L-AMB group. The overall mortality 3 months after the end of all therapy 
was 19 (17.6%) in the control group versus 23 (18.1%) in the L-AmB group.
dIsCussIon
In 2008, the efficacy of inhaled L-AmB for the prevention of IPA was demonstrated in 
the context of a RCT. In 2010, this resulted in a BI recommendation for the use of this 
intervention in the European Conference on Infections in Leukaemia (ECIL) guidelines 
for AML patients during remission induction and consolidation chemotherapy [9]. It is 
difficult to predict how interventions work in real-life outside the context of a RCT. In 
this study we established the external validity of the RCT outcomes in a real-life AML 
patient population. Overall, the incidence of IPA was significantly higher in historical 
control patients than patients inhaling aerosolized L-AmB (23.4% versus 9.5%). No 
specific exclusion criteria were used apart from an already established IPA diagnosis at 
the time of AML diagnosis for which antifungal therapy instead of prophylaxis needed 
to be initiated. Apart from its efficacy, the use of L-AmB inhalation seems to be cost 
saving in regard to diagnostics and voriconazole therapy. These cost-savings more than 
compensated for the costs related to L-AmB inhalation itself. 
The difference in IPA incidence was more pronounced during the 2nd than the 1st 
chemotherapy cycle. This may be the result of undiagnosed IPA at baseline in a small 
number of patients for which systemic therapy rather than inhalation prophylaxis 
should have been given. Only a study in which a high-resolution CT is performed in all 
patients at baseline to exclude patients with pre-existent intrapulmonary lesions could 
confirm this. One wonders if prophylaxis with a broad spectrum azole during the first 7 
to 10 days may further reduce the IPA incidence during the 1st chemotherapy cycle. 
We did not observe any major safety issues. The incidence of ICU admissions 
was comparable in both groups and none of the ICU admissions in the L-AmB group 
could be related to L-AmB inhalation. Still, an easier and more convenient way to get 
amphotericin-B inside the lungs would be very welcome. An inhalation amphotericin-B 
powder was developed several years ago, has favourable pharmacokinetic properties 
Liposomal amphothericin-B inhalation in AML 47
and seems effective in an animal model [10]. Unfortunately, as far as we know no clinical 
trials are planned.
This study has some limitations. Considering that medicine evolves quickly, a time 
related bias might occur when controls are not from the same calendar year as cases. 
However, no considerable change has occurred in the chemotherapeutic agents that 
were used in the 1st and 2nd chemotherapy cycles during the study period of 2005 till 
2012. Secondly, the diagnostic procedures have remained unchanged throughout the 
study and therefore diagnostic bias is unlikely. 
We observed no difference in overall mortality 3 months after all therapy (including 
HSCT if applicable) between the L-AmB and control group. However, this comparison 
is likely to be confounded by indication as the chances of getting an allogeneic HSCT 
is less likely for patients with IPA and higher for patients in more recent years (due to a 
change in the AML risk classification). We also did not observe a decrease in the mortal-
ity attributable to IPA. This is not surprising, given the fact that IPA related mortality has 
decreased substantially with voriconazole therapy. It was estimated to be as low as 10% 
in a comparable AML patient population [3]. It is therefore not surprising that, despite 
the relatively large study population, no significant reduction in overall mortality was 
demonstrated. 
Other prophylactic regimes to prevent IA have been studied in hematological 
patients with prolonged chemotherapy-induced neutropenia and in allogeneic HSCT 
patients. Prophylaxis with posaconazole showed a significant decrease in IFD (including 
IA) in both of these patient groups [11,12]. Voriconazole and itraconazole as prophylaxis 
have been investigated in allogeneic HSCT patients. Voriconazole showed no difference 
in the incidence of IFD in comparison to fluconazole in patients undergoing allogeneic 
HSCT [13]. Itraconazole reduced the incidence of IFD [14] and invasive mold infections 
[15] in comparison to fluconazole. However, the itraconazole groups in these two 
studies suffered significantly more gastrointestinal intolerance and toxicity, limiting its 
success as prophylaxis. Low dose L-AmB at 50 milligrams intravenously every other day 
reduced the incidence of IFD (including IA) in hematological patients with prolonged 
chemotherapy-induced neutropenia [16]. However, the control group in this study did 
not receive fluconazole as anti-yeast prophylaxis. No nephrotoxicity was observed and 
few patients discontinued L-AmB prophylaxis because of skin rash and infusion-related 
fever. However, patients with renal insufficiency or liver dysfunction were excluded from 
participating in this study, whereas in our current study all patients were included except 
for those who had preexistent IA. Lastly, micafungin as prophylaxis has been studied 
in allogeneic HSCT patients during their neutropenic period [17]. The study showed 
that micafungin reduced the IFD incidence, but the reduction in IA was not statistically 
significant, possibly because micafungin was only administered during the hospital stay 
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(18 days on average). The cost-effectivity of these intravenously administered antifun-
gals remains to be demonstrated.  
Aspergillus fumigatus was cultured in five patients, all in the control group at a time 
when azole resistance testing was not performed as a routine procedure in our hospital. 
Azole susceptibility testing was performed in one of the five patients who developed 
probable pulmonary and cerebral aspergillosis during the 2nd chemotherapy cycle. He 
was treated with voriconazole and caspofungin. Despite treatment, patient deteriorated 
clinically and died of progressive IA. The isolate that was cultured from sputum showed 
resistance to itraconazole (minimum inhibitory concentration (MIC) 16 µg/ml) and 
voriconazole (MIC 8 µg/ml). In the new millennium, azole resistant Aspergillus fumigatus 
has become a significant problem in the Netherlands [18,19]. More recently, resistance 
was also observed in several other European countries [20-23]. This is probably the 
consequence of extensive agricultural azole use [24]. The use of L-AmB inhalation may 
therefore become an attractive option for the prevention of IPA when prophylactic as 
well as therapeutic azole use becomes less effective.
With the current study results available and together with the clinical trial data from 
2008, we think it is time to move forward and study the use of L-AmB inhalation in other 
patients at high risk for IPA, in particular in patients with serious graft versus host disease.
Prophylactic L-AmB inhalation administered twice a week to AML or MDS patients 
undergoing remission induction and consolidation chemotherapy resulted in a substan-
tial decrease in IPA incidence. Furthermore, the costs of inhalation therapy were more 
than compensated by a decrease diagnostic costs and voriconazole therapy costs, both 
of which decreased significantly. 
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AbstrACt
Introduction
Testing cerebrospinal fluid (CSF) for the presence of galactomannan (GM) antigen may 
help in diagnosing cerebral aspergillosis (CA). However, the use of CSF GM as a diagnos-
tic test never been validated. We evaluated its diagnostic performance by comparing 
the CSF GM levels at different cut-offs in patients with probable and proven CA to those 
without CA. 
methods
Patients from 2 tertiary referral hospitals with suspected CA between 2004-2014 and in 
whom CSF GM had been determined, were selected. EORTC/MSG definitions of invasive 
aspergillosis and CA were used but excluding the to-be-validated-test (=CSF GM) as a 
microbiological EORTC/MSG criterion. 
results
The study population consisted of 44 patients (4 proven CA, 13 probable CA and 27 no 
CA). Of the 17 patients with CA, 15 had a CSF GM of ≥2.0. In patients without CA, 26 of 
the 27 had a CSF GM of <0.5 and 1 had a CSF GM of 8.2. When a GM CSF cut-off level of 
1.0 was used, the sensitivity, specificity, positive and negative predictive values were 
88.2%, 96.3%, 93.8% and 92.9%, respectively. The same results were found when using a 
CSF GM cut-off of 0.5 or 2.0.
Conclusion
GM in CSF has a high diagnostic performance for diagnosing CA and may be useful to 
diagnose or virtually rule out the infection without the need for a cerebral biopsy. 
Galactomannan antigen testing in CSF 55
IntroduCtIon
Cerebral aspergillosis (CA) is a rare and often fatal invasive fungal disease (IFD) [1,2]. 
The diagnosis is challenging as radiological findings are non-specific and cerebrospinal 
fluid (CSF) cultures are only positive in less than one-third of the cases [3,4]. Moreover, 
obtaining brain tissue for histopathological examination, the diagnostic gold standard, 
is frequently not feasible. Galactomannan (GM) antigen detection in CSF is one of the 
microbiological criteria of the revised European Organization for Research and Treat-
ment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) criteria 
[5]. However, its diagnostic performance has been little studied. To date, only 3 studies 
totalling 25 patients have described the value of CSF GM, only 2 of which in patients 
with suspected CA [3,6,7]. In these 2 studies, CSF GM levels were higher in patients with 
than without CA, and sensitivity and specificity were 80% and 100% [6,7]. Based on 
these limited data, GM antigen test in CSF seems a promising test, even though no posi-
tive and negative predictive values (PPV, NPV) were determined, and no formal cut-off 
was established. This study evaluated the diagnostic performance of the Platelia™ GM 
antigen test (Bio-Rad, Marnes-la-Cocquette) in CSF of patients with suspected CA.
metHods
This retrospective study was performed at the Erasmus University Medical Center (Eras-
mus MC) in the Netherlands and University Hospitals Leuven (UZ Leuven) in Belgium. 
Patients in whom a CSF GM had been performed, were considered to be “suspected CA” 
and were selected. In the Erasmus MC, internal medicine, haematology and paediatric 
patients were selected from January 2004 to March 2015. In the UZ Leuven, internal 
medicine and haematology patients from May 2007 to December 2014 were retained. 
Data on age, sex, underlying disease, microbiology and radiology results were collected. 
Patients were excluded if no pulmonary or cerebral radiology was present, or no serum 
and BAL GM had been performed.
The diagnostic performance of the GM antigen test in CSF was evaluated by com-
paring the GM antigen level in CSF of patients with proven or probable CA to patients 
without CA. Patients with proven, probable or no CA were selected in two steps. First, 
invasive aspergillosis (IA) was defined or ruled out according to the revised EORTC/MSG 
criteria [5]. To avoid inclusion of the test that we wanted to validate (CSF GM) into the 
gold-standard, CSF GM was removed from the microbiology criteria. To avoid overlap 
between the definition of IA and CA, cerebral radiology was also excluded from the clini-
cal EORTC/MSG criteria. This was deemed necessary because otherwise patients with an 
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isolated serum GM ≥ 0.5 and a focal cerebral lesion (e.g. cerebral infarction) but without 
any other evidence of IA elsewhere would fit the probable CA definition. 
Subsequently, proven or probable CA was determined in patients with proven or 
probable IA. IA remains uncertain in patients with possible IA or in patients with only 
an isolated positive microbiological criterion but no clinical or radiological criterion. 
Therefore, these patients were excluded from the analysis. Probable CA was diagnosed 
when cerebral radiological signs compatible with IFD (e.g. focal lesions, meningeal 
enhancement) were present on top of a proven or probable IA elsewhere in the body. 
Proven CA was diagnosed when cerebral pathological evidence of IA or a positive CSF 
Aspergillus culture was present on top of the IA criteria. Patients with proven or prob-
able IA who had non-specific radiological cerebral signs (no focal lesion, no meningeal 
enhancement) were excluded from analysis. Patients classified as being without CA had 
no IA and did not have cerebral abnormalities or had a convincing alternative diagnosis 
for the cerebral abnormalities. Patients were only included once and those who had 
more than one episode of suspected CA, were classified according to the highest CA 
category. Per patient, only the CSF GM at diagnosis was included. 
The diagnostic performance of GM antigen in CSF were evaluated by comparing the 
GM antigen level at different cut-offs in proven and probable CA cases to those without 
CA. CSF GM levels were correlated with serum levels and CSF cultures. The independent 
t-test or Mann-Whitney-U test was used as appropriate to compare the CSF and serum 
GM values (IBM SPSS Statistics, version 21).
In addition, an extra sensitivity analysis was performed to look at the diagnostic per-
formance of CSF GM when cerebral radiology was not excluded from the clinical EORTC/
MSG criteria. For this sensitivity analysis, CSF GM cut-off of 1.0 was used.
results 
GM was determined in 205 CSFs of 157 patients. Eighty patients were excluded because 
of insufficient microbiology (n = 10), radiology (n = 47) or both (n = 23). Further, 12 
patients with possible IA, 9 with an isolated microbiology criterion and 12 with cerebral 
findings not compatible with IFD were excluded (figure 1). Therefore, the evaluable 
study population consisted of 44 patients (4 proven CA, 13 probable CA and 27 no CA). 
Table 1 shows the clinical, radiological and microbiological findings for those with CA. 
Fifteen of the 17 patients with CA had CSF GM ≥ 2.0. In the patients without CA, 26 had 
CSF GM <0.5 and 1 had CSF GM of 8.2. When a GM CSF cut-off level of 1.0 was used, the 
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sensitivity, specificity, PPV and NPV were 88.2%, 96.3%, 93.8% and 92.9% (table 2). The 
same results were found when a cut-off of 0.5 or 2.0 was used. With increasing cut-off 
values of 3.0 / 4.0 / 5.0, the sensitivity decreased to 76.5 / 70.6 / 58.8% (table 3). As a 
sensitivity analysis, we looked at the impact of including cerebral radiology in the clini-
cal EORTC/MSG criteria using a GM cut-off of 1.0; this decreased the sensitivity from 88.2 
to 76.0% (table 4). 
Total patients in whom CSF GM 
was determined
n = 157
77 in whom  IA could be diagnosed 
or excluded
11 proven IA
18 probable IA
21 possible IA or only microbiology 
criterion
27 no IA
80 excluded because of insufficient data
10 data microbiology incomplete
47 data radiology incomplete
23 data microbiology and radiology incomplete
33 excluded
21 possible IA or only microbiological criterion
12 cerebral findings not compatible with 
invasive fungal disease
44 proven / probable / no IA
6 proven IA
11 probable IA
27 no IA
44 proven / probable / no CAa
4 proven CA
13 probable CA
27 no CA
figure 1. Flowchart of the 44 patients with suspected cerebral aspergillosis (CA).
Two patients with proven IA had histopathological evidence of IA outside the cerebrum and therefore were 
classified as probable CA cases. CSF, cerebrospinal fluid; GM, galactomannan; IA, invasive aspergillosis.
Of the 17 CA patients, 3 were culture positive (2 CSF and 1 biopsy) and all grew A. 
fumigatus.
Serum GM was available in 16/17 patients with CA. CSF GM was higher than serum 
GM in 10 patients and lower in 1 patient with probable CA (table 1). The mean GM in 
CSF was higher than in serum (4.89 versus 3.72; p-value = 0.27). In the patients without 
CA, serum GM was available in 25/27 patients. CSF GM was higher than serum GM in 4 
patients, lower in 4 patients, and equal in the remaining 17 patients. The median GM was 
0.1 in CSF and 0.1 in serum (p-value = 0.77).
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table 2. Cerebrospinal fluid (CSF) galactomannan (GM) related to patients with suspected cerebral asper-
gillosis (CA).
Patients with CA Patients without CA total
Csf with positive gm 
(≥ 0.5 / 1.0 / 2.0)
15 1 16
Csf with negative gm 
(<0.5 / 1.0 / 2.0)
2 26 28
total 17 27 44
Sensitivity   = 15 / 17 = 0.8824
Specificity   = 26 / 27 = 0.9630
Positive predictive value  = 15 / 16 = 0.9375
Negative predictive value  = 26 / 28 = 0.9286 
table 3. Diagnostic performance of galactomannan (GM) in cerebrospinal fluid (CSF) according to different 
cut-offs.
  Cut-off value of gm in Csf
0.5 1.0 2.0 3.0 4.0 5.0
sensitivity (%) 88.2 88.2 88.2 76.5 70.6 58.8
specificity (%) 96.3 96.3 96.3 96.3 96.3 96.3
PPv (%) 93.8 93.8 93.8 92.9 92.3 90.9
nPv (%) 92.9 92.9 92.9 86.7 83.9 78.8
table 4. Sensitivity analysis of galactomannan (GM) in cerebrospinal fluid (CSF).
Cut-off value of gm in Csf
gm level < 1.0 gm level ≥ 1.0
Proven CA 0 4
Probable CA 7 15
Possible CA 1 2
no CA 44 4
total 52 25
For the sensitivity analysis, cerebral radiology was included in the clinical criteria of the revised European 
Organization for Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group. Suf-
ficient data of 77 patients were available to diagnose or exclude cerebral aspergillosis (CA). Patients with 
probable or proven cerebral aspergillosis (CA) were compared to patients without CA. Patients with pos-
sible CA were excluded. When a GM level of 1.0 in CSF was used, the sensitivity was 76.0% (19/25). 
dIsCussIon
In this study, the GM antigen test on CSF showed a good performance for diagnosing CA 
in patients with proven/probable CA when using a cut-off of 0.5 to 2.0. To validate the 
CSF GM antigen test, we logically had to exclude CSF GM from the EORTC/MSG criterion. 
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This made it possible to measure the sensitivity of CSF GM to diagnose CA. As such, we 
found that in patients with a proven/probable CA based on culture, tissue biopsy or GM 
in serum or BAL in combination with a suspected radiological cerebral finding, 88.2% 
of the patients had a positive CSF GM, while cultures were only positive in 17.6% of the 
cases. As explained in the methods, we chose to remove the cerebral radiology from the 
clinical EORTC/MSG criteria. In a sensitivity analysis, we retained the cerebral radiology 
in the criteria and observed a decrease in sensitivity to 76% (CSF GM cut-off of 1.0). We 
think that this decrease is rather the result of more misclassifications of patients in the 
probable CA group. However, we cannot formally prove this.
The CSF GM antigen test is included in the revised EORTC/MSG [5]. However, only 2 
studies reported on GM antigen testing in CSF in a total of 10 patients with CA. Viscoli et 
al. measured GM on CSF from 5 patients with proven/probable CA [7]. The median GM 
level was 10.52 and was significantly higher in patients with CA compared to patients 
without CA. Kami et al. compared different non-culture based diagnostics on CSF of 5 
patients with proven CA and 11 patients with leukemic, bacterial, viral or mucor men-
ingitis [6]. The GM antigen test was positive in 4 of the 5 CSF in patients with proven CA 
and negative in all patients without CA. Based on the findings of Viscoli et al. and Kami 
et al., the CSF GM was included in the revised EORTC/MSG definitions. Finally, Antinori 
et al. reviewed the literature on Aspergillus meningitis, which is not the same as CA, and 
found that CSF GM was performed in 15 of the 93 cases [3]. The median CSF GM was 6.58 
with a range of 2.2 to 578. The sensitivity was 86.7%. Our study, in which 17 patients with 
CA and 27 without CA were included, confirms that CSF GM is a useful test to rule in or 
rule out CA.
Among the patients without CA in our study, there was 1 patient with positive CSF 
GM of 8.2. This patient had a cerebral abscess on magnetic resonance imaging. As he 
did not have any other localisations of IA, and no positive culture or brain biopsy he was 
classified as having no CA according to our study criteria in which we excluded CSF GM. 
However, according to the revised EORTC/MSG, this patient had probable IA and was 
treated with voriconazole. He died 17 days later. Because no autopsy was performed, 
we cannot exclude that this patient had CA, but this is an intrinsic problem when a new 
diagnostic test is being validated.
This study has limitations. The study was performed retrospectively and for logistical 
reasons, patients could be selected only from the departments where 1 of the co-authors 
worked. Secondly, we excluded patients who according to EORTC/MSG had a possible IA 
or had an isolated positive microbiological criterion. Including these uncertain IA cases 
as suffering from IA (or the opposite) would unavoidably lead to an uncertain number of 
misclassification. Therefore, to make a validation of GM antigen testing in CSF possible, 
we could only but exclude them. 
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In conclusions, GM detection in CSF showed a good diagnostic performance when 
a cut-off of 0.5 to 2.0 was used, and using GM in CSF, CA can be diagnosed or virtually 
ruled out without the need for cerebral biopsy.
Galactomannan antigen testing in CSF 63
referenCes
 1  Jantunen E, Volin L, Salonen O, Piilonen A, Parkkali T, Anttila VJ, et al. Central nervous system as-
pergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2003;31(3):191-
196. 
 2  Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. 
Clin Infect Dis. 2001;32(3):358-366. 
 3  Antinori S, Corbellino M, Meroni L, Resta F, Sollima S, Tonolini M, et al. Aspergillus meningitis: a 
rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 
cases. J Infect. 2013;66(3):218-238. 
 4  Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergil-
losis: a series of 14 cases from a general hospital and review of 123 cases from the literature. 
Medicine (Baltimore). 2012;91(6):328-336. 
 5  De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of 
invasive fungal disease from the European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-
1821. 
 6  Kami M, Ogawa S, Kanda Y, Tanaka Y, Machida U, Matsumura T, et al. Early diagnosis of central 
nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and 
enzyme-linked immunosorbent assay. Br J Haematol. 1999;106(2):536-537. 
 7  Viscoli C, Machetti M, Gazzola P, De Maria A, Paola D, Van Lint MT, et al. Aspergillus galactomannan 
antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral 
aspergillosis. J Clin Microbiol. 2002;40(4):1496-1499. 

Chapter 5.1
Direct detection of Aspergillus and azole resistance of 
Aspergillus fumigatus on bronchoalveolar lavage fluid. 
Validation of a new Aspergillus real-time PCR.
Ga-Lai M. Chong
Wendy W.J. van de Sande
Gijs J.H. Dingemans
Giel R. Gaajetaan
Alieke G. Vonk
Marie-Pierre Hayette
Dennis W. E. van Tegelen
Guus F.M. Simons
Bart J.A. Rijnders
J Clin Microbiol 2015;53:868-874
66 Chapter 5.1
AbstrACt
Introduction 
Azole resistance in Aspergillus fumigatus is increasingly reported. We describe the valida-
tion of AsperGenius®, a new multiplex real-time polymerase chain reaction (PCR) assay 
consisting of two multiplex real-time PCRs: one which identifies the clinically relevant 
Aspergillus species, and one which detects the TR34, L98H, T289A, Y121F mutations in 
Cyp51A and differentiates susceptible from resistant A. fumigatus strains. 
methods
The diagnostic performance was tested on 37 bronchoalveolar lavage (BAL) samples 
from hematology patients and on 40 BAL samples from intensive care unit (ICU) patients 
using BAL galactomannan ≥1.0 or positive culture as the gold standard for the presence 
of Aspergillus. 
results
In the hematology and ICU groups combined, there were 22 BAL samples with IA (2 
proven, 9 probable and 11 non-classifiable). Nineteen of the 22 BAL samples were posi-
tive according to the gold standard. The optimal cycle threshold value for the presence 
of Aspergillus was <36. Sixteen of the 19 BAL samples had a positive PCR (2 Aspergillus 
species and 14 A. fumigatus). This resulted in a sensitivity, specificity, positive and nega-
tive predictive value of 88.9%, 89.3%, 72.7% and 96.2% for the hematology group and 
80.0%, 93.3%, 80.0% and 93.3% in the ICU group, respectively. The Cyp51A real-time 
PCR confirmed 12 wildtype and 2 resistant strains (1 TR34/L98H and 1 TR46/Y121F/T289A 
mutant).  
Conclusion
The AsperGenius® multiplex real-time PCR allows for a sensitive and fast detection of 
Aspergillus species directly in BAL samples. More importantly, this assay detects and 
differentiates wildtype from resistant strains even if BAL cultures remained negative.
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IntroduCtIon
Aspergillus fumigatus is the most frequent cause of invasive mould infections in im-
munocompromised patients. Its mortality varies substantially and depends on patient 
characteristics and the extent of disease. Mortality in intensive care unit (ICU) patients 
with invasive aspergillosis (IA) can be as high as 90% [1]. In hematology patients, a 
relatively low mortality is observed when the diagnosis is made early and treatment 
with voriconazole, the current standard of care [2], is initiated promptly [3]. In 2002, the 
landmark study by Herbrecht et al. showed that treatment of IA with voriconazole re-
sulted in an improved survival [4]. However, a series of recent publications described the 
appearance of azole resistance in A. fumigatus [5-10]. This resistance is caused by a muta-
tion in the Cyp51A gene of A. fumigatus at position 98 (L98H) together with a 34-basepair 
tandem repeat (TR) in the promoter region (TR34). Cyp51A encodes for cytochrome p450 
sterol 14α-demethylase, the target of azoles. The majority of these mutated strains were 
cultured from patients never exposed to azoles. It is assumed that resistance develop-
ment is caused by environmental azole exposure [11]. More recently, van der Linden et 
al. described a second mutation, a 46-basepair TR combined with the point mutations 
Y121F and T289A [12]. In this study, 47 of 921 patients (5.1%) were diagnosed with TR34/
L98H and 13 (1.4%) with the TR46/Y121F/T289A mutation. Occasionally, other mutations 
have also been described [13-16]. Infections with azole resistant strains are associated 
with a very high mortality [17]. 
Currently, the absence of a non-culture based, fast and readily available azole sus-
ceptibility testing method compromises the identification of azole resistance. This is a 
major limitation as the mortality of IA increases substantially when the initiation of ad-
equate therapy is delayed [18]. Furthermore, most Aspergillus infections are diagnosed 
indirectly using galactomannan (or beta 1-3 d-glucan) testing because cultures remain 
negative in most patients. Therefore, even if culture based azole resistance testing would 
become broadly available, this would only be helpful in a subset of patients. 
This study describes the laboratory and first clinical validation of AsperGenius®, a 
new Aspergillus real-time polymerase chain reaction (PCR) that detects Aspergillus spe-
cies directly from bronchoalveolar lavage (BAL) and simultaneously identifies the most 
prevalent Cyp51A mutations in A. fumigatus. 
metHods
This retrospective study was performed at the Erasmus University Medical Center in the 
Netherlands. The following information was obtained: age, sex, mortality, underlying 
disease, reason for ICU admission, hospital admission duration, presence and treatment 
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of IA. For the Aspergillus PCR, we used stored BAL samples of historical patients. BAL 
samples of hematological and ICU patients were selected because these patients are at 
high risk for IA.
Processing of bAl samples
BAL samples from ICU patients (1-2 ml) were incubated with 0.1 M dithiothreitol (DTT) 
to reduce viscosity. This was not needed for BAL samples from neutropenic hematology 
patients. Subsequently, all BAL samples were centrifuged at high speed (10 min at 13400 
g). After centrifugation, the supernatant and the pellet were processed in different ways. 
The supernatant was added to 2 ml NucliSENS® lysis buffer (BioMérieux, Boxtel, the 
Netherlands) and incubated for 10 min at room temperature. An Internal Control (IC) 
was added to the BAL to monitor PCR inhibition, DNA-extraction efficiency and manual 
handling errors. The pellet was transferred to green bead tubes (Roche Diagnostics, 
Indianapolis, USA) and 500 µl NucliSENS® lysis buffer was added together with 5 µl of 
IC. The pellets were subsequently bead-beaten in a MagNA Lyser instrument (Roche 
Diagnostics) for 45 sec at 6500 rpm. Proteinase K (Roche Diagnostics) was added and 
incubated for 10 min at 65 °C, and subsequently inactivated for 10 min at 95 °C. After 
centrifugation, the supernatant of the lysed pellet suspension was transferred to a new 
tube. DNA from both supernatant and pellet was extracted with the NucliSENS® min-
iMAG magnetic extraction (BioMérieux) according to the manufacturer’s instructions. 
The DNA from both the pellet and supernatant were tested separately.
Aspergenius® multiplex real-time PCr assay
The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Nether-
lands) was used for the detection of Aspergillus species and the identification of prevalent 
mutations conferring resistance against triazoles. The AsperGenius® species multiplex 
assay allows for specific detection of A. fumigatus complex, A. terreus and Aspergillus 
species by targeting the 28S rRNA multicopy gene. The A. fumigatus probe detects the 
most relevant species of the Fumigati complex: A. fumigatus, A. lentulus, A. udagawae and 
A. viridinutans. The Aspergillus species probe specifically detects A. fumigatus, A. terreus, 
A. flavus and A. niger. In addition the A. nidulans could be detected based on sequence 
information. Detection of the IC is included. The AsperGenius® resistance multiplex as-
say targets the single copy Cyp51A gene of A. fumigatus and detects TR34, L98H, Y121F 
and T289A to differentiate wildtype from mutant A. fumigatus strains via melting curve 
analysis. The real-time PCR was performed according to the manufacturer’s instructions. 
Detection of four different fluorescent labels (emission spectra: 495 nm, 530 nm, 598 nm, 
645 nm) was enabled by using the Rotor-Gene Q (Qiagen, Heidelberg, Germany) for all ex-
periments. The real-time PCR assay was first validated on DNA of 131 A. fumigatus cultures 
including resistant strains (Erasmus University Medical Center) before testing BAL samples. 
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These strains were identified to the species level on morphology and by sequencing of the 
internal transcribed spacer region. Furthermore, the assay was tested for cross reactivity 
with species selected on their prevalence in the respiratory tract and/or their genomic 
similarity. The specificity was tested for the following species: P. marneffei, P. chrysogenum, 
Fusarium species, Scedosporium species, R. oryzae, S. cerevisae, C. neoformans, C. albicans ,C. 
lustaniae, C. krusei, C. dubliniensis, C. guilliermondii, C. tropicalis, C. glabrata, C. parapsilosis, 
P. jirovecii, B. pertussis, E. coli, H. influenzae, M. catarrhalis, P. aeruginosa, S. aureus, S. pneu-
moniae, K. pneumoniae, C. pneumoniae, L. pneumoniae, M. pneumoniae.
Each extracted BAL sample was tested in duplicate and a no template control (blank) 
was included in each run to exclude contamination. A sample was considered positive 
when one of the duplicates showed increased fluorescence above the threshold. Syn-
thetic single-stranded DNA targets (IDT, Heverlee, Belgium) were included in the assay 
as a standard (positive control) for the melting peaks. These positive control sequences 
were tested simultaneously with the BAL samples to determine if the melting peak 
represents wildtype or resistant A. fumigatus strains. 
gold standard
BAL samples with a positive galactomannan (≥ 1.0) or positive BAL or sputum cultures 
for Aspergillus were selected as the gold standard for positivity. True negatives were BAL 
samples with a negative BAL galactomannan in combination with a negative culture 
from BAL or sputum. BAL samples with only a positive serum galactomannan (≥ 0.5) 
were considered to be negative as there was no microbiological evidence of the pres-
ence of Aspergillus. 
Classification of IA
The European Organization for Research and Treatment of Cancer/Invasive Infectious 
Diseases Study Mycoses Group (EORTC/MSG) criteria for IA were used to classify patients 
into possible, probable or proven IA. A patient is considered to have possible iA if a new 
and otherwise unexplained well-defined intrapulmonary nodule (with or without halo 
sign), an air-crescent sign, or a cavity within an area of consolidations is radiologically 
documented in an immunocompromised host. probable iA is diagnosed when on top of 
these radiological findings microbiological proof of A. fumigatus infection is documented 
by galactomannan antigen detection (Platelia™ Bio-Rad inc.) or positive cultures of A. fu-
migatus. Galactomannan was considered positive in BAL fluid if ≥ 1.0 and in serum when 
≥ 0.5. proven iA is defined as histopathologic evidence of invasive mould infection and 
microbiological proof of A. fumigatus infection. Immunocompromised patients who had 
a positive galactomannan test but who could not be categorized into probable IA, be-
cause the radiology of the lungs was non-specific, were referred as non-classifiable iA, a 
category not included in the EORTC/MSG definitions. In clinical practice, these patients 
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are treated similarly to patients with probable IA because the outcome of these patients 
is comparable to patients with probable IA [19]. Note that most ICU patients with a clini-
cal diagnosis of IA will fall into this non-classifiable category because in contrast to the 
neutropenic patients, the findings on high-resolution computed tomography or chest 
X-ray in ICU patients with IA is mostly non-specific [1].
PCr cut-off analysis
To determine the most appropriate Aspergillus PCR cut-off for clinically significant 
positivity, we first analysed the cycle threshold (Ct) values of the Aspergillus PCR on 37 BAL 
samples of 34 hematological patients. Three patients in the hematology group underwent 
a BAL twice at different times and therefore contributed two BAL samples each. The low-
est Ct value of the pellet or supernatant was used. The optimal cut-off was assessed with 
receiver operator characteristic (ROC) curves. Areas under the curve (AUC) were estimated 
to determine discriminatory power (IBM® SPSS® statistics, version 21). In a second set of 
40 BAL samples from 39 ICU patients we confirmed the usefulness of the cut-off that was 
obtained in the hematology population. The sensitivity, specificity, positive and negative 
predictive values (PPV, NPV) were calculated for the two groups separately and combined. 
results
The AsperGenius® multiplex real-time PCR assay was first tested on 131 A. fumigatus 
strains. Based on the PCR assay, 17 resistant strains were identified which all carried the 
TR34/L98H mutation. These data were confirmed by sequencing the Cyp51A regions. 
Furthermore, the specificity of the assay was tested with species selected on their preva-
lence in the respiratory tract and/or their genomic similarity. No cross-reactivity was 
observed for the A. fumigatus, A. terreus and the resistant probes. Limited cross-reactivity 
was observed with the Aspergillus species probe for R. oryzae and P. chrysogenum that 
resulted in false positive signals when using a 1000 times higher DNA load (50 picogram) 
than the A. fumigatus DNA load needed to get a PCR positive results with a CT of 36 (50 
fentogram or 2 DNA copies/ml).
In the hematology and ICU groups combined, there were 22 BAL samples with prov-
en, probable or non-classifiable IA (table 1). More detailed information on the complete 
set of hematology and ICU BAL samples can be found in the supplement. There were 
three patients with non-classifiable IA, one in the hematology group and two in the 
ICU group who had negative BAL galactomannan and culture, but had a positive serum 
galactomannan. Because BAL galactomannan tests and cultures were negative, there 
was no microbiological evidence that Aspergillus was present in these BAL samples. 
Therefore, these three BAL samples were counted as negatives in the statistical analysis. 
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The ROC curves for the different groups are shown in figure 1. The diagnostic ac-
curacy as given by the AUC for the hematology group was 0.92 (95% CI 0.79 – 1.00; 
p-value < 0.001). The AUC was 0.91 (95% CI 0.76 – 1.00; p-value < 0.001) for the ICU 
group and 0.91 (95% CI 0.81 – 1.00; p-value < 0.001) for the two groups combined. The 
most optimal Ct value cut-off for the Aspergillus species PCR was < 36 for the 37 BAL 
samples of the hematology patients. Table 2 shows the IA classification related to the Ct 
< 36 cut-off and table 3 shows the BAL samples according to the gold standard related 
to the Ct < 36 cut-off. In the hematology group, the Ct < 36 cut-off resulted in a sensi-
tivity, specificity, PPV and NPV of 88.9%, 89.3%, 72.7% and 96.2%, respectively. In the 
ICU group (n=40), the Ct < 36 cut-off value resulted in a sensitivity, specificity, PPV and 
NPV of 80.0%, 93.3%, 80.0% and 83.3%, respectively. Therefore, the overall sensitivity, 
specificity, PPV and NPV was 84.2%, 91.4%, 76.2% and 94.6%, respectively. 
Hematology and ICU group
Hematology group ICU group
Aspergenius® species multiplex PCR
No discrimination
Cycle threshold value 40
Cycle threshold value 35
Cycle threshold value 30
B
B
B
B
A
A
A
A
C
C
C
C
figure 1. Receiver operator characteristic curves of AsperGenius® species multiplex real-time polymerase 
chain reaction (PCR) in bronchoalveolar lavage in the hematology, intensive care (ICU) group and com-
bined.
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table 2. Epidemiological classification of invasive aspergillosis (IA) related to cycle threshold (Ct) cut-off 
of 36.
Classification 
of IA
Hematology group
bAl sample n = 37
ICu group
bAl samples n = 40
Ct < 36 
cut-off
Ct ≥ 36 
cut-off
total Ct < 36 
cut-off
Ct ≥ 36 
cut-off
total
Proven IA 0 0 0 2 0 2
Probable IA 6 0 6 2 1 3
Non-classifiable 
IA
3 1 4 4 3 7
Possible 2 1 3 0 5 5
No IA 0 24 24 2 21 23
Note: BAL, bronchoalveolar lavage. ICU, intensive care unit.
table 3. Bronchoalveolar lavage (BAL) samples with positive galactomannan or cultures according cycle 
threshold (Ct) cut-off of 36.
bAl samples Hematology group
bAl sample n = 37
ICu group
bAl samples n = 40
Ct cut-off 
< 36
Ct cut-off 
≥ 36
total Ct cut-off 
< 36
Ct cut-off 
≥ 36
total
BAL samples with positive 
galactomannan ≥ 1.0 and/or 
with positive culture
8 1 9 8 2 10
BAL samples with negative  
galactomannan < 1.0 and 
negative culture 
3 25 28 2 28 30
Note: ICU, intensive care unit
In the hematology and ICU patients combined, 19 BAL samples of patients with 
proven, probable or non-classifiable IA were identified based on the gold standard. 
From these 19 BAL samples, 16 had a positive Aspergillus PCR (15 positive for both the 
pellet and supernatant, 1 positive for only the pellet). Fourteen of the 16 BAL samples 
had a positive A. fumigatus PCR and the remaining two were Aspergillus species. In all 14 
positive A. fumigatus PCR BAL samples, the Cyp51A resistance PCR was successful. Twelve 
strains were determined as wildtype and two as mutant strains. One sample had a TR46/
Y121F/T289A mutation and the other had a TR34/L98H mutation. More information on 
the melting curves of the mutant strains can be found in the supplement. Both patients 
of these BAL samples showed clinical failure of voriconazole therapy. The first patient 
was treated with allogeneic stem cell transplantation for acute myeloid leukaemia. The 
patient died of culture positive pulmonary and cerebral IA developed during voricon-
azole prophylaxis (3 days before he died, the single serum voriconazole level was high at 
8 mg/L). The second patient developed IA during remission induction chemotherapy for 
acute myeloid leukaemia. The patient showed an increased serum galactomannan level, 
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progressive pulmonary infiltrates and pleural effusion (galactomannan levels in pleural 
fluid were > 2.0) despite 14 days of therapeutic voriconazole serum levels (>4 mg/L, 
supplement figure S4). Cultures were repeatedly negative. The patient survived after 
surgical drainage and 8 weeks of liposomal amphotericin-B combined with voriconazole.
dIsCussIon
In this study, the AsperGenius® multiplex real-time PCR showed good performance 
characteristics for the diagnosis of IA directly on clinical samples in 2 distinct patient 
populations at risk for this infection. In addition to the fast and correct identification 
of A. fumigatus, this PCR simultaneously differentiated azole susceptible from resistant 
strains. In contrast, current conventional microbiological tools for susceptibility testing 
of A. fumigatus are rarely helpful because they are time-consuming, not widely available 
and patients with IA are mostly culture negative. This multiplex real-time PCR assay tack-
les these problems by enabling diagnosis within hours after a BAL sample is submitted 
to the laboratory. 
In the last decade, the use of galactomannan testing and high-resolution computed 
tomography of the lungs allowed for an early diagnosis of IA. Together with the avail-
ability of voriconazole as the preferred therapy, this resulted in a major decrease in 
IA-related mortality [3,20]. However, now that  azole resistance in A. fumigatus is increas-
ing [5-10], the availability of azole resistance testing with a short turn-around time is 
critical to secure this improved survival in patients with IA. The PCR that was validated 
in this study can serve this purpose. In accordance with the PCR results, patients can be 
switched to other non-azole antifungal therapy in an early phase and not when patients 
clinically deteriorate. 
The ROC curves showed that the most optimal Ct value cut-off was 36. This cut-off 
was comparable to the cut-off described for the 2 Aspergillus PCR assays tested by Torelli 
et al. [21]. Moreover, these PCR assays were validated on BAL samples of hematology and 
ICU patients, the same subset of patients as in the present study. Given these observa-
tions, the 36 Ct value cut-off is probably accurate. 
In the hematology group, there were one false negative and two false positive Asper-
gillus PCR results when compared with the gold standard. The false negative result was 
in a BAL sample of a patient with non-classifiable IA (patient no. 5 in table 1). The lung 
abnormalities could also be a side effect of the chemotherapy that the patient received 
for her acute promyelocytic leukaemia. It is possible that this patient did not have IA and 
that the galactomannan of 1.1 in BAL was false positive. The two false positive Aspergil-
lus PCR BAL samples were from patients with possible IA. The BAL galactomannan of 
the first patient was 0.7 and of the second was 0.4. The first patient was treated with 
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antifungal therapy because there was no alternative diagnosis. In the second patient, a 
lung biopsy was performed that showed an organizing pneumonia without signs for a 
fungal infection. As with every diagnostic test, there is no galactomannan cut-off with 
a 100% diagnostic accuracy. A BAL galactomannan cut-off of 0.5 has an increased sen-
sitivity but a somewhat lower specificity [22]. For PCR validation purpose of this study, 
we considered a higher specificity more important and therefore we selected the 1.0 
galactomannan cut-off as the gold standard. 
The PCR assay was performed on DNA extracted from both the pellet and the super-
natant of the BAL. The DNA extraction from the pellet is more labour intensive than the 
extraction of free-circulating DNA from the supernatant. Therefore, it is reassuring that 
15 of 16 supernatants were PCR positive. In the remaining patient only the PCR of the 
DNA extracted from the pellet was positive (Ct value < 36).  In this particular patient, the 
PCR positivity of the pellet was corroborated by a positive sputum culture. Therefore, 
it may be reasonable and more time efficient to first test the supernatant and only test 
the pellet if the supernatant is negative in patients with a positive Aspergillus culture, a 
positive galactomannan, or a very high clinical suspicion.  
The Aspergillus species probe showed cross-reactivity for the P. chrysogenum and R. 
oryzae. P. chrysogenum is rarely pathogenic in humans. R. oryzae can cause comparable 
symptoms as invasive aspergillosis, but the clinical prevalence is low. Furthermore, for 
both these species, a 1000 times higher load of DNA was needed to get a Ct-value result 
of 35 with the Aspergillus species probe. Thus, we believe that these species will not 
compromise the performance of the PCR.
This study has also some limitations. The validation was performed on readily avail-
able leftover BAL fluids from historical patients. At the clinical microbiology laboratory 
of the Erasmus University Medical Center, all superfluous BAL fluids are stored at -20 
oC for future research purposes. Therefore, no selection bias occurred during storage 
of the samples. Nevertheless, the results of this study should be confirmed on a larger 
sample set from different hospitals and ideally prospectively collected across different 
countries. Another limitation is the fact that only the Cyp51A mutations that are included 
in the PCR, will be detected. As such, this PCR will not replace culture-based sensitivity 
testing and when this PCR is used, the results should be interpreted in the epidemiologi-
cal context. Finally, the diagnostic characteristics of every test and in particular the PPV 
will depend on the background incidence of the population tested. Therefore, the PPV 
and NPV we describe may be different in other patient populations.
When confirmed in a larger study, this PCR may be incorporated in the EORTC/MSG 
criteria. The Aspergillus PCR could be used in combination with galactomannan testing 
as it provides information on the Aspergillus species involved and azole resistance.
In conclusion, this new multiplex real-time PCR allows for a sensitive and fast de-
tection of Aspergillus. Furthermore, it can differentiate wildtype from resistant strains 
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even on culture negative BAL samples. This enables on-time and targeted therapy in 
IA-patients.
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figure s1. Ct-values of AsperGenius® species multiplex real-time polymerase chain reaction (PCR) in the 
hematology group. 
37 bronchoalveolar lavage samples of hematology patients with probable IA (n=6), with non- classifiable IA 
(n=4) and no IA (n=24). “a” = patient (no. 5 in table 1) with galactomannan in BAL of 1.1 and in serum of 0.1. 
The vertical line represents the Ct < 36 cut-off. Ct ≥ 36 are negative (neg) samples. 
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   
  

   
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figure s2. Ct-values of AsperGenius® species multiplex real-time polymerase chain reaction (PCR) in the 
intensive care (ICU) group. 
40 BAL samples of ICU patients with proven (n = 2), probable IA (n=3), non-classifiable IA (n=7), possible IA 
(n=5) and no IA (n=23). The vertical line represents the Ct < 36 cut-off. Ct ≥ 36 are negative (neg) samples. 
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figure s3. Melting curves of the A. fumigatus Cyp51A region.
(A) Patient with an azole susceptible A. fumigatus (green) compared to the mutant (red) and wildtype L98 
control (black). 
(B) Patient infected with an azole resistant A. fumigatus TR34/L98H (green) compared to mutant (red) and 
wildtype TR34 control (black). 
(C) Patient infected with an azole resistant A. fumigatus TR46/Y121/T289 (green) compared to mutant (red) 
and wildtype T289 control (black). 
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Treatment with voriconazole 
Treatment with ambisome 
figure s4. Patient with azole resistant invasive aspergillosis, bronchoalveolar lavage sample showed a 
TR34/L98H mutation. 
Patient was initially treated with voriconazole. After 15 days of treatment, X-ray and computed tomography 
of the chest showed progressive pulmonary infiltrates and pleural effusion. Liposomal amphotericin-B was 
added to the treatment. Serum galactomannan eventually became negative after 2 months of voricon-
azole-liposomal amphotericin-B double therapy. 
(A) Chest X-ray before start treatment with voriconazole. 
(B) Computed tomography of the chest before start treatment with voriconazole. 
(C) Chest X-ray 15 days after start treatment with voriconazole. 
(D) Computed tomography of the chest 15 days after start treatment with voriconazole. 
(E) Serum galactomannan levels during treatment. 
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table s1. Characteristics of the patients of the bronchoalveolar (BAL) samples of the hematology and ICU 
group.
Hematology group
bAl samples n = 37
ICu group
bAl samples n = 40
mean age in years 58.9 (19.8-83.2) 52.8 (18.3-73.2)
underlying hematological disease (%)
Acute myeloid leukaemia 24 (63.2%) -
Acute lymphatic leukaemia 2 (5.3%) -
Chronic lymphatic leukaemia 2 (5.3%) -
Non-Hodgkin Lymphoma 2 (5.3%) -
Multiple myeloma 4 (10.5%) -
Myeloproliferative neoplasms 3 (7.9%) -
Myelodysplastic syndrome 1 (2.6%) -
reason ICu admission (%)
Pneumonia - 22 (55.0%)
Interstitial lung abnormalities - 3 (7.5%)
Pulmonary edema - 3 (7.5%)
Livercirrosis / failure / transplantation - 2 (5.0%)
Neurological cause - 3 (7.5%)
Sepsis - 6 (15.0%)
Multiorgan failure - 1 (2.5%)
Invasive aspergillosis (%)
Proven 0 2 (5.0%)
Probable 6 (16.2%) 3 (7.5%)
Possible 3 (8.1%) 5 (12.5%)
Non classifiable 4 (10.8%) 7 (17.5%)
No IA 24 (64.9%) 23 (57.5%)
treated with following antifungal therapya
Abelcet 1 (2.7%) 0
Ambisome 6 (16.2%) 6 (15.0%)
Anidulafungin 0 3 (7.5%)
Caspofungin 2 (5.4%) 5 (12.5%)
Fungizone 2 (5.4%) 1 (2.5%)
Micafungin 0 5 (12.5%)
Posaconazol 1 (2.7%) 1 (2.5%)
Voriconazol
No antifungal therapy
22 (59.5%)
14 (37.8%)
18 (45.0%)
18 (45.0%)
mortality (%)
At 6 weeks 7 (18.4%) 20 (50.0%)
At 12 weeks 10 (26.3%) 22 (55.0%)
Hospital admission duration (days)
Hospital stay in total 47.9 (0-388.0) 49.0 (3.0-216.0)
IC stay - 25.7 (2.0-133.0)
a Some patients were treated with more than one antifungal therapy.
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AbstrACt 
objectives
In patients with invasive aspergillosis (IA), fungal cultures are mostly negative. Con-
sequently, azole resistance often remains undetected. The AsperGenius® multiplex 
real-time PCR assay identifies clinically relevant Aspergillus species and 4 resistance as-
sociated mutations (RAM: TR34/L98H/T289A/Y121F) in the Cyp51A gene. This multicenter 
study evaluated the diagnostic performance of this assay on bronchoalveolar lavage 
(BAL) fluid and correlated the presence of RAMs with azole treatment failure and mortal-
ity.
methods
Stored BAL samples from patients with hematological diseases suspected for IA were 
used. BAL samples that were galactomannan/culture positive were considered positive 
controls for the presence of Aspergillus. Azole treatment failure and 6-week mortality 
was compared in patients with and without RAMs that had received ≥5 days of voricon-
azole monotherapy. 
results
201 patients contributed each 1 BAL sample, of which 88 were positive controls and 
113 negative controls. The optimal cycle threshold cut-off value for the Aspergillus spe-
cies PCR was <38. With this cut-off, the PCR was positive in 74/88 positive controls. The 
sensitivity, specificity, positive and negative predictive values were 84%, 80%, 76% and 
87%, respectively. 32/74 BAL samples were culture negative. Azole treatment failure 
was observed in 6/8 patients with a RAM compared to 12/45 patients without RAMs 
(p-value=0.01). Six-week mortality was 2.7 times higher in in patients with RAMs (50.0% 
versus 18.6%, p-value=0.07).
Conclusion
The AsperGenius® assay had a good diagnostic performance on BAL and differentiated 
wildtype from A. fumigatus with RAMs, also in culture negative BAL samples. Most im-
portantly, detection of RAMs was associated with azole treatment failure.
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IntroduCtIon
Invasive aspergillosis (IA) is the most frequent pulmonary mold infection among im-
munocompromised patients with hematological diseases, and is usually caused by 
Aspergillus fumigatus [1,2]. The triazole voriconazole is currently recommended for first 
line therapy [3]. However, (pan)azole resistance in A. fumigatus has been reported in-
creasingly over the past decade with a prevalence ranging from 1.0% to as high as 20.0% 
[4-11]. This is worrisome because a study showed that the mortality in culture positive 
IA caused by an azole resistant strain was 88% [11]. Azole resistance is often caused 
by mutations in the Cyp51A gene that encodes for the lanosterol 14α-demethylase, the 
target enzyme for azoles. Two mutation patterns in this gene account for a large part of 
azole resistance mechanisms: TR34/L98H and TR46/T289A/Y121F [6,9-12].
Aspergillus cultures of respiratory specimens are positive in at most 26% of the IA cas-
es [13,14]. Given the low sensitivity of the cultures, most cases are diagnosed indirectly 
by detection of galactomannan (GM) [13]. However, in the absence of a positive culture, 
azole resistance remains undetected. Thus, the lack of a fast and readily available azole 
susceptibility test compromises the initiation of adequate treatment in case of azole 
resistance. The commercially available AsperGenius® multiplex real-time polymerase 
chain reaction (PCR) assay consists of 2 PCRs: the species PCR identifies the clinically 
relevant Aspergillus species, and the resistance PCR detects the TR34, L98H, T289A and 
Y121F resistance associated mutations (RAM) that represent the prevalent mutation 
combinations TR34/L98H and TR46/T289A/Y121F in the Cyp51A gene. In a recent single-
center study, the diagnostic performance of the species PCR on bronchoalveolar lavage 
(BAL) samples of patients with hematological diseases showed a sensitivity, specificity, 
positive and negative predictive values (PPV, NPV) of 89%, 89%, 73% and 96%, respec-
tively, when a cyclic threshold (Ct) value of <36 was used [15]. Moreover, the resistance 
PCR was able to detect RAMs in a culture negative patient with IA [15]. 
The purpose of this retrospective multicenter study was to confirm the diagnostic 
performance of the AsperGenius® assay in a large population of patients with hema-
tological diseases and to evaluate if the molecular detection of the above-mentioned 
RAMs correlate with azole treatment failure and mortality. 
metHods
study design
This retrospective study was performed at 3 Dutch and 2 Belgian hospitals (Erasmus Univer-
sity Medical Center, Leiden University Medical Center, University Medical Center Groningen, 
Ghent University Hospital and University Hospitals Leuven). The AsperGenius® assay was 
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performed on 1 milliliter stored leftover BAL samples on which GM (Platelia™ Bio-Rad inc.) 
and culture had already been performed because of a clinical suspicion of IA. Only BAL 
samples from patients with hematological diseases were included. Collecting BAL samples 
ended on 31st of May, 2015. All available leftover BAL samples with a minimum volume 
of 1 milliliter before this date were obtained. BAL samples were stored at -20 degrees in 
4 hospitals and at -80 degrees in 1 hospital. The following information was retrieved from 
medical files: age, sex, underlying disease, duration of hospitalization, documentation of IA 
and the antifungal treatment given. In addition, 6 and 12-week mortality was documented. 
Because this was a retrospective study, no data on the BAL procedure itself was registered.
The study consisted of 2 parts. First, the optimal Ct value and diagnostic performance 
of the species probe of the PCR were determined. Secondly, treatment failure and 6-week 
mortality were determined in all patients who had received azole monotherapy for at 
least 5 days and in whom the resistance PCR successfully discriminated wildtype from 
Cyp51A mutated A. fumigatus. Patients with A. fumigatus without RAM (=wildtype) were 
compared to those with A. fumigatus containing a RAM. Patients were excluded from the 
azole treatment failure analysis if (i) a non-A. fumigatus or mixed infection was present 
(e.g. A. fumigatus and A. terreus), (ii) patients were treated with non-azole therapy or 
combination therapy, (iii) the antifungal therapy or duration was unknown, or (iv) pa-
tients received no therapy. Azole treatment failure was defined as a switch from an azole 
to any other antifungal drug class. Data of the patient population with hematological 
diseases of the previous study (n=10) were pooled with the data of the current study for 
the specific analysis of azole treatment failure and 6-week mortality [15]. The pooling of 
data was deemed necessary and appropriate because of (i) the rarity of patients infected 
with RAMs and (ii) the identical methodology and same study site in both studies.
One BAL sample per patient was included in the study. If for a given patient multiple 
BAL samples were available, the BAL sample of the period with the highest IA classifica-
tion was selected. In case of multiple BAL samples for a given patient with the same IA 
classification, 1 BAL sample was randomly selected.
PathoNostics tested the BAL samples blindly and was not involved in the analysis of 
the results. GMC and BJAR analyzed the data. 
ethics
The medical ethics committees approved the study under the reference numbers MEC-
2014-628, P14.337, UC UZG 2014/1217 and S57319. For one Dutch center, local approval 
was not necessary as approval given by another Dutch medical ethics committee also 
implied approval for that center. In centers with an opt-out system, all included patients 
were cross-checked with the list of patients that had objected to the opt-out system. 
In one center, opt-out forms were sent to the surviving patients to give them the op-
portunity to refuse the use of their clinical data.
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Categorization of bAl samples 
BAL samples with a positive GM (≥1.0) and/or a positive Aspergillus culture of the BAL, 
sputum or lung biopsy (<6 days after the date of the BAL) were considered positive con-
trols for the presence of Aspergillus in BAL samples. Negative controls were BAL samples 
with a negative BAL GM in combination with a negative culture from BAL, sputum or 
biopsy. BAL samples from patients with only a positive serum GM (≥0.5) but a negative 
BAL GM were considered as negative controls as there was no microbiological evidence 
of the presence of Aspergillus in the BAL sample itself on which the PCR was performed.
definitions of invasive fungal disease
Patients were categorized as having proven, probable or possible invasive fungal disease 
according to the revised European Organization for Research and Treatment of Cancer/
Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) consensus criteria [16]. In 
addition, patients with appropriate host criteria and positive microbiological findings but 
with non-specific radiological features were classified as non-classifiable disease. Although 
this category is not included in the EORTC/MSG definitions, in clinical practice, these pa-
tients are treated similarly to those with probable IA given their similar outcome [17]. 
Processing of bAl samples
One milliliter of the BAL sample was used for DNA-extraction. Samples were processed 
as described previously [15], with the exception that DNA was extracted from the BAL 
supernatant and pellet by using the NucliSENS® easyMag® (bioMérieux). The onboard 
lysis protocol and 50 microliter elution was selected for this purpose before the DNA 
eluate was used in the AsperGenius® assay. The AsperGenius® assay was performed on 
the BAL supernatant and pellet separately. A LightCycler 480 II (Roche) was used to per-
form the AsperGenius® assay. For the determination of the Ct values, the 2nd derivative 
function of the LightCycler 480 software (v1.5.62) was applied.
Aspergenius® multiplex real-time PCr assay 
The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Nether-
lands) was used to detect Aspergillus species and Cyp51A gene mutations. The species 
PCR allows for detection of A. fumigatus complex, A. terreus and Aspergillus species 
by targeting the 28S rRNA multicopy gene. The A. fumigatus probe detects the most 
relevant species of the Fumigati complex: A. fumigatus, A. lentulus, and A. felis. The As-
pergillus species probe specifically detects A. fumigatus, A. terreus, A. flavus and A. niger. 
An internal control is included to monitor for inhibition or manual handling errors. The 
resistance PCR targets the single copy Cyp51A gene of A. fumigatus and detects TR34/
L98H/Y121F/T289A mutations to differentiate wildtype from mutant A. fumigatus via 
melting curve analysis.
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Each extracted BAL sample was tested in duplicate and a no template control (blank) 
was included in each run to exclude contamination. A sample was considered positive 
when one of the duplicates showed increased fluorescence above the threshold. The 
positive control from the assay was used as a standard for the melting peaks and was 
tested simultaneously with the BAL samples to determine if the melting peak represents 
wildtype or A. fumigatus with RAM. The resistance PCR was deemed successfully when 
the supernatant or pellet showed melting peaks for (i) at least 1 of the TR34 or L98H, 
together with (ii) at least 1 of T289A or Y121F resistance markers.
statistical analysis 
The optimal Ct cut-off and diagnostic performance was determined for the species 
probe of the PCR using the earlier Ct value of the supernatant or pellet. Using the con-
trols as described above, the receiver operator characteristic (ROC) curve and its area 
under the curve (AUC) were determined (IBM® SPSS® statistics, version 21). The closest 
to (0,1) point and Youden index were used to further assess the optimal Ct cut-off [18]. 
The sensitivity, specificity, PPV and NPV were calculated for all BAL samples in total and 
per hospital. The positive and negative likelihoods were calculated for the most optimal 
Ct value.
As an additional sensitivity analysis, we determined the ROC curves, AUC and di-
agnostic performance when using the patients with EORTC/MSG proven, probable IA 
versus patients without IA. This was thought to be appropriate because the EORTC/MSG 
criteria are often used for antifungal therapy studies. Because clinicians tend to treat 
patients with non-classifiable IA in the same way as proven or probable IA [17], we did a 
second sensitivity analysis in which patients with proven, probable or non-classifiable IA 
were compared to patients without IA. 
For the azole treatment failure and 6-week mortality analysis, the 2-sided Fisher’s 
exact test was used, with a p-value<0.05 considered statistically significant. 
results
In total, 228 BAL samples from 201 patients were available. Samples were obtained 
between December 2007 and May 2015. No patients refused to have their clinical data 
used for the purpose of this study. As only 1 BAL per patient was used, 201 BAL samples 
were available for the analysis. Seven patients with proven, probable or non-classifiable 
IA were counted as negative controls since there was no evidence of Aspergillus in the 
BAL itself from culture or GM (5 positive serum GM, 1 positive sinus culture and 1 posi-
tive lung biopsy culture obtained 16 days after the BAL). The clinical characteristics of 
the 201 patients are summarized in table 1.
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table 1. Clinical characteristics of the 201 hematology patients who contributed bronchoalveolar lavage 
(BAL)  fluid samples.
Patients  (n = 201)
Age, mean years (range) 56.6 (17.5 – 82.6)
male gender (n,%) 132 (65.7)
diagnosis (n,%)
Acute myeloid leukemia 78 (38.8)
Acute lymphocytic leukemia 16 (8.0)
Chronic lymphocytic leukemia 13 (6.5)
Myelodysplastic syndrome 17 (8.5)
Hodgkin’s lymphoma 10 (5.0)
Non-Hodgkin’s lymphoma 38 (18.9)
Myeloproliferative disorders 8 (4.0)
Plasma cell disorders 11 (5.5)
Aplastic anemia 3 (1.5)
Othera 7 (3.5)
Allogeneic stem cell transplantation (n,%) 82 (40.8)
Invasive aspergillosis (n,%)
Proven 9 (4.5)
Probable 43 (21.4)
Non-classifiable 43 (21.4)
Possible 32 (15.9)
No IA 74 (36.8)
bAl galactomannan and/or culture positive or negative (n,%)
Galactomannan and culture positive 28 (13.9)
Galactomannan positive and culture  negative 56 (27.9)
Galactomannan negative and culture positive 4 (2.0)
Galactomannan and culture negative 113 (56.2)
treated with following antifungal therapy (n,%)b 
Amphotericin B lipid complex 6 (3.0)
Liposomal amphotericin B 40 (19.9)
Conventional amphotericin B deoxycholate 4 (2.0)
Caspofungin 26 (12.9)
Itraconazole 3 (1.5)
Posaconazole 18 (9.0)
Voriconazole 112 (55.7)
Study anidulafungin versus placebo 3 (1.5)
Study voriconazole versus isavuconazole 3 (1.5) 
Study voriconazole versus posaconazole 6 (3.0)
No antifungal therapy 56 (27.9)
mortality (%) after IA diagnosis
At 6 weeks 50 (24.9)
At 12 weeks 65 (32.3)
Hospital admission duration (days, range)
Hospital stay in total 40.7 (2 – 236)
a Monoclonal B-cell lymphocytosis, auto-immune hemolytic anemia, sickle cell disease, hemophagocytic 
lymphohistiocytosis, T-cell prolymphocytic leukemia.
b There were patients who were treated with more than one antifungal therapy. Some patients were treated 
within a clinical trial in which the prescribed antifungal therapy was unknown for physicians.
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Eighty-eight BAL samples were positive controls, of which 74 (84.1%) were positive 
for the species PCR (58 positive in supernatant and pellet, 10 only positive in supernatant 
and 6 only positive in pellet). The species PCR detected 66 A. fumigatus, 2 A. fumigatus 
combined with A. terreus, 2 A. terreus and 4 A. species. Thirty-two of these 74 (43.2%) BAL 
samples were culture negative and only GM positive.
Twenty-three BAL samples from negative controls were species PCR-positive. Five of 
these 23 BAL samples were from patients with proven, probable or non-classifi able IA 
(3 diagnosed on positive serum GM, 1 on positive sinus culture, and 1 on positive lung 
biopsy pathology plus culture). Eleven BAL samples were from patients without IA and 
7 from patients with possible IA.
The ROC curve of the species PCR is shown in fi gure 1. The diagnostics accuracy as 
given by AUC was 0.890 (CI 95% 0.842–0.939; p-value<0.001). The closest to (0,1) point 
designated Ct<38 as optimal cut-off , while the Youden index designated Ct<36 as 
optimal cut-off  (table S1). The Ct cut-off  of <38 resulted in a sensitivity, specifi city, PPV 
and NPV of 84.09%, 79.65%, 76.29% and 86.54%, respectively. A Ct cut-off  of <36 gave 
values of 70.45%, 95.56%, 92.58% and 80.60%, respectively (table 2). Because a higher 
sensitivity was preferred over a higher specifi city, the Ct value of <38 was chosen for the 
purpose of subsequent analyses that we performed. The positive likelihood ratio was 
4.13 and the negative likelihood ratio 0.20. Table 3 shows the distribution of the BAL 
samples according to their IA classifi cation. Table S2 shows the diagnostic performance 
per hospital. As a sensitivity analysis, the diagnostic characteristics were calculated when 
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figure 1. Receiver operator characteristic curve of species probe of the AsperGenius® PCR in the bronchoal-
veolar lavage fl uid samples of the 201 patients with hematological diseases.
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patients with proven or probable IA were considered as positive controls and compared 
to patients without IA. The sensitivity increased to 88% when the <38 Ct cut-off was 
used. See table 2 and figure S1 for the ROC curves when patients with proven, probable 
or non-classifiable IA were considered as positive controls.
table 2. Diagnostic performance of the species probe of the AsperGenius® PCR according to different cycle 
threshold (Ct) cut-offs and positive/negative controls.
Ct value cut-off of 
the Aspergenius® 
species PCr
diagnostic 
performancea
Positive control 
versus negative 
control 
bAl samples as 
defined in this 
studyb 
n = 201
Proven, probable 
or non-classifiable 
IA versus no IAc
n = 169
Proven or probable 
IA versus no IA
n = 126
<36 Sensitivity (%) 70.45 68.42 76.92
Specificity (%) 95.58 98.65 98.65
PPV (%) 92.54 98.48 97.56
NPV (%) 80.60 70.87 85.88
<37 Sensitivity (%) 73.86 71.58 78.85
Specificity (%) 90.27 94.59 94.59
PPV (%) 85.53 94.44 91.11
NPV (%) 81.60 72.16 86.42
<38 Sensitivity (%) 84.09 83.16 88.46
Specificity (%) 79.65 85.14 85.14
PPV (%) 76.29 87.78 80.70
NPV (%) 86.54 79.75 91.30
<39 Sensitivity (%) 88.64 87.37 90.38
Specificity (%) 62.83 72.97 72.97
PPV (%) 65.00 80.58 70.15
NPV (%) 87.65 81.82 91.53
a PPV, positive predictive value. NPV, negative predictive value.
b Bronchoalveolar (BAL) samples with a positive GM (≥1.0) and/or positive culture for Aspergillus of BAL, 
sputum or lung biopsy at most 5 days from date of the BAL were considered positive controls. BAL samples 
with a negative BAL GM in combination with a negative culture from BAL, sputum or lung biopsy were 
considered negative controls.
c Proven and probable IA was defined according to the revised European Organization for Research and 
Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) criteria. Non-classi-
fiable is defined as a patient with EORTC/MSG host and microbiological criteria fulfilled and a pulmonary 
infiltrate without a halo or air-crescent or well-defined nodule. IA, invasive aspergillosis. No IA was defined 
as no proven IA, no probable IA, no non-classifiable IA or no possible invasive fungal disease.
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table 3. Distribution of the bronchoalveolar lavage (BAL) samples according to their invasive aspergillosis 
(IA) classification and species probe of the AsperGenius® PCR using cycle threshold (Ct) value of <38 as 
cut-off. 
Classification of IA
bAl samples
n = 201
Ct <38 Ct ≥38 total
Proven 9 0 9
Galactomannan and culture positive 5 0
Only galactomannan positive 3 0
Only culture positive 1 0
Probable 37 6 43
Galactomannan and culture positive 11 0
Only galactomannan positive 22 6
Only culture positive 4 0
non-classifiable 33 10 43
Galactomannan and culture positive 12 0
Only galactomannan positive 20 10
Only culture positive 1 0
Possible 7 25 32
no IA 11 63 74
total 97 104 201
Note: galactomannan in BAL and serum. Culture in BAL and elsewhere in the body.
In the 201 BAL samples, the species PCR was positive in 97 BAL samples (figure 2). The 
resistance PCR was successfully performed in 68/97 BAL samples. Fifty-seven patients 
had a wildtype A. fumigatus and 11 patients had an A. fumigatus with RAM (TR34/L98H 
mutation (n=7), TR46/T289A/Y121F mutation (n=1) and TR34/L98H mutation combined 
with a wildtype A. fumigatus (n=3)). One or two resistance markers were not detected 
in 9/73 BAL samples (L98H in 4, TR34 in 5 and T289A in 2). But based on the detection 
of the other corresponding resistance marker (e.g. successful amplification of L98H in 
4 patients in combination with unsuccessful TR34 amplification), a conclusion could be 
drawn on the presence of A. fumigatus wildtype or resistant due to TR34/L98H or TR46/
T289A/Y121F. 
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Controls
Cyclic threshold (Ct) 
of the AsperGenius®  
species PCR
AsperGenius® 
resistance PCR
BAL samples
n = 201
Positive
88
Negative
113
Ct ≥38
14
Ct <38 
74
Ct ≥38
90 
Ct <38 
23
2 A. fumigatus 66 A. fumigatus
2 A. fumigatus + A. terreus
2 A. terreus
4 A. spp
4 A. fumigatus 12 A. fumigatus
1 wildtype
51 wildtype
7 TR34/L98H
3 TR34/L98H + wildtype
6 wildtype
1 TR46/T289A/Y121F
Sensitivity 84%
PPV 76%
figure 2. Bronchoalveolar lavage (BAL) samples divided according to positive/negative controls and spe-
cies probe of the AsperGenius® PCR and resistance PCR. 
Two patients had a co-infection with an A. fumigatus and A. terreus. 
For the azole treatment failure and 6-week mortality analysis, resistance data from 
the 68 patients were included together with 10 patients with hematological diseases 
from the previous study (8 wildtype, 1 TR34/L98H and 1 TR46/T289A/Y121F).[15] As such, 
the total group consisted of 78 patients of whom 65 were infected with wildtype A. 
fumigatus and 13 with A. fumigatus carrying a RAM. Twenty-five of these 78 patients 
were excluded from the analysis as described in the methods and figure 3. After exclu-
sion, 45 patients with wildtype A. fumigatus remained and 8 with an A. fumigatus that 
contained RAMs. The patients infected with wildtype had 5 proven, 20 probable, 17 non-
classifiable IA and 3 possible IA. In patients infected with A. fumigatus containing RAM, 
4 had probable, 3 had non-classifiable and 1 had possible IA. A. fumigatus was cultured 
in 23/53 patients (3 with and 20 without RAMs). Data on antifungal susceptibility testing 
were available for 7/23 A. fumigatus cultures (5 azole susceptible and 2 azole-resistant) 
and correlated with the results of the resistance PCR. Azole treatment failure was ob-
served in 12/45 patients with wildtype A. fumigatus compared to 6/8 patients with A. 
fumigatus with RAM (p-value=0.01). Six-week mortality was 2.7 times higher in patients 
with detected RAM (18.6% without versus 50.0%, p-value=0.07).
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Total patients
n = 78
65 with wildtype A. fumigatus
13 with A. fumigatus with 
resistance associated mutations
8 TR34/L98H
3 TR34/L98H combined with wildtype
2 TR46/T289A/Y121F
45 with wildtype A. fumigatus
8 with A. fumigatus with 
resistance associated mutations
6 TR34/L98H
2 TR46/T289A/Y121F
20 excluded
3 mixed infections
2 had <5 days azole therapy
3 non-azole combined with azole therapy
7 non-azole therapy from start
3 antifungal therapy or duration unknown
2 untreated
5 excluded
3 TR34/L98H combined with wildtype
2 had <5 days azole therapy
figure 3. Inclusion for the azole treatment failure and 6-week mortality analysis.
dIsCussIon
This retrospective multicenter study showed that the AsperGenius® species PCR has a 
good diagnostic performance on BAL samples of patients with hematological diseases. 
The sensitivity, specificity, PPV and NPV were 84%, 80%, 76% and 87%, respectively, 
when a Ct cut-off of <38 was used. 
The 2 most frequently used statistical methods to analyze a ROC curve are the closest 
to (0,1) and Youden index. In this study, they led to contradictory results on the most 
appropriate Ct cut-off values (36 and 38, respectively). Given the important clinical 
consequences of a missed IA diagnosis, a later Ct cut-off of 38 that results in a better 
sensitivity may be preferred by the clinician if the resulting loss in specificity is accept-
able. Therefore, we favor the use of the Ct cut-off of <38 which is later than the Ct cut-off 
of <36 that we reported in the previous smaller single center study.[15] The current 
sensitivity was somewhat lower than in the previous single center study (89%),[15] and 
may be explained by the fact that a standard volume of 1 milliliter BAL was used in this 
study versus 1-2 milliliter in the previous study. The lower volume may have decreased 
the sensitivity. The difference in sensitivity observed between the study centers may be 
explained by differences in the way the BAL is performed in each center. For example, 
centers may differ in the volume used to perform the BAL, or a bronchoscopist may 
lavage 2 different parts of the lung but send it in 1 container to the laboratory which 
may result in a diluted DNA content if Aspergillus is present in only 1 part of the lung. 
Unfortunately, the way the BAL procedure was done in each patient was not registered. 
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The difference in sensitivity could not be explained by the differences in BAL storage 
methods. One hospital stored its BAL samples at -80 degrees and had a sensitivity of 
75%, while the other 4 hospitals stored at -20 degrees and had a sensitivity of 71% to 
100%. The difference could neither be explained by the duration of BAL storage before 
the PCR was performed because 2 hospitals contributed BAL samples from the period 
2014 to 2015 and had a different sensitivity of 88% and 100%. 
As with all diagnostic tests, a test should be interpreted within the context of the 
prevalence of the disease. When azole resistance is low in a certain area, it is expected 
that the PPV of the PCR will probably drop. Based on the positive and negative likelihood 
ratios of 4.13 and 0.20, respectively, one can determine the post-test probability in a 
Fagan nomogram to take the prevalence in the patient population into account.
On top of the detection of Aspergillus, the AsperGenius® resistance PCR was able to 
differentiate A. fumigatus without a RAM (=wildtype) from RAM-positive A. fumigatus, 
even in culture negative BAL samples. Most importantly, patients infected with RAM-
positive A. fumigatus failed significantly more often on azole treatment than those 
infected with a wildtype A. fumigatus (75% versus 27%, p-value=0.01). Therefore, this 
study is the first to show that PCR-detected resistance is clinically relevant. The incidence 
of azole treatment failure and the 6-week mortality was determined in the pooled data 
of the current and previous study [15]. The sole reason to pool the data of both studies 
is the fact that azole resistant IA is still a rare disease with only 13 cases detected in 
the 83 PCR-positive patients of the 251 patients included both studies. Given the small 
numbers, a multivariate analysis was not possible to investigate other predictors of 
azole treatment failure.
To date, the AsperGenius® assay has been studied on serum samples of patients with 
hematological diseases in which the species PCR had a sensitivity and specificity of 79% 
and 100%, respectively, when a Ct cut-off of 39 was used [19]. Next to the AsperGenius® 
assay, other Aspergillus PCRs have been tested on BAL samples and sensitivities varied 
between 38% and 94% [20-22]. Therefore, the sensitivity of the species PCR found in this 
study is comparable but with the added advantage that RAMs are detected simultane-
ously. There are other PCRs alike the AsperGenius® assay that detect Cyp51A mutations 
directly on BAL samples [23-25]. Spiess et al. described the detection of Cyp51A muta-
tions on 189 clinical samples in their 1st and 2nd studies combined and found the TR34/
L98H mutation on 2 BAL samples and 1 cerebral biopsy [23,24]. Zhao et al. found in 
their study the Cyp51A mutations M220 and PL216 which are also associated with azole 
resistance, on 2/94 BAL samples. These studies along with the current study show that 
detection of Cyp51A mutation on BAL samples is possible, also on culture negative BAL 
samples. The current study is the first to show that the detection of RAMs is clinically 
associated with azole treatment failure.
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The study has limitations. First, only Cyp51A mutations included in the assay can be 
detected. To date, more than 15 Cyp51A gene-mediated resistance mechanisms have 
been described [26]. The included mutations TR34/L98H and TR46/T298A/Y121F originate 
from the environment in contrast to Cyp51A mutations that are patient acquired after 
prolonged azole treatment [7,27,28]. The prevalence for the TR34/L98H mutation can ac-
count up to 90.2% of the azole resistant A. fumigatus, while for the TR46/T289A/Y121F up 
to 26.9% [6,9-12]. However, the prevalence varies per region. For example, a study from 
the United Kingdom found only 2 TR34/L98H mutations among the 45 azole-resistant A. 
fumigatus isolates [7]. The assay should therefore be interpreted within the context of the 
local prevalence of the Cyp51A mutations. Besides the Cyp51A mutations, non-Cyp51A 
mechanisms that confer azole resistance have been reported [4,6,8-11]. Therefore, PCR 
testing does not replace culture-based sensitivity testing that should be performed as 
well. Second, we studied the BAL samples from December 2007 to May 2015. Azole resis-
tance has increased over the past decade [4-11]. Eleven of the 201 (5.5%) patients were 
infected with an A. fumigatus containing a RAM, which may be an underestimation of 
RAMs in the current population. Lastly, the retrospective nature of the study is another 
limitation. Antifungal susceptibility testing was not performed routinely in the past. 
Therefore, the PCR results could only be correlated with the phenotypical resistance in a 
small portion of the patients. However, in a prospective study, it would be unacceptable 
to test BAL samples real-time without reporting the detected Cyp51A mutations back to 
the clinician which obviously will lead to a switch from an azole to a non-azole therapy. 
Therefore, this retrospective study had the advantage that it became possible to report 
on 8 patients treated with azoles despite the fact that, in retrospect, they had been 
infected with RAM-positive and therefore azole resistant A. fumigatus.
In conclusion, the AsperGenius® assay showed a good diagnostic performance in de-
tecting IA in patients with hematological diseases and the detection of RAM-positive A. 
fumigatus was associated with azole treatment failure, also when patients were culture 
negative. Therefore, early detection of RAMs by PCR can lead to a prompt adaptation of 
the antifungal regimen, hopefully contributing to a more favorable outcome of azole 
resistant A. fumigatus in future patients.
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figure s1. Additional receiver operator characteristic (ROC) curves of species probe of the AsperGenius® 
PCR in the bronchoalveolar lavage fluid samples.
ROC curve I uses proven (n=9), probable (n=43) and non-classifiable IA (n=43) as positive controls versus no 
IA (n=74) as negative controls. The diagnostics accuracy as given by area under the curve (AUC) was 0.902 
(CI 95% 0.855 – 0.949; p-value<0.001). ROC curve II uses proven and probable IA as positive controls versus 
no IA as negative controls. The AUC was 0.925 (CI 95% 0.871 – 0.979; p- value<0.001). 
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online supplement table s1. Selection of the best cycle threshold (Ct) cut-off using the closest to (0,1) 
point and Youden index criteria.
Criteria to test optimal 
cut-off a 
Positive versus negative
bAl samples as defined 
in this studyb 
n = 201
Proven, probable or 
non-classifiable IA 
versus no IAc
n = 169
Proven or probable IA 
versus no IA
n = 126
Closest to (0,1) point
Ct <36 0.2988 0.3161 0.2312
Ct <37 0.2789 0.2893 0.2183
Ct <38 0.2583 0.2246 0.1881
Ct <39 0.3887 0.2984 0.2869
youden index
Ct <36 0.6603 0.6707 0.7557
Ct <37 0.6413 0.6617 0.7344
Ct <38 0.6374 0.6830 0.7360
Ct <39 0.3887 0.6034 0.6335
a The closest to (0,1) point selects the lowest distance between a point on a receiver operator curve (ROC) 
and the point (0,1) as best cut-off. The Youden index selects the maximum vertical distance between the 
ROC curve and the diagonal or chance line as best cut-off. 
b Bronchoalveolar (BAL) samples with a positive galactomannan (GM) of ≥1.0 and/or positive culture for As-
pergillus of BAL, sputum or lung biopsy at most 5 days from date of the BAL were considered gold standard 
positive. BAL samples with a negative BAL GM in combination with a negative culture from BAL, sputum or 
lung biopsy were considered gold standard negative.
c Proven and probable IA was defined according to the revised European Organization for Research and 
Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) criteria. Non-classi-
fiable is defined as a patient with EORTC/MSG host and microbiological criteria fulfilled and a pulmonary 
infiltrate without a halo or air-crescent or well-defined nodule. IA, invasive aspergillosis. No IA was defined 
as no proven IA, no probable IA, no non-classifiable IA or no possible invasive fungal disease.
online supplement table s2. Diagnostic performance of the AsperGenius® species PCR per hospital using 
cycle threshold value cut-off of <38.
diagnostic 
performancea
overall 
n = 201
Hospital 1
n = 34
Hospital 2
n = 34
Hospital 3
n = 37 
Hospital 4
n = 33
Hospital 5
n = 63
sensitivity (%) 84.09 87.50 90.00 100.00 75.00 70.59
specificity (%) 79.65 61.11 75.00 82.14 76.47 86.96
PPv (%) 76.29 66.67 96.43 64.29 75.00 66.67
nPv (%) 86.54 84.62 50.00 100.00 76.47 88.89
a PPV, positive predictive value. NPV, negative predictive value.
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AbstrACt 
objectives
Aspergillus lentulus and Aspergillus felis are sibling species within the Aspergillus section 
Fumigati and sporadically cause invasive aspergillosis (IA). They are phenotypically 
similar but can be reliable identified by molecular techniques. The AsperGenius® assay 
detects (1) the genus Aspergillus, A. fumigatus and A. terreus at the species level, and (2) 
Cyp51A mutations TR34/L98H and T289A/Y121F of A. fumigatus. We report two cases with 
biopsy proven IA caused by A. lentulus and A. felis, and the contribution of the AsperGe-
nius® assay in their identification.
methods
A. lentulus and A. felis isolates were obtained from biopsy cultures. Identification was 
conducted using a sequence-based approach. The AsperGenius® assay was tested on 
these two isolates and several other control A. fumigatus, A. lentulus and A. felis species 
complex isolates. 
results
The AsperGenius® resistance PCR did not detect the TR34 target in A. lentulus and A. 
felis in contrast to A. fumigatus. In addition, melting peaks for L98H and Y121F markers 
differed between A. lentulus, A. felis and A. fumigatus. The melting curves of the Y121F 
marker were particularly suitable to discriminate the species. This was confirmed by test-
ing additional isolates (three A. fumigatus, six A. lentulus, twelve A. felis species complex).
Conclusion
The AsperGenius® resistance PCR can be used for accurate interspecies discrimination 
of A. fumigatus, A. lentulus and A. felis of the Aspergillus section Fumigati. The latter two 
species are often azole resistant. The ability to identify them to the species level enables 
improved management. 
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IntroduCtIon
Invasive aspergillosis (IA) is mainly caused by A. fumigatus, an Aspergillus species in the 
section Fumigati [1,2]. The standard therapy for IA is voriconazole [3]. A relatively low 
mortality is observed when the diagnosis is made early and treatment with voriconazole 
is initiated promptly [4,5]. However, over the past decade, azole resistance has emerged 
worldwide and poses a threat as IA with azole resistant A. fumigatus is associated with 
high mortality of 88% [6-8]. Resistance in A. fumigatus is often caused by two common 
mutations (TR34/L98H and TR46/T289A/Y121F) in the Cyp51A gene that encodes for 
lanosterol 14α-demethylase, the target enzyme for azoles [6-8]. In addition to infections 
caused by azole resistant A. fumigatus strains, there are also IA cases caused by species 
morphologically similar to A. fumigatus, so called intrinsic azole resistant ‘sibling species’ 
[1,9-13]. These sibling species also belong to the Aspergillus section Fumigati and can be 
reliable distinguished from A. fumigatus by molecular sequencing. 
One of these sibling species was described in 2005 and was named A. lentulus 
because of its slow sporulation as lentulus means ‘somewhat slow’ in Latin [14]. Subse-
quently, several reports described patients with IA caused by A. lentulus [1,9,11,13,15]. 
The majority of these reported patients died despite treatment. The A. lentulus isolates 
cultured from these patients had higher minimum inhibitory concentrations (MIC) 
values for voriconazole, itraconazole, posaconazole, amphotericin-B and caspofungin 
in comparison to A. fumigatus. The intrinsic low susceptibility for azoles of A. lentulus 
can partly be explained by its Cyp51A gene. This hypothesis is supported by (i) the ob-
servation that A. lentulus without a Cyp51A gene has significantly lower MIC values for 
azoles, (ii) A. fumigatus transformants harboring the Cyp51A gene of A. lentulus showed 
significantly higher MIC values than the A. fumigatus wildtype strains [16], (iii) Saccha-
romyces cerevisiae strains expressing the A. lentulus Cyp51A gene were significantly less 
susceptible for azoles than those strains expressing an A. fumigatus Cyp51A gene [17].
Another sibling species in the section Fumigati that sporadically causes IA is A. felis. 
To date, only two human cases of IA caused by A. felis have been reported [10,12]. In 
both cases, the isolates were initially misidentified as A. viridinutans and later identified 
as A. felis [18,19]. These isolates had high MICs to voriconazole and itraconazole, but low 
MICs to posaconazole and caspofungin, and variable MICs to amphotericin B [10,12]. The 
resistance mechanism of A. felis remains unclear. 
The occurrence of IA due to resistant A. fumigatus (sibling) species warrants empha-
sis on prompt identification of these infecting species and their resistance profile. As 
in vitro drug susceptibility testing is often not feasible, as cultures remain negative or 
sibling species fail to sporulate, molecular techniques are an option. The AsperGenius® 
multiplex real-time polymerase chain reaction (PCR) assay detects the genus Aspergillus, 
A. fumigatus and A. terreus to the species level. In addition, it detects the aforementioned 
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two most common mutation combinations of A. fumigatus that are associated with 
azole resistance. The sensitivity and specificity of the assay ranged from 84.1% to 84.2% 
and 79.7% to 91.4% in bronchoalveolar (BAL) fluid, and was 78.8% and 100% in serum, 
respectively [20-22]. Here, we report two patients with proven IA caused by A. lentulus 
and A. felis species complex, respectively, and the contribution of the AsperGenius® as-
say to their identification.
metHods
The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Nether-
lands) detects Aspergillus species and mutations in the Cyp51A gene of A. fumigatus. The 
assay consists of two PCRs: species PCR and resistance PCR. The species PCR identifies 
the fungus by targeting the 28S rRNA multicopy gene. The Aspergillus species probe 
detects A. fumigatus, A. terreus, A. flavus and A. niger. The A. fumigatus probe detects 
relevant Aspergillus of the section Fumigati. An internal control is included to monitor for 
inhibition or manual handling errors. The resistance PCR targets the single copy Cyp51A 
gene of A. fumigatus and detects the TR34, L98H, Y121F and T289A mutations to differ-
entiate wild-type (WT) from mutant A. fumigatus strains via melting curve analysis. The 
resistance PCR does not likely detect and identify species outside the section Fumigati 
due to differences in the Cyp51A gene nucleotide sequence [23]. 
We first performed the AsperGenius® assay on cultured sibling strains obtained from 
the two clinical cases to examine i) if the resistance PCR yielded (characteristic) melting 
curves and ii) if melting curve analysis could be a tool for interspecies discrimination of 
Aspergillus siblings from both WT and mutant Aspergillus fumigatus. In addition iii), to 
assess the precision of the assay, a larger set of strains was tested:  six A. lentulus isolates 
and twelve A. felis species complex isolates (five A. felis, four A. parafelis and three A. 
pseudofelis) obtained from the CBS-KNAW Fungal Biodiversity Centre (Utrecht, the Neth-
erlands) and the 3 control A. fumigatus isolates (one WT, one TR34/L98H, one TR46/T289A/
Y121F). The assay was performed on the isolates in one experiment. Historical data were 
used to assess the precision of the assay for controls.
The spores of the cultured isolates were dissolved and 50 microliter solution was used 
for DNA extraction. Samples were processed as BAL pellets (including bead-beating), as 
described previously [20]. The extracted DNA was tested in duplicate and a template 
control (blank) was included in each run to exclude contamination. For the species PCR, 
a sample was considered positive when one of the duplicates showed fluorescence 
above the threshold. For the resistance PCR, the positive control from the assay was used 
as a standard for the melting peaks and was tested simultaneously to determine if the 
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melting peak represents wildtype or Cyp51A mutations. A Rotor-Gene Q (Qiagen, Hilden, 
Germany) instrument was used to perform the AsperGenius® assay.
CAse rePort 1
A 68-year-old man underwent an upfront allogeneic hematopoietic stem cell trans-
plantation (HSCT) with a matched unrelated donor for myelodysplastic syndrome, 
refractory anemia with excess of blasts-1. The allogeneic HSCT was complicated by acute 
graft-versus-host-disease (GvHD) of the skin grade II, for which he was treated with myco-
phenolic acid 1080 mg twice daily, prednisolone 1 mg/kg daily and cyclosporine of which 
the dose was based through levels (therapeutic range 250 to 350 µg/l). After recovery 
of his GvHD, mycophenolic acid was discontinued and prednisolone was tapered to 10 
mg daily. Fifty-one days after the allogeneic HSCT, patient was admitted to the hospital 
because of fever and renal insufficiency. Physical examination showed a temperature of 
38.9 °C, but no other abnormalities. Laboratory tests revealed haemoglobin of 4.3 mmol/l, 
total leucocyte count of 17.3 × 109/l (absolute neutrophil count of 14.6 × 109/l, no further 
differentiation), C-reactive protein of 181 mg/l and creatinine of 158 µmol/l. Chest X-ray 
showed bilateral multiple round densities. High resolution computed tomography (HRCT) 
of the lungs showed multiple round lung lesions with cavitations, suspect for IA. At admis-
sion, patient was treated with piperacillin/tazobactam 4000/500 mg four times daily for 
non-neutropenic fever. The antibiotics were discontinued after 3 days as blood cultures 
remained negative and HRCT showed radiological signs consistent with pulmonary IA. 
Voriconazole was started 400 mg twice daily on the first day and 200 mg twice daily 
afterwards. A BAL was performed, but cultures remained negative. Furthermore, BAL and 
serum galactomannan were both negative. Consequently, IA was downgraded to ‘possible’ 
according to criteria of the European Organization for Research and Treatment of Cancer/
Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) [24]. Despite treatment 
the patient showed no improvement and continued to have fever. No therapeutic drug 
monitoring (TDM) of voriconazole was performed. After six days of treatment with vori-
conazole, antifungal therapy was switched to liposomal amphotericin-B 350 mg daily (5 
mg/kg) without success. In the same period, patient developed sepsis with P. aeruginosa 
due to covered perforation based on diverticulitis, for which he received conservative 
treatment with ceftazidime 2000 mg daily for 17 days. Also, patient had reactivation of 
Epstein-Barr virus (serum viral load of 6.75 × 103 geq/ml), suspect for post-transplant 
lymphoproliferative disease (PTLD). As differential diagnosis of the lung abnormalities 
was invasive fungal disease or PTLD, a biopsy of the lung abnormalities was performed. 
Lung biopsy showed fibrosis with areas of necrosis with fungal septate hyphae. Culture 
of the lung biopsy revealed Aspergillus section Fumigati, and the culture was sent to a 
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referral laboratory for further identification and sensitivity testing. Patient was switched 
to treatment with posaconazole 300 mg twice daily for proven IA with Aspergillus section 
Fumigati. Concurrently, patient developed progressive renal failure and GvHD of the skin 
and liver. His clinical condition deteriorated and he died 90 days post-transplantation. 
Post-mortem, the isolate was identified as A. lentulus and had MIC values of 2 µg/ml for 
amphotericin-B, 2 µg/ml for voriconazole, 0.5 µg/ml for itraconazole and 0.125 µg/ml for 
posaconazole, respectively. The isolate was deposited in the CBS-KNAW Fungal Biodiver-
sity Centre culture collection (CBS 141342) after confirrmation as A. lentulus by sequence 
analysis of the internal transcribed spacer (ITS) region, and a part of the β-tubulin (BenA) 
and calmodulin (CaM) gene (GenBank numbers will follow).
CAse rePort 2
A 54-year-old man was transferred to our hospital because of neutropenic fever. His 
medical history revealed relapsed chronic lymphocytic leukaemia (CLL). He had been 
treated with two regimens of chemotherapy. Initially, he had been treated with fludara-
bine 40 mg/m2 and cyclophosphamide  250 mg/m2 every four weeks, which was discon-
tinued after two cycles because of fludarabine induced pancytopenia. Subsequently, he 
had been treated with 8 cycles of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, 
vincristine 2 mg and prednisolone 40 mg/m2 every three weeks. Shortly after his second-
line therapy, patient developed pancytopenia due to refractory CLL. Because initially the 
pancytopenia presented with only thrombocytopenia, he was treated with predniso-
lone 1 mg/kg due to suspected autoimmune thrombocytopenia associated with CLL. In 
the same period, patient was admitted to the general hospital because of polymicrobial 
sepsis with Fusobacterium, Klebsiella oxytoca and Enterococcus faecium, for which he was 
treated with cefuroxime 750 mg six times daily, gentamicin 300 mg daily and vanco-
mycin 1000 mg three times daily. In addition, patient was diagnosed with probable IA 
(lung abnormalities on HRCT and serum galactomannan optical density index of 0.5) 
for which he was treated with voriconazole 200 mg twice daily. Because of these severe 
infectious complications, patient was transferred to Erasmus University Medical Center 
for further treatment of his CLL. On transfer, the prednisolone was already discontinued. 
Antibiotic treatment for the sepsis and voriconazole were continued. During screening 
for third-line chemotherapy, patient developed neutropenic fever again. Follow-up 
HRCT showed that the initial consolidation of the right upper lobe had regressed, but a 
new pleural mass was found in the left upper lobe. Biopsy of this mass was performed 
and cultured Aspergillus. Because of its poor sporulation, it was not possible to deter-
mine the sensitivity and an A. fumigatus sibling species was suspected. The isolate was 
initially identified as A. viridinutans by sequencing of the BenA gene. As the lung biopsy 
Interspecies discrimination of A. fumigatus and sibling spp 111
culture became positive under voriconazole (no TDM performed), the then unidentified 
Aspergillus species, was considered to be azole-resistant and antifungal therapy was 
switched to liposomal amphotericin-B 290 mg daily (5 mg/kg) for proven IA. Despite 
the switch to liposomal amphotericin-B, patient continued to have neutropenic fever 
and developed dyspnea due to progressive infiltrates. As there were no therapeutic 
options to treat the patient for his CLL during an active infection and no improvement 
was observed after switching therapy to liposomal amphotericin-B, treatment was dis-
continued. Patient died of uncontrolled infection shortly after discontinuing liposomal 
amphotericin-B. Postmortem, the infecting isolate was re-identified as A. felis species 
complex (CBS 141341) based on sequencing the ITS region, and a part of the BenA and 
CaM gene. No MICs were available for this A. felis species complex isolate.
results 
The AsperGenius® assay was performed on isolates obtained from lung biopsy in case 
report 1 and from pleural mass biopsy in case report 2. Both isolates gave positive signals 
for the Aspergillus species and Aspergillus section Fumigati. First, it was examined if the 
resistance PCR yielded (characteristic) melting curves (figure 1) and melting temperature 
(Tm; table 1) values, respectively, for all Cyp51A markers of the case isolates in comparison 
to A. fumigatus WT and mutants (TR34/L98H and TR46/T289A/Y121F). The TR34 target was 
not detected in the A. lentulus and A. felis species complex strains in contrast to WT or 
mutant A. fumigatus. The L98H target showed lower Tm-values for the A. lentulus and A. 
felis species complex compared to WT or mutant A. fumigatus. Comparable Tm-values 
for the T289A target were found for A. fumigatus, A. lentulus  and A. felis species complex. 
The Y121F target showed the most different Tm-values for all three sibling species: the 
Tm variation was 13.5 °C degrees between A. lentulus and A. felis species complex, 3.0 °C 
degrees between A. fumigatus WT and A. lentulus, and 16.5 °C degrees between A. fumiga-
tus WT and A. felis species complex (table 1). Thus, the absent TR34 melting curve with the 
species specific Y121F melting curve indicates that melting curve analysis is indeed a tool 
to discriminate Aspergillus siblings from both WT and mutant Aspergillus fumigatus.
To assess the precision of the findings the melting curves of six more A. lentulus and 
twelve more A. felis species complex strains were analyzed next to the 3 control WT and 
mutant A. fumigatus strains (figure 2). The results of the TR34, T289A and Y121F targets 
were confirmed for all strains tested. However, the Tm-values of the L98H target were 
more variable: three different Tm-regions were found for A. lentulus and two different 
Tm-regions for A. felis species complex (table 2). Based on the results, again, two targets, 
i.e. TR34 and Y121F can be used to differentiate the siblings A. lentulus and A. felis species 
complex from WT and mutant A. fumigatus.
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figure 1. Melting curves of the resistance PCR on lung biopsy cultures of the two sibling species from the 
cases and control A. fumigatus isolates.
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To evaluate the precision of the Tm-value differences between wildtype A. fumigatus, 
A. lentulus and A. felis, we reviewed Tm-values of nine other clinical WT A. fumigatus 
strains from patients at the Erasmus University Medical Center that we had previously 
tested with the AsperGenius® assay in the period of January 2015 to June 2016. For the 
L98H target, the Tm-values of these nine strains ranged from 60.2 to 61.7 °C degrees, 
which overlapped with the A. lentulus and A. felis. However, the Tm-values of the Y121F 
target ranged from 62.5 to 63.3 °C degrees and therefore confirmed that the Tm-values 
did not overlap with the Tm-values of the A. lentulus and A. felis species complex isolates. 
table 1. Melting temperature (Tm) values of the resistance PCR of A. lentulus, A. felis species complex and 
wildtype or mutant A. fumigatus isolates (controls). 
Name Origen Tm values
TR34 L98H T289A Y121F
A. lentulus isolates
CBS 141342 (Isolate from case 1) Clinical, NL ND 54.0 63.0 60.0
CBS 116884 Environmental, Korea ND 54.0 63.0 59.0
CBS 117887 Clinical, USA ND 54.0 63.0 59.0
CBS 117886 Clinical, USA ND 58.0 63.0 59.0
CBS 612.97 Clinical, NL ND 58.0 63.0 59.0
CBS 117884 Clinical, USA ND 61.0 63.0 59.5
CBS 117885 Clinical, USA ND 61.0 63.0 59.0
A. felis species complex isolates
CBS 141341 (Isolate from case 2) Clinical, NL ND 60.5 63.0 46.5
DTO 159-C7 (A. parafelis) Cat, Australia ND 59.0 62.5 46.0
DTO 176-F1 (A. parafelis) Environmental, DE ND 59.0 62.5 46.0
CBS 130245T (A. felis) Cat, Australia ND 60.5 62.5 46.0
CBS 130247 (A. felis) Cat, Australia ND 60.5 62.5 46.0
CBS 130248 (A. felis) Cat, Australia ND 60.5 62.5 46.0
CBS 130249 (A. felis) Cat, Australia ND 60.5 62.5 46.0
CBS 130246 (A. felis) Cat, Australia ND 60.5 62.5 46.0
CBS 130250 (A. pseudofelis) Cat, UK ND 60.0 62.5 48.0
DTO 175-H3 (A. parafelis) Environmental, Portugal ND 60.0 62.5 48.0
CBS 140762T (A. parafelis) Clinical, Spain ND 60.0 62.5 48.0
CBS 140766 (A. pseudofelis) Clinical, Spain ND 60.0 62.5 48.0
CBS 140763T (A. pseudofelis) Clinical, Spain ND 60.0 62.5 48.0
A. fumigatus isolates (controls)
Wildtype Clinical, NL 64.5 61.5 63.0 63.0
Mutant TR34/ L98H Clinical, NL 66.5 65.5 63.0 63.0
Mutant TR46/Y121F/T289A Clinical, NL 64.5 61.5 67.5 68.0
Note: DE, Germany. NL, the Netherlands. UK, United Kingdom. USA, United States of America. ND, not de-
tected.
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figure 2. Precision: melting curves of the resistance PCR on the isolates provided by the Fungal Biodiversity 
Centre. 
table 2. Melting temperature (Tm) and interspecies differentiation of Aspergilus section Fumigati species 
with the resistance PCR.
A. 
fumigatus 
WT
A. fumigatus 
TR34/ L98H
A. fumigatus 
TR46/Y121F/
T289A
A. lentulus A. felis Conclusion
L98H 61.5
(historical 
precision 
of 60.2 to 
61.7)
65.5 61.5 54.0/58.0/61.0 59.0/60.5 Differentiation of A. fumigatus TR34/
L98H with other Fumigati species. 
Differentiation of A. fumigatus from 
siblings species not possible.
TR34 64.5
(historical 
precision 
of 63.5 to 
65.0)
66.5 64.5 ND ND Differentiation of A. fumigatus TR34/
L98H with A. fumigatus WT. 
Absence of TR34 can be indicative 
for a Fumigati species combined 
with L98H Tm value lower than that 
of WT (61.5).
T289A 63.0
(historical 
precision 
of 62.5 to 
63.7)
63.0 67.5 63.0 62.5 Differentiation of A. fumigatus 
TR46/Y121F/T289A with other 
Fumigati species. No differentiation 
possible of  A. fumigatus wildtype, 
A. fumigatus TR34/L98H, A. felis, A. 
lentulus.
Y121F 63.0
(historical 
precision 
of 62.5 to 
63.3) 
63.0 68.0 59.0 46.0 No differentiation of A. fumigatus 
WT with A. fumigatus TR34/L98H. 
Differentiation possible of all other 
Fumigati species.
Note: ND, not detected. WT, wild-type. Tm, melting temperature.
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dIsCussIon
The results reported here showed that the resistance PCR of the AsperGenius® assay not 
only detects the two most common mutation combinations in the Cyp51A gene of the A. 
fumigatus that are associated with azole resistance, but can also be used for interspecies 
discrimination of the Aspergillus section Fumigati. Using lung biopsy cultures from two 
patients with proven IA, we observed that the resistance PCR showed melting curves/
Tm-values for A. lentulus and A. felis species complex that were different from those of 
A. fumigatus WT or A. fumigatus with TR34/L98H or TR46/T289A/Y121F mutations. As a 
result, the resistance PCR could differentiate A. fumigatus, A. lentulus and A. felis species 
complex. These results were confirmed on 18 additional isolates.
A. lentulus and A. felis species complex belong to Aspergillus section Fumigati and 
can sporadically cause IA. They have often high MICs for voriconazole [1,9-13,15]. For A. 
lentulus, its intrinsic low susceptibility for azoles can be explained partly by its Cyp51A 
gene [16,17]. For A. felis species complex, its resistance mechanism is unclear. The cur-
rent results suggest that the Cyp51A gene of the A. felis is partly alike that of A. fumigatus 
as the resistance PCR gives signals for the L98H, T298A and Y121F targets. Given that 
voriconazole is the recommended first line therapy for IA [3], a fast identification of 
Aspergillus species that are less susceptible or resistant to voriconazole is important 
to select the appropriate antifungal therapy. Currently, identification of the two tested 
sibling species is challenging for two reasons. Firstly, most patients with IA are culture 
negative and are diagnosed based on a positive galactomannan in serum or BAL fluid 
[5]. Secondly, if a culture is available, the identification and susceptibility testing of A. 
lentulus and A. felis species complex are difficult as they (i) have slow or poor sporulation 
and (ii) are morphologically similar to A. fumigatus except for their inability to grow at 50 
°C degrees, and (iii) one or more genes have to be sequenced to confirm their identity 
[14,19]. Moreover, this identification process is time consuming and often has to be 
performed in a reference laboratory. 
The AsperGenius® assay detects several clinical relevant Aspergillus species and 
differentiates wildtype from azole resistant A. fumigatus directly on clinical samples, 
even in culture negative IA [20,22]. The assay was tested on isolates of two patients 
with proven IA caused by A. lentulus and A. felis species complex. As the A. fumigatus 
probe detects these two aspergilli because they are part of the section Fumigati, we 
investigated if the resistance PCR could discriminate the siblings from A. fumigatus. This 
is crucial information, as one would not want to report an isolate as sensitive, when 
in fact it is resistant to azole treatment (very major error). This would be the case if a 
sibling would be identified as ‘A. fumigatus by the A. fumigatus probe’ and sensitive if 
the resistance PCR of the sibling would be conform the WT melting curve. However, 
the resistance PCR was able to differentiate between A. fumigatus, A. lentulus and A. 
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felis species complex. Not all markers of the resistance PCR were suitable. The T289A 
marker did not differentiate between the three sibling species. The L98H marker could 
differentiate WT A. fumigatus from TR34/L98H mutant control, but was not able to dif-
ferentiate A. lentulus or A. felis species complex. Remarkably, differences were observed 
in the L98 region between A. lentulus strains as well as A. felis species complex strains. 
This is probably caused by small variations in the L98 sequence region. The TR34 marker 
showed no melting curves for A. lentulus and A. felis species complex in contrast to the 
wildtype or mutated A. fumigatus, which is indicative of a sibling species when the L98H 
probe produces i) a melting curve and ii) the melting temperature is lower than that of 
the WT A. fumigatus (63 °C degrees). This is important as the resistance PCR is a single 
copy PCR and sometimes the TR34 might not yield a result whereas the L98H does, which 
is a known sensitivity issue with low copy numbers. Most importantly, the Y121F marker 
clearly differentiated A. lentulus and A. felis species complex from the wildtype as well 
as the mutant A. fumigatus, and was also able to differentiate between A. lentulus and A. 
felis species complex. In other words, the resistance PCR can aid in preventing to report 
a very major error (a sibling species as WT i.e. sensitive to azoles).
The case and control A. fumigatus, A. lentulus and A. felis species complex strains 
were tested in one experiment. To assess the precision of this 3 °C degrees difference 
of the Tm-values from A. fumigatus and A. lentulus, we reviewed historical data and no 
overlap was observed for the Y121F. Therefore, when both the melting curve analysis of 
the TR34 and Y121F markers are analyzed, A. lentulus and A. felis species complex could be 
differentiated from the A. fumigatus WT and A. fumigatus with TR34/L98H or TR46/T289A/
Y121F azole resistance combinations.  
In 2014, Sugui et al. published the results of a phylogenetic analysis on 19 isolates 
from the section Fumigati, of which nine were A. felis or A. viridinutans [25]. Within 
these nine isolates, three novel species were distinguished and named A. pseudofelis, 
A. parafelis and A. pseudoviridinutans. These novel species showed increased MIC values 
to itraconazole and voriconazole, which is similar to A. felis [10,12,25]. The AsperGenius® 
assay was tested on five A. felis, four A. parafelis and three A. pseudofelis strains. Due 
to the uncertainty of the taxonomy and no clinical consequences regarding antifungal 
therapy, we preferred to refer the strains as A. felis species complex.
There are a few limitations. First, the resistance PCR detects and identifies polymor-
phisms in the Cyp51A gene as these polymorphisms result in different melting curves. 
However, susceptibility testing on isolates should be done if possible, to confirm the 
exact phenotype as well. However, culture-based susceptibility testing is time consum-
ing and often impossible with poorly or non-sporulating species like A. lentulus or A. felis 
species complex. Secondly, the resistance PCR was not tested on other siblings in the 
Fumigati section. To date, the Aspergillus section Fumigati has up to at least 63 species, 
of which 17 have been reported to be opportunistic pathogens to humans and/or other 
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mammals [26]. Except for the A. fumigatus, the other 16 pathogenic Aspergillus species, 
of which A. lentulus and A. felis species complex are among the more ‘frequent’, are 
described in case reports or as a very small part of collections of clinical isolates [26]. We 
were unable to test if more sibling species of the section Fumigati would have the same 
melting curves or Tm-values as found in the sibling species in this current report. Further 
research using the AsperGenius® assay and other sibling species is therefore needed.
We conclude that the AsperGenius® assay accurately detects and differentiates A. fu-
migatus WT, A. fumigatus TR34/L98H and A. fumigatus TR46/T289A/Y121F from the sibling 
species A. lentulus and A. felis species complex using the azole resistance targets TR34 and 
Y121F. A. lentulus and A. felis species complex are often azole resistant. Retrospectively, 
the promptly identification of these two sibling species on species/complex level could 
have enabled improved management in the two cases.
118 Chapter 6
referenCes
 1  Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a 
problem in Spain? Antimicrob Agents Chemother. 2013;57(6):2815-2820. 
 2  Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and 
outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: 
analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 
2009;48(3):265-273. 
 3  Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice 
Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious 
Diseases Society of America. Clin Infect Dis. 2016. 
 4  Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, et al. Outcome 
and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-
myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin 
Infect Dis. 2008;47(12):1507-1512. 
 5  Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination anti-
fungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-89. 
 6  Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus 
fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9(5):697-711. 
 7  van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et 
al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. 
Emerg Infect Dis. 2011;17(10):1846-1854. 
 8  Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we 
retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2015. 
 9  Alhambra A, Catalan M, Moragues MD, Brena S, Ponton J, Montejo JC, et al. Isolation of Aspergil-
lus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev 
Iberoam Micol. 2008;25(4):246-249. 
 10  Coelho D, Silva S, Vale-Silva L, Gomes H, Pinto E, Sarmento A, et al. Aspergillus viridinutans: an 
agent of adult chronic invasive aspergillosis. Med Mycol. 2011;49(7):755-759. 
 11  Montenegro G, Sanchez Puch S, Jewtuchowicz VM, Pinoni MV, Relloso S, Temporitti E, et al. Phe-
notypic and genotypic characterization of Aspergillus lentulus and Aspergillus fumigatus isolates 
in a patient with probable invasive aspergillosis. J Med Microbiol. 2009;58(Pt 3):391-395. 
 12  Pelaez T, Alvarez-Perez S, Mellado E, Serrano D, Valerio M, Blanco JL, et al. Invasive aspergillosis 
caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with 
leukaemia. J Med Microbiol. 2013;62(Pt 3):474-478. 
 13  Zbinden A, Imhof A, Wilhelm MJ, Ruschitzka F, Wild P, Bloemberg GV, et al. Fatal outcome after 
heart transplantation caused by Aspergillus lentulus. Transpl Infect Dis. 2012;14(5):E60-63. 
 14  Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling 
species of A. fumigatus. Eukaryot Cell. 2005;4(3):625-632. 
 15  Gurcan S, Tikvesli M, Ustundag S, Ener B. A Case Report on Aspergillus lentulus Pneumonia. Balkan 
Med J. 2013;30(4):429-431. 
 16  Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Role of Aspergillus lentulus 
14-alpha sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother. 
2011;55(12):5459-5468. 
 17  Alcazar-Fuoli L, Cuesta I, Rodriguez-Tudela JL, Cuenca-Estrella M, Sanglard D, Mellado E. Three-
dimensional models of 14alpha-sterol demethylase (Cyp51A) from Aspergillus lentulus and Asper-
Interspecies discrimination of A. fumigatus and sibling spp 119
gillus fumigatus: an insight into differences in voriconazole interaction. Int J Antimicrob Agents. 
2011;38(5):426-434. 
 18  Alvarez-Perez S, Mellado E, Serrano D, Blanco JL, Garcia ME, Kwon M, et al. Polyphasic character-
ization of fungal isolates from a published case of invasive aspergillosis reveals misidentification 
of Aspergillus felis as Aspergillus viridinutans. J Med Microbiol. 2014;63(Pt 4):617-619. 
 19  Barrs VR, van Doorn TM, Houbraken J, Kidd SE, Martin P, Pinheiro MD, et al. Aspergillus felis 
sp. nov., an emerging agent of invasive aspergillosis in humans, cats, and dogs. PLoS One. 
2013;8(6):e64871. 
 20  Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, et al. Validation 
of a New Aspergillus Real-Time PCR Assay for Direct Detection of Aspergillus and Azole Resistance 
of Aspergillus fumigatus on Bronchoalveolar Lavage Fluid. J Clin Microbiol. 2015;53(3):868-874. 
 21  White PL, Posso RB, Barnes RA. Analytical and Clinical Evaluation of the PathoNostics AsperGenius 
Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs during 
Testing of Serum Samples. J Clin Microbiol. 2015;53(7):2115-2121. 
 22  Chong GM, van der Beek MT, von dem Borne PA, Boelens J, Steel E, Kampinga GA, et al. PCR-based 
detection of A. fumigatus Cyp51A mutations on bronchoalveolar lavage. A multi-center valida-
tion of the AsperGenius assay® in 201 patients with hematological disease suspected for invasive 
aspergillosis. J Antimicrob Chemother (in press). 
 23  Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two differ-
ent 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and 
other Aspergillus species. J Clin Microbiol. 2001;39(7):2431-2438. 
 24  De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of 
invasive fungal disease from the European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-
1821. 
 25  Sugui JA, Peterson SW, Figat A, Hansen B, Samson RA, Mellado E, et al. Genetic relatedness versus 
biological compatibility between Aspergillus fumigatus and related species. J Clin Microbiol. 
2014;52(10):3707-3721. 
 26  Frisvad JC, Larsen TO. Extrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergil-
lus Section Fumigati. Front Microbiol. 2015;6(1485. 

Chapter 7
General discussion and summary
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IntroduCtIon 
Invasive aspergillosis (IA) is a life threatening opportunistic infection that is usually 
caused by A. fumigatus [1,2]. It is the most common invasive fungal disease (IFD) in im-
munocompromised patients with an underlying hematological disease and is associ-
ated with a substantial increase in morbidity, mortality as well as health care costs [3-5]. 
Ever since voriconazole has been shown to be the superior treatment for this infection 
[6], it has become the cornerstone of IA therapy [7]. However, in 2002 azole resistance 
was reported for the first time in Dutch patients infected with A. fumigatus and its 
prevalence has continued to increase from that moment on [8,9]. The prompt diagnosis 
and appropriate treatment of an infection with an azole-resistant A. fumigatus is difficult 
[10,11]. A better insight into the different aspects of IA (diagnostics, outcome but also 
prevention) will facilitate its optimal management. In this thesis several studies on the 
epidemiology, prevention and diagnosis of IA are described with a particular focus on 
high-risk patients with an underlying hematological disease. The current chapter sum-
marizes and discusses the main findings in paragraph 2. Recommendations for future 
research are given in paragraph 3.
mAIn fIndIngs And dIsCussIon
Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation
IA is a common IFD in recipients of allogeneic hematopoietic stem cell transplantation 
(alloHSCT) [1,12-22]. The reported incidences vary from 2.3% up to 15.0% and the mor-
tality is substantial in this particular patient group [12-18,20]. Primary prophylaxis with 
voriconazole or posaconazole significantly reduces the incidence of IA in alloHSCT re-
cipients and is recommended in those receiving corticosteroids and/or other therapies 
for graft-versus-host disease (GVHD) [7,23,24]. However, apart from GVHD, many other 
risk factors for post-transplant IA have been described, such as older age, neutropenia, 
non-related donor, reactivation of cytomegalovirus (CMV) and a history of pre-transplant 
IFD [12-16,19,20,22,25,26]. Moreover, IA is most frequently observed in the first year 
post-transplantation, but a substantial part of the recipients develops IA later [12,16,17]. 
Therefore, the best timing and duration of primary prophylaxis can be difficult to decide. 
Recognizing risk factors may help in selecting those patients that are at highest risk 
and therefore benefit most of primary prophylaxis. We conducted a retrospective study 
to determine the incidence, outcome and risk factors of IA in alloHSCT recipients. All 
patients who underwent their first alloHSCT in the Erasmus University Medical Center 
between 2004 and 2014, were included. IA was classified according to the European 
Organization for the treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria 
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[27]. In addition, patients with a positive microbiological criterium but with non-specific 
radiological findings were defined as having non-classifiable IA. These patients were 
included, as clinicians tend to treat them similar to patients with probable IA. 
A total of 663 patients received their alloHSCT in the indicated period. We found an 
incidence of proven, probable, non-classifiable IA of 13.0% within the 12-months post-
transplantation and 15.5% in the entire follow-up time. All-cause mortality was signifi-
cantly higher in patients with than without IA. An increase in the incidence of IA was ob-
served in 2012 and 2013. This may be explained by different reasons. First, a long-lasting 
demolition and renovation of a neighboring hospital building was initiated from 2011 
onwards at the site where all alloHSCT recipients were transplanted and followed after 
alloHSCT. Hospital constructions and demolitions have been associated with increased 
IA in patients with underlying hematological disease [28,29]. Second, azole resistance 
has emerged in the Netherlands over the past 15 years [9,11]. In our cohort, 6 recipients 
had developed probable or non-classifiable IA due to azole-resistant A. fumigatus. As 
fungal cultures often remain negative and because antifungal susceptibility testing was 
not a standard procedure in the first half of the observation period, the actual number 
of patients infected with azole-resistant A. fumigatus may have been higher. As primary 
prophylaxis with triazoles does not prevent azole-resistant IA, the emergence of azole 
resistance may have contributed to the increased incidence in IA as well.
To study the risk factors, we performed a nested case-control study within the to-
tal cohort. Ninety-nine patients with proven, probable and non-classifiable IA (cases) 
were compared to 198 patients without IA (controls). A backward logistic regression 
showed that the risk factors for developing IA were neutropenia, lymphocytopenia, 
pulmonary comorbidity, CMV reactivation, renal impairment and the use of systemic 
corticosteroids. Also, a higher dose of corticosteroids was associated with a higher risk 
of IA, suggesting a dose-effect relationship. Most of these risk factors were also found 
by others [13,16,22,25,26]. However, this study is the first to identify renal impairment as 
an independent risk factor for IA [12,21,25]. Remarkably, and in contrast to some other 
studies, pre-transplant IA and GVHD was eliminated among others in the logistic regres-
sion analysis [12-14,16,19,20,22,25]. Perhaps pre-transplant IA was not found to be risk 
factor, because patients with pre-transplant IA are often treated with secondary prophy-
laxis during alloHSCT. Also, selection bias may partially explain this finding because a 
subset of patients in need for an alloHSCT who develop IA may no longer be eligible for 
the transplantation. As for GVHD, patients with acute or chronic GVHD are almost always 
treated with systemic corticosteroids. Consequently, these variables are highly associ-
ated. In an additional univariate analysis, acute and chronic GVHD were analyzed as one 
variable and found to be a risk factor. However, any form of GVHD was eliminated when 
added to our current model, presumably because of the strong and dose dependent 
effect of corticosteroids. Our results do not reject the hypothesis that GVHD in se is a 
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risk factor, but with the current study design, it was not possible to disentangle to what 
extent the presence of GVHD and corticosteroid therapy are independent risk factors 
for IA.
In conclusion, 15.5% of the patients develops IA post-transplantation and these 
patients have a worse outcome than those patients without IA. Although the majority 
of the patients develop IA in the first-year post-transplantation, there is a continued risk 
on developing IA after the first year as well. The risk factors that we have identified for 
IA should help clinicians deciding to start or to discontinue antifungal prophylaxis in 
the appropriate patient at the correct time. In the Erasmus University Medical Center, 
primary prophylaxis was formerly prescribed to alloHSCT recipients with GVHD who 
were treated with second line anti-GVHD treatment. Based on the results of this study, 
primary prophylaxis was extended to all alloHSCT recipients who are treated with high-
dose corticosteroids. In the view of the increasing azole resistance, continued assess-
ment of IA in this patient group is needed to monitor the effect of primary prophylaxis 
with triazoles.
Inhalation of liposomal amphotericin-b to prevent invasive pulmonary 
aspergillosis
Chemotherapy-induced prolonged neutropenia can be complicated by invasive pulmo-
nary aspergillosis (IPA). In 2008, a randomized controlled trial (RCT) showed that lipo-
somal amphotericin-B (L-AmB) inhalation twice a week prevented IPA in patients with 
acute myeloid leukemia (AML) [30]. This resulted in a BI recommendation for the use of 
this intervention in European Conference on Infections in Leukaemia (ECIL) guidelines 
[31]. After the RCT, prophylaxis with L-AmB inhalation became the standard of care for 
patients with AML undergoing remission induction chemotherapy at Erasmus University 
Medical Center in 2009. Nonetheless, it is difficult to predict how interventions work in 
real-life outside the context of a RCT. In chapter 3, we describe a prospective population-
based study in which we establish the external validity of the RCT outcomes in a real-life 
AML patient population. In total, 127 consecutive AML patients prophylactically inhaled 
L-AmB during their 1st and 2nd remission induction chemotherapy; 108 patients treated 
for AML at the same sites from 2005 to 2008 served as controls. A significant decrease 
in probable and proven IPA was observed in the L-AmB inhalation group (L-AmB group 
9.5% vs control group 23.4%, p=0.0064). Systemic antifungal therapy given at any time 
during the entire AML therapy decreased from 52.8% to 29.9%. Apart from its efficacy, 
the use of L-AmB inhalation was also cost saving in regard to diagnostics and voricon-
azole therapy (minus 1816 euro/patient). These cost savings more than compensated 
for the costs related to L-AmB inhalation itself (1292 euro/patient). No L-AmB inhalation 
related serious adverse events were observed. 
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Apart from the current study and the randomized study by Rijnders et al., a third 
randomized controlled study on the use of amphotericin-B (AmB) inhalation for the pre-
vention of IPA in patients with an underlying hematological disease has been published 
[30,32]. Schwartz et al. evaluated the effectiveness of conventional AmB inhalations in 
382 patients who were neutropenic for at least 10 days after chemotherapy or autolo-
gous stem cell transplantation. No difference was found in the IPA incidence or mortality 
between the inhalation group and no inhalation group. This may be explained by the 
fact that conventional AmB was used. Conventional AmB can impair the function of the 
pulmonary surfactant in contrast to L-AmB that exhibits a surfactant-like function [33]. 
Moreover, another inhalation system was used in this study which could also affect the 
efficacy of the inhaled medication. 
L-AmB inhalation was already the standard of care in the Erasmus University Medical 
Center when the current study was initiated. Therefore, we compared patients inhaling 
L-AmB to historical control patients to evaluate the efficacy and cost-effectiveness in 
real-time. Considering that medicine evolves quickly, a time-related and diagnostic 
bias might occur when controls are not from the same calendar year as cases. However, 
no considerable changes occurred in the chemotherapeutic agents that were used 
for treating AML and the diagnostic procedures remained unchanged throughout the 
study. Hence, it is unlikely that a time-related or diagnostic bias has occurred.
In an unselected AML patient group, L-AmB inhalation resulted in a statistically 
significant and clinically relevant decrease in IPA that was also cost saving. With the cur-
rent study results available together with the clinical trial data from 2008, we think it is 
time to move forward and study the use of L-AmB inhalation in other patients at high 
risk for IPA, in particular in patients with serious GVHD. Moreover, it is time that L-AmB 
inhalation is used outside the Erasmus University Medical Center as this approach does 
not suffer from a decreased efficacy in the context of triazole resistance problem in the 
Netherlands. Preventing IA will avoid the need for expensive combination antifungal 
therapy for patients with IA. Indeed, as a result of the increasing prevalence of azole-
resistant A. fumigatus, combination therapy is now recommended in the SWAB guideline 
on invasieve fungal infections (2017) when triazole resistance cannot be excluded by 
culture or Cyp51A PCR testing [34].
galactomannan antigen testing on cerebrospinal fluid 
Cerebral aspergillosis (CA) is a rare and often fatal fungal disease (IFD) [4,35]. The di-
agnosis is challenging as radiological findings are non-specific and cerebrospinal fluid 
(CSF) cultures are only positive in less than one-third of the cases [36,37]. Moreover, 
obtaining brain tissue for histopathological examination, the diagnostic gold standard, 
is frequently not feasible because of the risk of complications in patients with an under-
lying hematological disease who are often trombocytopenic. We postulated that testing 
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cerebrospinal fluid (CSF) for the presence of galactomannan (GM) may help in diagnos-
ing cerebral aspergillosis (CA) [27,36,38,39]. Although GM antigen detection is one of 
the microbiological criteria in the EORTC/MSG criteria, the test has never been validated 
properly [27]. In chapter 4, we described the findings on the diagnostic performance 
of CSF GM antigen. The CSF GM levels were compared at different cut-offs in patients 
with probable and proven CA to those without CA. The revised IA and CA definitions 
of the EORTC/MSG were used but excluding the to-be-validated-test (=CSF GM) as a 
microbiological EORTC/MSG criterion. The study population consisted of 44 patients (4 
proven CA, 13 probable CA and 27 no CA). When a cut-off of 0.5 to 2.0 was used, GM 
detection in CSF had a good diagnostic performance with a sensitivity, specificity, posi-
tive and negative predictive values were 88.2%, 96.3%, 93.8% and 92.9%, respectively.
To analyze the diagnostic performance of a diagnostic test, a gold standard needs 
to be chosen to allow for a comparison of the old and new diagnostic test. For GM anti-
gen testing on CSF, the gold standard would be a positive cerebral biopsy to definitely 
prove the presence of CA. However, cerebral biopsies are not often performed. Hence, 
we chose to exclude CSF GM from the EORTC/MSG criteria to allow for the evaluation 
of CSF GM testing. CA was diagnosed in two steps: first, we examined if patients had 
proven or probable IA outside the cerebrum. Subsequently, these patient with proven 
or probable IA were diagnosed with CA if they also had suspected cerebral lesions. This 
was deemed necessary because otherwise patients with an isolated serum GM ≥0.5 and 
a focal cerebral lesion (e.g. cerebral infarction) but without any other evidence of IA 
elsewhere would fit the probable CA definition. Using this approach, a good diagnostic 
performance was found with the GM cut-off of 0.5 to 2.0. 
The CSF GM antigen test is included in the revised EORTC/MSG [27]. However, so far 
only 2 studies have reported on GM antigen testing in CSF in a total of 10 patients with 
CA [38,39]. Viscoli et al. measured GM on CSF from 5 patients with proven and probable 
CA, and found a significantly higher GM level in patients with CA compared to patients 
without CA [39]. Similarly, Kami et al. found that the GM antigen test was positive in 4 of 
the 5 CSF of patients with proven CA and negative in all patients without CA [38]. Finally, 
Antinori et al. reviewed the literature on Aspergillus meningitis, which is not the same as 
CA, and found that CSF GM was performed in 15 of the 93 cases [36]. The median CSF GM 
was 6.58 with a range of 2.2 to 578. The sensitivity was 86.7%. 
Retrospective studies have the limitation that only those data that are readily avail-
able can be analyzed which may reduce the population size and study power. Unfortu-
nately, this was also a limitation in our current study. GM antigen had been tested on CSF 
of 157 patients admitted to the hematology, internal medicine and pediatric depart-
ments of 2 university hospitals in the period 2004 to 2014. Over half of the patients had 
to be excluded because not all data that were needed for the analysis were available. 
This resulted in a considerable reduction in size of the study population. Despite of that, 
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the current study population (n=44) was the largest study ever published on this topic 
and consisted of data over 10 years of 2 large academic hospitals. 
The results of our study on 44 patients show clearly that the first step in the diagnos-
tic approach to a patient in whom CA is considered, should be CSF GM antigen testing. 
If this test is positive, the diagnosis is almost certain and treatment should be initiated 
promptly. On the other hand, a negative CSF GM test makes the diagnosis of CA very 
unlikely.
diagnosis of azole-resistant Aspergillus fumigatus
Over the past 15 years, azole resistance in A. fumigatus has emerged worldwide [10,11]. 
This is a worrisome development as small case series have reported a very high mor-
tality in IA caused by azole-resistant A. fumigatus [40,41]. Moreover, the diagnosis of 
azole-resistant A. fumigatus is challenging as (i) cultures become positive only in about 
one-quarter of the IA cases, and (ii) conventional microbiological testing for azole 
susceptibility is not widely available and is time consuming [42,43]. The lack of a fast 
and readily available susceptibility testing method in particular for patients in whom 
cultures remain negative hampers the prompt initiation of adequate therapy in patients 
infected with an azole-resistant A. fumigatus. A potential solution to this problem may 
be the use of an Aspergillus polymerase chain reaction (PCR) assay that can detect the 
presence of Aspergillus DNA and can identify the Aspergillus to the species level. In ad-
dition, the detection of Aspergillus DNA may allow for the detection of mutations that 
confer resistance to azoles. This method may also be used on patient samples of which 
fungal cultures remain negative. Such a PCR was investigated in chapter 5.1 and 5.2. 
We described the results of two studies on the AsperGenius® multiplex real-time PCR, a 
commercially available Aspergillus assay that detects several Aspergillus species as well 
as the two most common mutation combinations in A. fumigatus that are associated 
with azole resistance in the Netherlands. In a retrospective single-center study (chapter 
5.1), the optimal cycle threshold (Ct) and diagnostic value of the aforementioned as-
say was used on 77 stored BAL samples of patients with an underlying hematological 
disease or admitted to the intensive care unit (ICU). BAL samples that were GM (≥1.0) 
and/or culture positive were considered positive controls for the presence of Aspergillus. 
Negative controls were BAL samples with a negative GM in combination with negative 
culture. We found that the optimal Ct for the presence of Aspergillus was <36. Using this 
Ct value, we found a good diagnostic performance with an overall sensitivity, specificity, 
positive and negative predictive values (PPV, NPV) of 84.2%, 91.4%, 76.2% and 94.6%, 
respectively. Moreover, we also identified two patients with IA caused by A. fumigatus 
with TR34/L98H and TR46/T298A/Y121F mutation combinations and who both failed 
azole therapy. 
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Subsequently, a multicenter study was performed to confirm the optimal Ct value 
and diagnostic performance of the AsperGenius® assay in a larger population of patients 
with underlying hematological diseases (chapter 5.2). In this multicenter study, we were 
also able to evaluate if the molecular detection of the resistance associated mutations 
(RAM) correlated with azole treatment failure and mortality. In 201 BAL samples of pa-
tients with an underlying hematological disease, the receiver operator character (ROC) 
curve was analyzed according to two different methods to select the optimal Ct value. 
These two methods led to contradictory results as to the most appropriate Ct cut-off 
values (36 and 38, respectively). Given the important clinical consequences of a missed 
IA diagnosis, a higher sensitivity was preferred. Therefore, the later Ct value cut-off of 
38 was chosen over 36 that was reported in the previous study and was used for the 
subsequent analyses. Using the Ct cut-off of <38, a sensitivity, specificity, PPV and NPV of 
84.1%, 79.7%, 76.3% and 86.5% was found. This sensitivity was somewhat lower than the 
sensitivity of 89% that was found in the single center study at a Ct cut-off of <36 in the 
hematology group. This difference may be explained by the fact that a standard volume 
of 1 milliliter BAL was used in multicenter study versus 1-2 milliliter in the single center 
study. The lower volume may have decreased the sensitivity. Also, we observed some 
differences in the sensitivity between the five study centers, which may be explained by 
differences in the way the BAL is performed in each center. For example, protocols may 
differ concerning the volume used to perform the BAL, or a bronchoscopist may lavage 
two different parts of the lung but send it in one container to the laboratory which may 
result in a diluted DNA content if Aspergillus is present in only one part of the lung. Un-
fortunately, the way the BAL procedure was done in each patient was not registered. The 
differences between the study centers could not be explained by difference in methods 
or duration in BAL storage.
For the evaluation of the diagnostic performance of the AsperGenius® assay, BAL 
samples with a positive GM (≥1.0) and/or a positive Aspergillus culture of the BAL, spu-
tum or lung biopsy were considered positives. Negative controls were BAL samples with 
a negative BAL GM in combination with a negative culture. Consequently, BAL samples 
of patients with specific radiological findings and positive serum GM, but negative 
BAL GM, were categorized as negatives. This categorization was chosen in favor of the 
EORTC/MSG criteria to ensure that there was evidence of Aspergillus in the BAL samples 
themselves. However, the EORTC/MSG criteria are often used as criteria for the presence 
of IA in antifungal studies, and therefore two extra sensitivity analyses were performed 
using the EORTC/MSG criteria as the diagnostic criteria. Moreover, clinicians tend to 
treat patients with non-specific radiological findings and positive GM in the same way 
as proven and probable IA. Therefore, these patients were also included in the sensitivity 
analyses and described as having ‘non-classifiable IA’. Patients without IA were compared 
to i) patients with proven or probable IA and ii) patients with proven, probable or non-
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classifiable IA. When using a Ct value of <38 as the cut-off for positivity, the sensitivity 
was 88% and 83%, respectively. 
In the next step, we analyzed if the detection of RAMs predicted azole treatment 
failure and 6-week mortality. Patients infected with a RAM-positive A. fumigatus failed 
indeed significantly more often during azole treatment than those infected with a 
wildtype A. fumigatus (75% versus 27%; p-value = 0.01). Also, 6-week mortality was 2.7 
times higher in patients with RAMs (50.0% versus 18.6%; p-value = 0.07). Therefore, this 
study was the first to show that azole resistance detected by PCR is an important clinical 
finding. This observation led to the implementation of this resistance PCR as standard 
diagnostic test in clinical practice at the Erasmus University Medical Center. When a 
patient with an underlying hematological disease is suspected for IA and a BAL is per-
formed, the AsperGenius® assay is performed together with a culture and GM antigen 
level measurement in the BAL sample. 
When using the test, it should be noted that the assay detects the two most com-
mon mutation combinations TR34/L98H and TR46/T289A/Y121F that confer pan-azole 
resistance in the Netherlands [9]. However, the prevalence of these two mutation com-
binations varies per region [41,44-49]. Moreover, Cyp51A mutations and non-Cyp51A 
mutations have been described and are not detected by the assay [41,44,45,47-49]. 
Therefore, conventional Aspergillus cultures with antifungal susceptibility testing are 
still necessarily to detect phenotypic resistance caused by other mechanisms. The assay 
should therefore be used in addition to conventional Aspergillus cultures and not as 
replacement. Also, clinicians should realize that the documentation of wildtype Cyp51A 
with the Aspergenius® assay makes the presence of an infection with an azole-resistant 
Aspergilllus much less likely but does not exclude its presence with 100% certainty. 
The retrospective design of this study is a limitation. For the diagnosis of azole-resis-
tant A. fumigatus, antifungal testing is preferred to confirm its phenotypical resistance. 
Unfortunately, susceptibility testing was not done routinely in the past and therefore 
the results of the AsperGenius® assay could not be correlated with the phenotypical 
resistance in a subset of the patients. However, it would not have been possible to study 
the azole treatment failure and 6-week mortality in a prospective study as it would have 
been ethically unacceptable to test BAL samples in real-time without reporting the 
detected RAMs to the clinician. Hence, the current design made it possible to report on 
8 patients treated with azoles despite the fact that, in retrospect, they had been infected 
with RAM-positive and therefore azole resistant A. fumigatus.
To conclude, the Aspergenius® assay had a good diagnostic performance in BAL 
samples and detects azole resistance caused by the two most common Cyp51A mutation 
patterns, even in culture negative BAL samples. Morerover, we demonstrated that PCR-
based resistance testing predicts azole treatment failure. Early detection of PCR-based 
resistance can lead to a prompt adaptation of the antifungal regimen and hopefully con-
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tributing to a more favorable outcome of azole resistant A. fumigatus in future patients 
Therefore, this test should be implemented as the standard diagnostic test in countries 
were the prevalence of azole resistance is 5% and certainly when it exceeds 10%. In 
2016, 12.9% of the A. fumigatus stains cultured from patients in the Netherlands were 
azole resistant [9]. Therefore, antifungal therapy should be guided by resistance testing 
just like this is the standard procedure in all Dutch hospitals for bacterial infections and 
antibiotic therapy. PCR-based resistant testing should be performed simultaneously 
next to the fungal culture in all centers that treat hematology patients at high risk for IA. 
Azole-resistant Aspergillus fumigatus sibling species
The AsperGenius® assay detects several Aspergillus species and the A. fumigatus Cyp51A 
mutations TR34, L98H, T289A and Y121F that are associated with azole resistance 
[11,41,50]. In chapter 6, we evaluated its contribution in identifying A. lentulus and A. fe-
lis, two rare but intrinsically azole-resistant sibling species within the Aspergillus section 
Fumigati [51-53]. Identification of these species with conventional culture techniques 
is difficult and time-consuming. The assay was tested on (i) two A. lentulus and A. felis 
strains obtained from biopsy proven invasive aspergillosis and (ii) control A. fumigatus 
(n=3), A. lentulus (n=6) and A. felis species complex (n=12) strains. The PCR melting curve 
analysis for L98H and Y121F markers differed and those of the Y121F marker were par-
ticularly suitable to discriminate the three species. 
A. fumigatus has up to 63 sibling species in its family, of which 17 have been de-
scribed to cause disease in humans [54]. Some of these sibling species, also called cryptic 
species, are intrinsically azole resistant and are difficult to distinguish from A. fumigatus 
sensu stricto by culture [51-53,55-58]. The AsperGenius® assay was investigated on A. 
lentulus and one A. felis strain that were cultured from patients with biopsy proven IA. 
We showed that it is possible to distinguish A. fumigatus, A. lentulus and A. felis from each 
other by using melting analysis of the PCR assay. This is important to avoid a major error 
in which the test would recognize the azole-resistant species as being azole sensitive. 
However, as sibling species are very rare, we were not able to investigate if the assay 
could also distinguish other sibling species.  
In conclusion, the assay can be used to rapidly discriminate A. fumigatus from A. len-
tulus and A. felis, which is important as the latter two Aspergillus species are intrinsically 
resistant for triazoles. 
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future dIreCtIons
The studies in this thesis have contributed to new insights into invasive aspergillosis in 
patients with an underlying hematological disease. This chapter will elaborate on some 
of the opportunities for future research based on these new insights. 
Over the past decade, azole resistance has emerged and its prevalence continues 
to rise in the Netherlands [9]. Azoles are the first choice treatment for patients with an 
IA because their use is clearly associated with a reduction in mortality [6,7]. However, 
in regions where azole resistance is higher than 10%, therapy that includes L-AmB or 
an echinocandin have been recommended [11,59]. The updated SWAB guideline on 
the management of invasieve fungal infections has now a chapter on azole-resistant 
A. fumigatus and recommends to start with combination therapy that includes an azole 
plus a second antifungal drug (L-AmB or an echinocandin) in critically ill patients sus-
pected of having IA. In less ill patients, azole monotherapy can still be given provided 
that the documentation of azole susceptibility or resistance is pursued by performing 
BAL sampling for culture and resistance PCR testing [34].
It has been shown that azole-resistant A. fumigatus with TR34/L98H and TR46/T289A/
Y121F originate from the environment [60]. Conidia of azole-resistant A. fumigatus are 
inhaled together with the conidia of azole sensitive A. fumigatus, and subsequently both 
can cause IA simultaneously in a single patient. Prophylaxis with azoles may therefore 
lead to outgrowth of the azole-resistant A. fumigatus in a high-risk patient. Whether the 
rising prevalence of azole resistance should change antifungal prophylaxis strategies 
is currently uncertain, but it seems obvious that the efficacy of azole prophylaxis will 
decrease in the context of an increasing prevalence of azole resistance in A. fumigatus 
in the environment. We showed that prophylaxis with L-AmB inhalation is effective in 
preventing IA in AML patients undergoing remission induction therapy (chapter 3). It 
is inhaled two times a week and is a good alternative for azole prophylaxis for patients 
who are hospitalized or for those who visit the outpatient clinic twice a week or more. 
However, L-AmB inhalation is not registered for the use as prophylaxis and the imple-
mentation is logistically somewhat challenging. However, this should in no way with-
hold hematology units from implementing L-AmB inhalation in the Dutch landscape of 
an ever increasing prevalence of azole resistance given the dramatic consequences of an 
infection with an azole-resistant A. fumigatus for the individual patient. As far as we know 
the Erasmus University Medical Center is still the only center in the Netherlands in which 
this strategy has become the standard of care prophylactic regime for patients with AML 
undergoing remission induction therapy. Now that it has been clearly demonstrated 
that L-AmB inhalation effectively protects neutropenic AML patients from developing 
IA,  further research should focus on other high-risk patients such as recipients of an 
alloHSCT.
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The AsperGenius® assay was shown to be of value in the diagnosis of IA caused by 
azole resistant A. fumigatus (chapter 5). There are still questions regarding the diag-
nostic performance of the assay. In the single-center and multicenter study, all the BAL 
samples were tested in a single laboratory. It would be of interest to see how the assay 
would perform in different laboratories. In the multicenter study, we showed that the 
detection of RAMs is associated with azole treatment failure. The question that now 
needs to be answered urgently is if the early detection of RAMs and the immediate 
switch to non-azole therapy will be able to improve the very high mortality observed 
in patients infected with an azole-resistant A. fumigatus. Ideally, this question should 
be investigated in a prospective multicenter study. Also, in a prospective study, suscep-
tibility testing could be performed and correlated with the results of the AsperGenius® 
assay. Such a prospective multicenter study was designed in 2016 and started in 2017, 
and was called the AzoRMan study, AZOle Resistance MANagement study (NCT number 
NCT03121235) [61]. In this study, a standard diagnostic and therapeutic protocol for IA 
is used in patients with an underlying hematological disease who present with new pul-
monary infiltrate suspicious for IA (figure 1). This protocol is comparable to the current 
approach that was already used in the Erasmus Medical University Center. The primary 
objectives of this study are:
1. To improve the outcome of patients infected with azole-resistant A. fumigatus by 
early detection of RAMs and with this, earlier initiation of the most appropriate 
therapy;
2. To monitor the prevalence of IA due to A. fumigatus strains carrying the TR34/L98H 
or TR46/T289A/Y121F RAMs in the Netherlands, in particular in culture negative 
patients.
All 8 university hospitals in the Netherlands have agreed to participate, and 60 of the 
280 patients were included as of March 2018.
To date, the AsperGenius® assay has been studied on Aspergillus cultures, BAL 
samples, serum and plasma. The assay had a sensitivity and specificity of 79% and 100% 
in serum, and 80% and 77.8% in plasma, respectively for the detection of Aspergillus 
[62,63].  However, successful amplification of the RAMs in serum was achieved only in 
50% of the proven and probable cases [62]. Therefore, future studies are needed with 
the aim of improving the sensitivity of the resistance PCR. In 2017, the ARPOS study 
(Azole Resistance PCR Prospective Optimisation-study) was designed and will study the 
diagnostic performance of Aspergillus PCRs on serum or plasma of immunocompro-
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mised patients with an underlying hematological disease. The primary objectives of this 
study are:
1. To determine the best serum or plasma volume to generate the best diagnostic 
performance;
2. To determine whether serum or plasma is the best medium of Aspergillus DNA ex-
traction;
3. To compare different available Aspergillus species PCRs and to determine which PCR 
is most suitable to be used in a future large prospective clinical study that will evalu-
ate the use of serum or plasma Aspergillus PCR for the early diagnosis of IA;
figure 1. Diagnostic and therapeutic protocol used in the AzoRMan study.
A minimum inhibitory concentration of >2 in culture susceptibility testing means that the A. fumigatus 
is voriconazole resistant according to the method of the Clinical Laboratory Standards Institute. TR34/TR46 
means that a resistant associated mutation (RAM) is detected via the AsperGenius® PCR and the Aspergillus 
isolate is considered as resistant. PCR and culture negatieve means that the AsperGenius® PCR and culture 
was not successful, and therefore no conclusions can be drawn about the absence or presence of azole 
resistance. Galactomannan <0.7 is considered negative for BAL fluid samples. * Posaconazole should not 
be considered an option if the posaconazole MIC is >1 mg/L. This flowchart was taken from the protocol of 
the AzoRMan study.
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4. To determine what the percentage is of conclusive resistance PCR results that show 
the presence or absence of of the TR34/L98H and TR46/Y121F/T289A mutation com-
binations when the PCR is performed on serum/plasma of patients with probable or 
proven IA (based on the result obtained from PCR testing on BAL fluid).
The study will start recruiting patients in the Erasmus University Medical Center and 2 
Belgian hospitals in 2018.
fInAl remArks
The studies described in this thesis resulted in valuable new insights into the epidemiol-
ogy, prevention and diagnostics of IA in high-risk patients with an underlying hemato-
logical disease. Several risk factors were found for developing IA in alloHSCT recipients. 
Prophylactic L-AmB inhalation was shown to decrease IPA in patients with AML and was 
also cost-effective. The added value of GM antigen testing on CSF was shown when the 
diagnosis of CA is to be confirmed. The AsperGenius® assay was proven to have a good 
diagnostic performance for the detection of IA in BAL samples and predicted azole treat-
ment failure when PCR-based resistance was detected. Finally, this assay was also able 
to discriminate A. fumigatus from two intrinsically azole-resistant sibling species and 
therefore avoiding a major error.
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IntroduCtIe
Invasieve aspergillose is een levensbedreigende opportunistische schimmelinfectie. Dit 
betekent dat deze infectie in principe voorkomt bij patiënten met een langdurig ernstig 
verlaagde weerstand en niet bij mensen met een normale weerstand. De ziekte wordt 
veroorzaakt door de schimmel Aspergillus. Er zijn verschillende Aspergillus soorten, 
maar de meest voorkomende verwekker voor invasieve aspergillose is de Aspergillus 
fumigatus. Aspergillus fumigatus is alom aanwezig in het milieu en wordt door mensen 
ingeademd. Bij gezonde mensen ruimt het immuunsysteem de Aspergillus fumigatus op. 
Bij patiënten met een langdurig verlaagde weerstand kan de Aspergillus fumigatus zich 
ontwikkelen tot een invasieve infectie waarbij weefsels en organen worden aangetast. 
Omdat Aspergillus fumigatus wordt ingeademd, zijn de longen het vaakst betrokken bij 
invasieve aspergillose. De infectie kan echter ook voorkomen in andere organen zoals 
de hersenen en de darmen.
Het vaststellen van de diagnose invasieve aspergillose kan moeilijk zijn en gebeurt 
vaak met behulp van de gereviseerde criteria van de European Organization for 
Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group 
(EORTC/MSG). Hierbij wordt de het voorkomen van de schimmelziekte aangegeven met 
‘bewezen’, ‘waarschijnlijk’ of ‘mogelijk’. Bewezen invasieve aspergillose betekent dat er 
sprake is van een weefselbiopt met tekenen van een schimmelinfectie of dat Aspergillus 
groeit uit een kweek welke is afgenomen van steriel lichaamsmateriaal. Het is echter 
vaak niet mogelijk om een invasieve aspergillose te bewijzen vanwege de risico’s op 
complicaties bij het afnemen van een biopt of omdat de patiënt te ziek is om een biopt 
te ondergaan. Daarom wordt de diagnose meestal indirect gesteld door middel van de 
criteria van ‘waarschijnlijke’ of ‘mogelijke’ invasieve aspergillose. Een ‘waarschijnlijke’ 
invasieve aspergillose bestaat uit drie verschillende criteria waaraan moet zijn voldaan: 
een vatbare patiënt, een klinisch criterium en een microbiologisch criterium. Een vat-
bare patiënt omvat een patiënt die een langdurig verlaagde weerstand heeft op basis 
van neutropenie (lage aantal van bepaald soort witte bloedcellen), immunosuppres-
siva (medicijnen die de weerstand verlagen) of een stamceltransplantatie. De klinische 
criteria omvatten o.a. specifieke afwijkingen in de longen, zoals de aanwezigheid van 
ronde afwijkingen met een halo- of crescent-teken. De microbiologisch criteria bestaan 
uit het aantonen van antistoffen tegen componenten van de Aspergillus celwand 
(galactomannan of Beta-(1,3)-d-glucan) of het kweken van Aspergillus uit niet steriel 
materiaal. Wanneer een patiënt voldoet aan één van elk van de patiënt, klinische en 
microbiologische criteria, dan is er sprake van een ‘waarschijnlijke’ invasieve aspergil-
lose. Wanneer een patiënt alleen voldoet aan de patiënt en klinisch criteria, dan wordt er 
gesproken van een ‘mogelijke’ invasieve aspergillose. Zoals de benaming het aangeeft, 
hangt de zekerheid van de diagnose af van het aantal aanwezige criteria. De EORTC/
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MSG criteria zijn opgesteld voor onderzoeksdoeleinden, maar worden in de kliniek ook 
gebruikt. Echter, zij omvatten niet alle patiënten die invasieve aspergillose hebben. Vat-
bare patiënten met een microbiologisch criterium, maar zonder een klinisch criterium, 
beschouwt men vaak toch als invasieve aspergillose hebbende. Deze patiënten worden 
ook zodanig behandeld, omdat onderzoek heeft aangetoond dat zij dezelfde complica-
ties en mortaliteit hebben als patiënten met een ‘waarschijnlijke’ invasieve aspergillose. 
Deze categorie bestaat niet in de EORTC/MSG criteria, maar wordt in dit proefschrift 
omschreven als ‘non-classifiable’ invasieve aspergillose.
Zoals eerder beschreven, hebben patiënten met een langdurig ernstig verlaagde 
weerstand een risico op het ontwikkelen van invasieve aspergillose. Eén van de vatbare 
patiëntengroepen zijn patiënten met een onderliggende hematologische ziekten 
(bloedziekten), die een langdurig verlaagde weerstand ontwikkelen door hun onder-
liggende ziekte (bijvoorbeeld acute leukemie) of door hun behandeling (intensieve 
chemotherapie of stamceltransplantatie). 2,3% tot 24% van de patiënten met acute 
leukemie of patiënten die een stamceltransplantatie hebben ondergaan, ontwikkelen 
een invasieve aspergillose. Een gedeelte van deze patiënten overlijdt aan de infectie. De 
eerstelijnsbehandeling bestaat uit voriconazol of posaconazol, welke medicijnen zijn uit 
de groep ‘azolen’. Wanneer de diagnose invasieve aspergillose snel wordt gesteld en de 
behandeling met azolen direct wordt gestart, dan is de kans op overlijden relatief laag. 
Het is daarom belangrijk om de diagnose zo spoedig mogelijk te stellen, zodat adequate 
behandeling zonder vertraging gestart wordt.
In dit proefschrift is er gekeken naar de incidentie, mortaliteit en risicofactoren van 
invasieve aspergillose in patiënten met een onderliggende hematologische ziekte. Daar-
naast werden nieuwe methoden om invasieve aspergillose te detecteren onderzocht.
InvAsIeve AsPergIllose en Allogene stAmCeltrAnsPlAntAtIe
Een gedeelte van de patiënten met een onderliggende hematologische malignit-
eit wordt behandeld met een allogene stamceltransplantatie. Dit betekent dat er een 
transplantatie plaatsvindt met stamcellen van een geschikte donor. Deze donor kan 
een familielid of onbekende persoon zijn, of zelfs navelstrengbloed van pasgeborenen. 
Stamcellen bevinden zich normaliter in het beenmerg en ontwikkelen zich tot verschil-
lende bloedcellen, zoals rode bloedcellen, witte bloedcellen en bloedplaatjes. Een allo-
gene stamceltransplantatie zorgt niet alleen voor het herstel van de verschillende bloe-
dcellen, maar helpt tevens in het behandelen van de onderliggende hematologische 
ziekte (Graft-versus-Disease effect). Patiënten die een allogene stamceltransplantatie 
ondergaan, hebben een langdurig verlaagde weerstand na de stamceltransplantatie. 
Enerzijds moet de weerstand opnieuw opgebouwd uit de donor stamcellen, anderzijds 
Nederlandse samenvatting 147
is de weerstand verlaagd door medicijnen. Dit laatste is nodig omdat de witte bloedcel-
len van de donor ook tegen weefsels en organen van de patiënt kunnen keren, hetgeen 
omgekeerde afstotingsreactie oftewel Graft-versus-Host Disease wordt genoemd. Een 
medicijn dat veel wordt gebruikt voor de behandeling van Graft-versus-Host Disease, 
zijn corticosteroïden. Patiënten met een allogene stamceltransplantatie hebben een 
verhoogd risico op het ontwikkelen van invasieve aspergillose. 
Het Erasmus Medisch Centrum heeft een grote afdeling hematologie waar allogene 
stamceltransplantaties plaatsvinden. In hoofdstuk 2 wordt een onderzoek beschreven 
waarin gekeken werd naar invasieve aspergillose bij patiënten die een allogene stam-
celtransplantatie hebben ondergaan in de periode van 2004 t/m 2014. Het doel van 
dit onderzoek was om naar de incidentie, mortaliteit en risicofactoren van invasieve 
aspergillose te kijken. In totaal kregen 663 patiënten een allogene stamceltransplan-
tatie. Twaalf maanden na transplantatie hadden 86 van de 663 patiënten invasieve 
aspergillose ontwikkeld (1.8% bewezen, 7.4% waarschijnlijk en 3.8% non-classifiable 
invasieve aspergillose). De mortaliteit op 12 maanden was 14% hoger in patiënten met 
invasieve aspergillose in vergelijking met patiënten zonder invasieve aspergillose (40% 
versus 26%; p-waarde <0.01). Het bepalen van de risicofactoren werd gedaan door 
middel van een case-control onderzoek, waarbij de karakteristieken van patiënten met 
een invasieve aspergillose (case) vergeleken werden met patiënten zonder invasieve 
aspergillose (control). Er werden 99 case patiënten gepaard met 198 control patiënten 
op basis van leeftijd, jaar van stamceltransplantatie en duur van follow-up. De volgende 
risicofactoren werden gevonden: een verminderd aantal van neutrofiele granulocyten 
en lymfocyten (allebei zijn witte bloedcellen), een verminderde longfunctie voorafgaand 
aan de allogene stamceltransplantatie, een verminderde functie van de nieren, het re-
activeren van cytomegalovirus en het gebruik van corticosteroïden bij de behandeling 
van Graft-versus-Host Disease. Een hogere dosis corticosteroïden werd geassocieerd 
met een hogere kans om invasieve aspergillose te ontwikkelen. Naar aanleiding van 
de resultaten uit dit onderzoek is het beleid aangepast betreffende de preventie van 
invasieve aspergillose. Patiënten die behandeld worden met een hoge dosis corticoste-
roïden krijgen nu ook therapie met azolen ter voorkoming van invasieve aspergillose.
InHAlAtIe vAn lIPosomAAl AmfoterICIne-b ter voorkomIng vAn 
InvAsIeve AsPergIllose
Patiënten die een acute myeloïde leukemie hebben, worden behandeld met intensieve 
chemotherapie. Zij hebben enkele weken geen tot zeer lage aantallen van afweercellen 
na de chemotherapie. In deze periode zijn patiënten zeer vatbaar voor allerlei verschil-
lende infectieziekten, waaronder invasieve aspergillose. In 2008 liet een onderzoek zien 
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dat het inhaleren van liposomaal amfotericine-B (L-AmB) de incidentie van invasieve 
aspergillose verlaagd van 14% naar 4%. L-AmB is een medicijn tegen invasieve asper-
gillose. In het onderzoek inhaleerden patiënten L-AmB 2x per week. Naar aanleiding 
van de bovenstaande resultaten wordt L-AmB inhalatie standaard voorgeschreven aan 
patiënten met acute myeloïde leukemie die intensieve chemotherapie ondergaan in het 
Erasmus Medisch Centrum. Hoofdstuk 3 beschrijft een prospectief onderzoek waarin we 
hebben gekeken naar de effectiviteit en kosten-baten van L-AmB inhalatie in patiënten 
met acute myeloïde leukemie, die behandeld werden met intensieve chemotherapie. 
In de periode van 2008 t/m 2012 waren er 127 patiënten die L-AmB hadden geïn-
haleerd gedurende hun eerste en tweede chemotherapie. Deze 127 patiënten werden 
vergeleken met 108 historische controle patiënten die waren behandeld voor acute 
myeloïde leukemie in de periode van 2005 t/m 2008. De controle patiënten hadden 
geen L-AmB geïnhaleerd. Er werd een significante daling in de incidentie van bewezen 
en waarschijnlijke invasieve aspergillose gezien in de patiënten die L-AmB hadden geïn-
haleerd (L-AmB groep 9,5% versus controle groep 34,4%; p-waarde=0,0064). Er werden 
geen ernstige bijwerkingen van de L-AmB inhalatie waargenomen. Daarnaast werden 
de kosten voor L-AmB en de bijbehorende apparatuur voor inhalatie ruimschoots 
gecompenseerd (1292 euro per patiënt) door de verminderde kosten in diagnostiek en 
gebruik van voriconazol (-1816 euro per patiënt). Concluderend was de inhalatie van L-
AmB effectief ter voorkoming van invasieve aspergillose en daarbij ook kosteneffectief.
gAlACtomAnnAn AntIgeentest In CerebrosPInAAl vloeIstof
Invasieve aspergillose komt meestal voor in de longen, maar kan ook voorkomen in 
andere organen. Wanneer invasieve aspergillose in de hersenen voorkomt, wordt dit 
cerebrale aspergillose genoemd. Cerebrale aspergillose is zeldzaam en gaat gepaard 
met een zeer slechte overleving. De diagnose kan moeizaam zijn doordat het beeldvor-
mend onderzoek van de hersenen niet specifiek is en Aspergillus in de hersenvloeistof 
slechts gekweekt wordt in minder dan een derde van de patiënten. Om de diagnose 
met zekerheid te stellen dient er een hersenbiopt afgenomen te worden. Dit is echter 
vaak niet mogelijk bij patiënten met een onderliggende hematologische ziekte van-
wege potentiele complicaties of ernstig ziek zijn. Daarentegen is het vaak wel mogelijk 
om hersenvloeistof af te nemen middels een lumbaalpunctie. Aspergillus kan indirect 
worden aangetoond door de bepaling van antigenen tegen galactomannan, een cel-
wand component welke vrijkomt tijdens de groei van Aspergillus. De galactomannan 
antigeentest behoort tot de microbiologische criteria van de EORTC/MSG criteria en kan 
op verschillende lichaamsmaterialen bepaald worden. De test is uitgebreid onderzocht 
op longvloeistof en bloed, maar er is weinig onderzoek verricht naar de bruikbaarheid 
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van deze test op hersenvloeistof. Hoofdstuk 4 beschrijft een onderzoek over de bruik-
baarheid van de galactomannan antigeentest op hersenvloeistof. Alle patiënten van het 
Erasmus Medisch Centrum en Universitair Ziekenhuis Leuven werden geïncludeerd bij 
wie een galactomannan antigeentest op de hersenvloeistof was bepaald in de periode 
van 2004 t/m 2014. De EORTC/MSG criteria werden gebruikt om de diagnose bewezen of 
waarschijnlijke cerebrale aspergillose te stellen. Omdat de galactomannan antigeentest 
op hersenvloeistof werd onderzocht, werd deze geëxcludeerd van de microbiologische 
criteria. De galactomannan antigeentest was uitgevoerd op 205 hersenvloeistoffen van 
157 patiënten. Bij een groot gedeelte van de patiënten waren de gegevens onvolledig. 
Deze patiënten werd daarom geëxcludeerd. Na exclusie bleven er 44 patiënten over, 
waarvan 4 patiënten met een bewezen cerebrale aspergillose, 13 patiënten met een 
waarschijnlijke cerebrale aspergillose en 27 patiënten zonder cerebrale aspergillose. Van 
de 17 patiënten met een cerebrale aspergillose hadden 15 patiënten een galactoman-
nan antigeentest met een waarde van 2,0 of hoger. Van de patiënten zonder cerebrale 
aspergillose, hadden 26 van de 27 patiënten een galactomannan antigeentest van 0,5 of 
lager, en 1 patiënt een galactomannan antigeentest van 8,2. Wanneer een galactoman-
nan cutoff waarde van 1,0 werd genomen, was de sensitiviteit 88,2% en de specificiteit 
96,3%. We vonden dezelfde resultaten bij een cutoff waarde van 0,5 of 2,0. Concluderend 
heeft de galactomannan antigeentest een goede diagnostische waarde en kan de test 
gebruikt worden voor het aantonen of uitsluiten van cerebrale aspergillose.
Azool-resIstente AsPergIllus fumIgAtus
Azolen zijn de eerstelijnsbehandeling voor invasieve aspergillose. In de afgelopen 15 
jaar is er sprake van een toenemende resistentie voor azolen. Deze azoolresistentie is 
ontstaan door overvloedig gebruik van azolen in de landbouw ter bescherming van de 
gewassen tegen schimmelinfecties. De agrarische azolen zijn qua chemische structuur 
vergelijkbaar met medische azolen, waardoor er kruisresistentie is ontstaan. Dit is een 
groot probleem, want onderzoek toont aan dat patiënten die geïnfecteerd zijn met 
een azoolresistente Aspergillus fumigatus, een zeer hoge mortaliteit van bijna 90% 
hebben. Azolen zijn bewezen superieur in de behandeling voor invasieve aspergillose 
ten opzichte van andere medicijnen als amfotericine-B en echinocandinen. Bovendien 
zijn azolen het enige anti-schimmel medicijn dat oraal gegeven kan worden, hetgeen 
van belang is omdat patiënten vaak langdurig behandeld moeten worden. Naast het 
probleem van therapie is de detectie van de azoolresistente Aspergillus fumigatus een 
uitdaging. Een gevoeligheidsbepaling naar anti-schimmel medicatie is mogelijk wan-
neer Aspergillus gekweekt is. Aspergillus fumigatus wordt echter in klein gedeelte van 
de patiënten gekweekt, waardoor een gevoeligheidsbepaling vaak niet mogelijk. Als 
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de Aspergillus wel wordt gekweekt, duurt het lang alvorens de gevoeligheidsbepaling 
bekend is. Dit komt omdat enerzijds de gevoeligheidsbepaling meestal gebeurt in een 
referentielaboratorium en anderzijds de Aspergillus langzaam groeit. 
Het grootste gedeelte van de azoolresistentie wordt veroorzaakt door mutaties in 
het Cyp51A gen van de Aspergillus fumigatus. Het Cyp51A gen codeert voor het lanestrol 
14-α-demethylase, een belangrijk enzym welke betrokken is in de bouw van de Asper-
gillus celwand. Dit enzym is tevens het aangrijpingspunt voor azolen. Mutaties in het 
Cyp51A gen kunnen zorgen voor azoolresistentie. Azoolresistentie in Nederland wordt 
voor bijna voor 90% veroorzaakt door twee mutatie combinaties in het Cyp51A gen: 
TR34/L98H en TR46/T298A/Y121F. Wanneer één van deze mutatie combinaties gevonden 
wordt, is er sprake van pan-azoolresistentie. Pan-azoolresistentie betekent dat er resis-
tentie is tegen alle soorten azolen. Indien de twee mutatie combinaties snel aangetoond 
kunnen worden, is het mogelijk om een patiënt adequater te behandelen door het 
starten van een andere anti-schimmel therapie dan azolen.
Het aantonen van gen kan gebeuren door middel van een polymerase-kettingreactie 
(polymerase chain reaction: PCR). De PCR is een moleculaire techniek waarbij snel en 
eenvoudig specifieke stukken DNA vermenigvuldigd kunnen worden. Een multiplex-
PCR is een PCR waarbij meerdere PCR producten tegelijkertijd aangemaakt worden. 
Idealiter zou een PCR voor het aantonen van Aspergillus DNA moeten voldoen aan twee 
voorwaarden: i) het aantonen van Aspergillus DNA direct op lichaamsmateriaal, ook 
wanneer er geen Aspergillus gekweekt wordt op datzelfde materiaal, en ii) het tevens 
aantonen van de meest voorkomende mutatie combinaties in het Cyp51A gen. Een 
dergelijke PCR is de AsperGenius® multiplex real-time PCR welke ontwikkeld werd door 
PathoNostics, een bedrijf in Maastricht. Deze commerciële PCR bestaat uit twee delen: 
de species PCR en de resistentie PCR. De species PCR toont de Aspergillus fumigatus, 
Aspergillus terreus en Aspergillus species aan. De resistentie PCR toont de mutaties TR34, 
L98H, T298A en Y121F mutaties in het Cyp51A gen welke correleren met de twee meest 
voorkomende mutatie combinaties TR34/L98H en TR46/T298A/Y121F. In hoofdstuk 5 wor-
den twee onderzoeken beschreven over de diagnostische waarde van de AsperGenius® 
PCR op broncho-alveolar lavage (BAL). Een BAL is vloeistof dat is verkregen na spoeling 
van de longen met water door middel van een bronchoscopie (longonderzoek). Dit 
longvloeistof wordt gebruikt voor een kweek en de bepaling van het galactomannan 
antigeentest. Hoofdstuk 5.1 beschrijft het eerste onderzoek waarbij de AsperGenius® 
PCR werd getest op 37 longvloeistoffen van patiënten met een onderliggende hema-
tologische ziekte en 40 vloeistoffen van patiënten van de intensive care. Het onderzoek 
werd verricht in het Erasmus Medisch Centrum. De uitslagen van de AsperGenius® PCR 
werden vergeleken met de uitslagen van galactomannan antigeentesten en kweken 
welke eerder waren uitgevoerd op de longvloeistoffen. De positieve controles waren 
de longvloeistoffen met een galactomannan van ≥1,0 en/of een positieve Aspergillus 
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kweek. De negatieve controles waren de longvloeistoffen met een negatieve uitslag 
voor de galactomannan antigeentest en Aspergillus kweek. Tweeëntwintig van de 77 
longvloeistoffen waren afkomstig van patiënten met invasieve aspergillose (2 bewezen, 
9 waarschijnlijk en 11 non-classifiable). Negentien van de 22 longvloeistoffen waren 
positieve controles. Negen longvloeistoffen hadden een positieve Aspergillus kweek. Er 
werd gekeken naar de optimale cyclic threshold van de PCR. De cyclic threshold is het 
aantal vermenigvuldigingen die nodig zijn om een echt signaal te vinden dat Aspergil-
lus aan te tonen. De optimale cyclic threshold waarde werd gevonden bij <36. Zestien 
van de 19 longvloeistoffen hadden een positieve species PCR, waarbij er 2 Aspergillus 
species en 14 Aspergillus fumigatus werden gevonden. Dit resulteerde in een sensitivit-
eit, specificiteit, positief en negatief voorspellende waarde van 88.9%, 89.3%, 72.7% en 
96.2% in de hematologie groep en 80.0%, 93.3%, 80.0% en 93.3% in de intensive care 
groep. De resistentie PCR werd verricht op de 14 longvloeistoffen waar een Aspergillus 
fumigatus was gevonden. De resistentie PCR vond twaalf wildtypes (oftwel Aspergillus 
fumigatus zonder Cyp51A mutaties TR34, L98H, T298A en Y121F welke meest waarschijn-
lijk gevoelig zijn voor azolen) en twee mutanten (één met TR34/L98H en één met TR46/
Y121F/T289A). De twee longvloeistoffen met een Aspergillus fumigatus met mutaties 
waren afkomstig van patiënten die gefaald hadden op azooltherapie. Samenvattend 
had de geteste PCR een goede diagnostische waarde en was het mogelijk om de PCR te 
gebruiken op longvloeistoffen welke geen positieve Aspergillus kweek hadden. Daarbij 
kon de PCR Cyp51A mutaties in de Aspergillus fumigatus aantonen, welke gerelateerd 
zijn met azoolresistentie.
Het single-center onderzoek van hoofdstuk 5.1 is vervolgd door een tweede onder-
zoek. Hoofdstuk 5.2 beschrijft het vervolgonderzoek over de AsperGenius® PCR waarin 
vijf ziekenhuizen in Nederland en België deelnamen. In dit multicenter onderzoek 
waren de doelen: i) het bevestigen van de optimale cyclic threshold en diagnostische 
waarde van de PCR op longvloeistoffen, en ii) het onderzoeken of de aanwezigheid van 
resistentie geassocieerde mutaties (RAM) gerelateerd is met het falen van de behandel-
ing met azolen of de mortaliteit op 6 weken na diagnose van invasieve aspergillose. 
Er waren 201 patiënten van wie een longvloeistof beschikbaar was. Achtentachtig van 
201 longvloeistoffen waren positieve controles en 113 waren negatieve controles. De 
optimale cyclic threshold werd onderzocht middels twee verschillende methoden: de 
closest to (0,1) en de Youden index. Deze twee methoden gaven respectievelijk een 
cutoff van <38 en <36 aan als beste cyclic threshold. We kozen de cyclic threshold van 
<38 aan als optimale cutoff, omdat deze gepaard gaat met een hogere sensitiviteit. Het 
missen van de diagnose invasieve aspergillose heeft namelijk grote negatieve gevolgen 
voor een patiënt. Met een cyclic threshold cutoff van <38, hadden 74 van de 88 positieve 
controles een uitslag van de species PCR. Van deze 74 longvloeistoffen waren er bij 32 
longvloeistoffen geen Aspergillus gekweekt. De sensitiviteit, specificiteit, positieve en 
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negatieve voorspellende waarden waren respectievelijk 84%, 80%, 76% and 87% bij 
een cyclic threshold cutoff van <38. Voor het bepalen van therapiefalen met azolen en 
mortaliteit op 6 weken werden de data van het eerste single-center onderzoek en het 
huidige onderzoek bij elkaar gevoegd. Dit werd gedaan omdat azoolresistentie nog 
relatief weinig voorkomt. In totaal waren er 78 patiënten die geïnfecteerd waren met 
wildtype Aspergillus fumigatus (n=65) of een Aspergillus fumigatus met RAMs (n=13). 
Vijventwintig van de 78 patiënten werden geëxcludeerd, omdat zij niet aan de vooraf 
opgestelde voorwaarden voldeden. Na de exclusie bleven er 53 patiënten over, waarvan 
45 met een wildtype Aspergillus fumigatus en 8 met Aspergillus fumigatus met RAMs (6 
TR34/L98H en 2 met TR46/Y121F/T289A). Het falen van azooltherapie werd gezien in 12 
van de 45 patiënten met een wildtype Aspergillus fumigatus versus 6 van de 8 patiënten 
met Aspergillus fumigatus met RAMs (p-waarde = 0,01). De mortaliteit op 6 weken was 
2,7 keer hoger in patiënten met een Aspergillus fumigatus met RAMs (18,6% zonder RAMs 
versus 50,0% met RAMs, p-waarde = 0,07). Hiermee werd voor het eerst beschreven dat 
er een associatie is tussen het falen van azooltherapie en het geïnfecteerd zijn met een 
Aspergillus fumigatus met RAMs. 
ondersCHeIdIng vAn Aspergillus fumigAtus, Aspergillus lentulus 
en Aspergillus felis
Er bestaan verschillende soorten Aspergilli. De Aspergillus fumigatus behoort tot de 
sectie Fumigati binnen de Aspergilli. De Aspergilli in de sectie Fumigati kunnen qua mor-
fologie (uiterlijk) op elkaar lijken, waardoor onderscheiding alleen mogelijk is op basis 
van moleculaire techinieken. Het onderscheid tussen verschillende Aspergilli binnen 
de sectie Fumigati is belangrijk, omdat sommigen intrinsiek resistent zijn voor azolen. 
Intrinsieke resistentie betekent dat deze resistentie een stabiel genetisch eigenschap 
is en gecodeerd is in het DNA. Dit in tegenstelling tot verworven resistentie, welke 
verworven kan worden door bijvoorbeeld mutaties in het DNA. Tot op heden omvat 
de sectie Fumigati 63 species, waarvan er 17 beschreven zijn die invasieve aspergillose 
kunnen veroorzaken bij mensen en/of zoogdieren. Twee van deze beschreven Aspergilli 
zijn de Aspergillus lentulus en Aspergillus felis. Beiden zijn intrinsiek resistent voor azolen 
en worden sporadisch gerapporteerd als verwekkers van invasieve aspergillose.
In hoofdstuk 6 beschrijven wij twee patiënten die een bewezen invasieve aspergil-
lose hadden ontwikkeld met respectievelijk een Aspergillus lentulus en Aspergillus felis. 
Deze twee Aspergilli waren gekweekt uit een biopt en identificatie werd verricht middels 
moleculaire technieken. De AsperGenius® PCR werd getest op deze twee Aspergilli en 
extra controle stammen van Aspergillus fumigatus, Aspergillus lentulus en Aspergillus felis. 
We onderzochten of de PCR deze drie Aspergilli kon onderscheiden, omdat Aspergillus 
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fumigatus meestal azoolgevoelig is en de Aspergillus lentulus en Aspergillus felis daaren-
tegen juist azoolresistent zijn. Indien er geen onderscheid gemaakt kan worden, zou dit 
kunnen leiden tot een inadequate behandeling van een patiënt die geïnfecteerd is met 
een Aspergillus lentulus of Aspergillus felis. 
De AsperGenius® resistentie PCR toonde variabele smeltpunten voor de drie ver-
schillende Aspergilli, maar kon geen onderscheid maken. De PCR detecteerde geen 
TR34 marker in de Aspergillus lentulus en Aspergillus felis. Dit was in tegenstelling tot de 
Aspergillus fumigatus waarin de TR34 kon worden aangetoond zowel in een wildtype 
als mutant. Daarnaast waren de smeltpunten van de L98H en Y121F markers verschil-
lend tussen Aspergillus fumigatus, Aspergillus lentulus en Aspergillus felis. Met name de 
Y121F marker was geschikt om de drie Aspergilli te onderscheiden. Dit resultaat werd 
ook geconfirmeerd door het testen van additionele isolaten (drie Aspergillus fumigatus, 
zes Aspergillus lentulus en twaalf Aspergillus felis). Concluderend was het mogelijk om 
Aspergillus fumigatus, Aspergillus lentulus en Aspergillus felis te onderscheiden middels 
de AsperGenius® PCR. 
ConClusIe
In dit proefschrift zijn meerdere onderzoeken verricht naar invasieve aspergillose bij 
patiënten met een hematologische ziekte. Dit resulteerde in nieuwe inzichten in de 
epidemiologie, risicofactoren en diagnostiek van invasieve aspergillose. Risicofactoren 
voor het ontwikkelen van invasieve aspergillose in allogene stamceltransplantatie 
patiënten zijn neutropenie, lymfocytopenie, een verminderde functie van de nieren, 
een verminder longfunctie, het reactiveren van cytomegalovirus en het gebruikt van 
prednisolon. Het inhaleren van L-AmB voorkomt invasieve aspergillose in patiënten met 
acute myeloïde leukemie tijdens hun intensieve chemotherapie. Deze profylactische 
behandeling is tevens kosteneffectief. De galactomannan antigeentest heeft een goede 
diagnostische waarde in het cerebrospinal vloeistof en kan gebruikt worden voor het 
aantonen of uitsluiten van cerebrale aspergillose. De AsperGenius® PCR heeft een goede 
diagnostische waarde op longvloeistoffen, ook wanneer er geen Aspergillus groeit uit 
de longvloeistof. Daarbij kon de PCR Cyp51A mutaties aantonen welke correleren met 
azoolresistentie. Het aantonen van deze Cyp51A mutaties was tevens geassocieerd met 
het falen van azooltherapie. Ten slotte is het mogelijk om met deze PCR onderscheid te 
maken tussen Aspergillus fumigatus, Aspergillus lentulus en Aspergillus felis, drie verwante 
Aspergilli uit de sectie Fumigati. 
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dAnkwoord
Een proefschrift komt tot stand door de inzet en wilskracht van veel mensen. Allereerst 
dank ik de patiënten voor hun deelname aan de verschillende onderzoeken. Daarnaast 
wil ik nog een aantal mensen in het bijzonder bedanken.
Graag wil ik mijn co-promotor Bart Rijnders bedanken. Beste Bart, toen ik mijn consult-
enstage infectieziekten kwam doen op de afdeling, had ik niet gedacht dat ik uiteindelijk 
zou blijven om te promoveren. Je daadkracht en snelheid hebben mij vaak versteld laten 
staan. Vele dank dat ik bij jou onderzoek mocht doen. Ik heb veel van je geleerd.  
Beste prof. dr. Verbon, beste Annelies, je bewaakte de tijdslijn tijdens mijn promotie 
traject. Toen ik langs kwam om aan te geven dat ik een carrière switch wilde maken, 
luisterde je rustig naar mijn verhaal en gaf mij goed advies. Hartelijk dank dat jij mijn 
promotor wilt zijn.
Beste prof. dr. Cornelissen, beste Jan, ik heb mijn opleiding tot internist-hematoloog 
onder jouw begeleiding afgerond. Tijdens de opleiding gaf je mij de gelegenheid om 
tijdelijk de opleiding te onderbreken om aan dit onderzoek te werken. Ik dank je dat je 
dit mogelijk hebt gemaakt en dat je mijn promotor wilt zijn.
Beste leden van de leescommissie, hartelijk dank voor de snelle beoordeling van mijn 
proefschrift. Ook bedank ik de leden van de grote commissie voor jullie deelname aan 
de oppositie.
Vele dank aan alle coauteurs voor jullie bijdragen aan de verschillende studies en het 
becommentariëren van de manuscripten. Daarnaast ben ik voor verschillende studies in 
andere studiecentra in Nederland en België geweest. Altijd werd ik hartelijk ontvangen 
door de medeonderzoekers en ondersteunende personeel en werd ik geholpen bij het 
terugzoeken van gegevens en BAL-vloeistoffen. Bedankt voor jullie vriendelijke hulp 
waardoor ik in korte tijd alles bij elkaar kon zoeken. Ook bedank ik Fleur Broekman, René 
van Engen en Jaap Kuipers: in tijden dat ik weinig tijd had om gegevens op te zoeken, 
hebben jullie mij geholpen met het opzoeken van data. Vele dank voor jullie hulp!
Ook dank aan de medewerkers van Pathonostics voor het verwerken van alle BAL vloe-
istoffen in de twee studies. Met name Gijs en Giel wil ik extra noemen: met jullie tweeën 
heb ik het meest gediscussieerd over de AsperGenius PCR. Bedankt voor jullie snelle en 
prettige samenwerking. 
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Tevens dank aan de collega’s van de hematologie: hartelijk dank aan mijn supervisoren, 
ik heb veel van jullie geleerd op de centrum locatie en Daniel den Hoed Kliniek. Aan 
de (oud) arts-assistenten, bij wijlen en tijden was de hematologie stage zwaar. Ik ben 
blij dat we veel steun aan elkaar hadden. Hartelijk dank voor jullie gezelligheid en aan-
wezigheid. Drie collegae wil ik nog extra noemen: Gerard, al vanaf het Maasstad zieken-
huis kennen wij elkaar. Dank je voor je gezelligheid en goede adviezen. Heel veel succes 
met je klinische en wetenschappelijke carrière. Jurjen, hartelijk dank voor je analyses en 
commentaren, ons stuk is er een stuk beter op geworden. Veel succes met het afronden 
van je opleiding. Tim, bedankt voor je gezelligheid. Ik wens je heel veel succes met het 
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in de New England Journal of Medicine. 
Vele dank aan alle collega’s van de MMIZ. Ik ben blij dat ik mijn opleiding tot arts-
microbioloog in het Erasmus MC doe. De sfeer is laagdrempelig en fijn. In het bijzonder 
wil ik nog de arts-assistenten en Alieke noemen: aan de arts-assistenten, toen ik tijdens 
mijn promotieonderzoek uit de Z-flat moest, werd ik gelukkig verwelkomd bij jullie op 
de kamer. Dank jullie allen voor de gezelligheid. Aan Alieke, toen ik langs kwam om te 
praten vanwege een carrière switch van hematologie naar medische microbiologie, zei 
je dat ik vooral mijn gevoel moest volgen. Ik ben blij dat ik je advies heb opgevolgd en 
heb geen spijt van mijn switch. Ik dank je hartelijk en ben blij dat jij mijn opleidster bent.
Beste mede-promovendi, beste Ingeborg, Anne, Hassna, Sabrina, Alexander, Bas en 
Casper, tijdens mijn promotieonderzoek ben ik menigmaal verhuisd tussen de Z-flat, de 
D-vleugel en het Na-gebouw. Maar waar ik ook zat, ik kon altijd rekenen op jullie wan-
neer ik vragen had over onderzoeks-gerelateerde zaken. Ik dank jullie allen en succes 
aan diegenen die hun onderzoek nog moeten afronden.
Beste vrienden, altijd was het goed als ik even wilde praten over mijn promotieonderzoek 
en welke hindernis er dan weer op het pad lag. Dank jullie allen voor jullie aanwezigheid 
en gezelligheid. 
Dear family from Hong Kong, when we are visiting Hong Kong, you always warmly wel-
come us and take us to different places. Thank you all for your kind hospitality. 
Lieve Anoesh, ondanks dat de afgelopen jaren moeilijk waren, is onze vriendschap geb-
leven. In de loop der jaren steunde jij mij bij verschillende belangrijke gebeurtenissen. Ik 
dank je dat jij mijn paranimf bent en wederom naast mij wilt staan om mij te steunen. Ik 
wens jou, Kyran en Michael veel geluk, op welke manier jullie ook samen zijn.
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Lieve Marlies en Ynze, lieve papa en mama, ik ben blij dat ik zulke lieve schoonouders 
heb die altijd geïnteresseerd zijn in hetgeen wat me bezighoudt en voor Boudewijn en 
mij klaar staan. Beste Caroline, Bart en Domino, het is altijd gezellig om bij jullie te zijn 
en superlekkere kip uit de oven te mogen eten. Lieve Kiek, onder uw handen wordt de 
tuin mooier en komen er steeds meer vogels aanvliegen. U heeft altijd een luisterend 
oor en geeft goed advies. U bent de oma die ik nooit heb gehad als kind. Ik hoop dat we 
nog veel Monopolie mogen spelen (en vaak verbonden kunnen sluiten om Boudewijn 
te verslaan). Wat een geluk dat ik zo’n lieve schoonfamilie heb.
Lieve Fung, lieve broer, ondanks dat je ooit hebt gezegd dat je nooit meer ceremonie-
meester of iets in die aard wilde zijn, ben ik blij dat je toch hebt toegestemd om mijn 
paranimf te zijn. Je aanwezigheid met goede cynische grappen is belangrijk voor mij. 
Dankjewel voor je steun. Ik wens je veel succes met alle werkzaamheden. Aan mamma: 
媽媽，我相信你看見女兒的成就，感到非常驕傲。謝謝你多年的愛護及耐心。若
是，爸爸今天能看見一切，相信他也會為他的一雙兒女以感到自豪。
Lieve Boudewijn, je bent mijn steun en toeverlaat. Ik ben gezegend dat we samen zijn. 
Ik hoop dat we samen nog vele wandelingen hand in hand mogen maken in de wijde 
natuur. 
